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The endothelins (ET-1, ET-2 and ET-3) are a family of 21-amino acid peptides with extremely potent
and characteristically sustained vasoconstrictor and vasopressor actions. ET-1 is the predominant
isoform in the vascular endothelium and is, therefore, likely to be the isoform of most importance in
regulation of vascular tone and blood pressure. The endothelins are synthesised from inactive
precursors (big endothelins) by an endothelin-converting enzyme. Two endothelin receptor subtypes,
ETa and ETb have been identified. The ETA receptor is mainly expressed in smooth muscle cells and
mediates vasoconstriction. The ETb receptor is mainly expressed on endothelial cells where it
mediates vasodilatation. However, the ETb receptor is also expressed on vascular smooth muscle
cells where it mediates vasoconstriction.
In this thesis I review the biology of endothelin as well as discuss the evidence supporting a
pathophysiological role for endothelin in a number of cardiovascular and renal diseases and
consequently, the potential for therapeutic intervention in this sytsem. In the studies described, I have
further investigated the physiology of the endothelin system as well as examined the pharmacology of
endothelin receptor antagonists in man. Finally, I have also examined the potential contribution of
endothelin to the pathophysiology of chronic renal failure and essential hypertension.
Study 1: Local inhibition of the enzyme neutral endopeptidase causes forearm vasoconstriction
probably by preventing endothelin breakdown.
Study 2: Big ET-3 is converted to the mature peptide ET-3 in the forearm circulation, but not in
capacitance vessels, of healthy volunteers.
Study 3: Sytemic infusions of TAK-044, a non-selective endothelin receptor antagonist, lower
systemic vascular resistance and blood pressure in man.
Study 4: Systemic doses of the endothelin receptor antagonist, TAK-044, completely blocks
the local vasoconstriction produced by intrabrachial artery infusion of ET-1 for up to 3 hours.
Study 5: Systemic doses of TAK-044 only partially block ET-1 mediated vasoconstriction for
12 hours with important implications for dosing schedules in potential therapeutic interventions.
Study 6: TAK-044 causes renal vasodilatation and lowers effective filtration fraction by a
relative decrease in glomerular filtration rate and increase in effective plasma flow in healthy
volunteers.
Study 7: TAK-044 lowers systemic vascular resistance and blood pressure in patients with
chronic renal failure, with a reduction in effective filtration fraction. Glomerular filtration rate is not
significantly affected.
Study 8: Forearm vasodilatation to BQ-123, a selective ETA receptor antagonist is not different
in patients with essential hypertension compared with normotensive controls. However,
vasoconstriction to ET-1 is impaired in hypertensive patients, whereas vasoconstriction to the
selective ETb receptor agonist, sarafotoxin S6c is not.
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CSF cerebrospinal fluid
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EC50 enzyme inhibition constant
EDHF endothelium derived hyperpolarising factor
EDTA ethylenediamine-tetraacetic acid
ERPF effective renal plasma flow
ERVR effective renal vascular resistance




FHR Fawn hooded rat
GFR glomerular filtration rate
HPLC high performance liquid chromatography
HR heart rate





IC50 inhibitory constant where an antagonist
causes an inhibitory response, the IC50 is the
molar concentration which produces 50% of
the maximum possible inhibition
iv intravenous
Km steady state concentration at which 50% of
maximum enzyme function is reached




L-NMMA NG-nitro-L-arginine methyl ester
LVDT linear variable differential transformer
M molar
MAP mean arterial pressure
mol moles





NOS nitric oxide synthase
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pA-2 the negative log of the concentration of an
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pH hydrogen ion concentration equal to -
log{H+}
PKC protein kinase C
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SI stroke index
SNP sodium nitroprusside
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1.1 The Vascular Endothelium: Historical Perspective
Historically, the vascular endothelium was thought only to be a semi-
selective barrier to the diffusion of macromolecules from the blood lumen
to the interstitial space. Indeed, Marcello Malpighi (1628-1694), a
founding father of modern anatomic pathology,!485' 487, 502] considered
the endothelium to be no more than an inert 'wallpaper' lining blood
vessels. In 1976, Moncada et alf361l demonstrated that endothelial cells
were a source of prostacyclin, a substance which inhibits platelet
aggregation and causes vascular relaxation. However, full recognition of
the endothelium as an important cardiovascular regulator did not come
until Furchgott's seminal paper in 1980 describing an endothelium-derived
relaxing factor,!1791 currently thought to be nitric oxide (NO).!422! In 1983
de Mey and Vanhoutte predicted the existence of an endothelium-derived
constricting factor.!122! This prediction culminated in 1988 with the
discovery of endothelin by Masashi Yanagiawa and colleagues. !635! The
discovery of endothelin has resulted in an explosion of research activity
with over 4000 publications in endothelin research during 1996 alone.t603!
It is now clear that the endothelium plays a key role in the regulation of
vascular tone producing a number of vasoactive mediators, and has been
the target of several of the most succesful pharmacological treatments in
the treatment of cardiovascular disease, including aspirin, nitrates and
angiotensin-converting enzyme (ACE) inhibitors (Figure l.l).!320!
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1.2 Endothelin
The endothelinst635!, comprise a family of three related peptides (ET-1,
ET-2 & ET-3), each of 21 amino acids, with two intra-chain disulphide
bridges linking paired cysteine residues (Figures 1.2 & 1.3).l242] Since
1988, there has been a major focus of research based on their potential
pathophysiological role in a number of cardiovascular diseases.t603! ET-1
is the most potent mammalian vasoconstrictor peptide known, P42> 63 51
with veins being 3 to 10 times more sensitive to the effects of ET-1 than
arteries, both in vhrol98! and in vz'vcJ"] ET-1 is also the major isoform
produced by endothelial cellst60! and is probably the most important
isoform in the cardiovascular system. The endothelins also show striking
structural similarities with a family of snake venoms, the sarafotoxins
(Figure 1.3).l197l
1.2.1 Endothelin genes and regulation
The first description of ET-lC635! was rapidly followed by the
identification of at least three genes encoding 'ET-like' sequences in
mammalian genomes.l242l These sequences have since been shown to
encode the precursors prepro ET-1, ET-2 and ET-3. In the human genome,
the ET-1 gene is found on chromosome 6,t6E the ET-2 gene on
chromosome H62! and the ET-3 gene on chromsome 20.[60]
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Like other eukaryotic genes, the genes that encode the endothelin
precursors have promoter regions through which external factors are able
to modulate transcription.!48' 225] Selective gene modification has
demonstrated regions necessary for high level transcription!303' 305> 624]
and also regions that might determine the tissue selectivity of ET-1
expression.!47] Extracellular factors can influence ET-1 generation both
positively and negatively through liberation of a series of intracellular
mediators that modulate gene transcription (Table 1.1). Several agents
enhancing ET-1 generation! 197] do s0 vja activation of protein kinase C
(PKC). Responsiveness to PKC is mediated by binding of the proto-
oncogenes Jun and Fos to the Activator Protein-1 (AP-1) transcription
regulatory element of the ET-1 promoter.!1 n, 304]
Recent studies have shown that different isoforms of the endothelin
precursor mRNA can arise due to the presence of alternative transcription
initiation sites in the ET-1 gene that are controlled by different promoter
regions!47! and also by alternative splicing of the ET-2 and ET-3 genes
during transcription.!416' 4171 The consequences for translation efficiency
and for subsequent conversion of the endothelin precursors remain to be
shown. Future investigations should also demonstrate whether insertion
polymorphisms identified in the non-coding region of the ET-1 gene!534]
might, like polymorphisms of the ACE gene,!74! prove to be related to risk
of developing cardiovascular disease.
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1.1.2 Processing of endothelin precursors
All of the endothelins are formed through a two-step processing pathway
from their respective precursor peptides. In the case of human ET-1
(Figure 1.4), removal of the signal sequence on secretion of the 212 amino
acid prepro ET-1 from the nucleus to cytoplasm is followed by the first
proteolytic step that cleaves between Lys^-Arg53 and Arg90-Arg91 to
release the 38 amino acid precursor big ET-l.!197! This step is thought to
be similar to the processing of other peptide hormones and may be
dependent on one of the recently described proprotein convertases.!497-
530] Furin, a proprotein convertase of the constitutive secretory pathway,
has been proposed as a likely candidate. 12"1
Big ET-1 is several orders of magnitude less active than ET-1 for
displacement of binding to endothelin receptors and also in stimulating
vascular constriction. t226l Final processing of big ET-1 to release the
biologically active ET-1 requires selective cleavage of the Trp21-Val22
bond in the carboxy terminal of big ET-1, cataysed by activity referred to
as endothelin-converting enzyme (ECE; Figure 1.5). Several ECE-like
enzymes have been identified!415> 579] These include serine proteases,!6351
aspartic proteases!554] an(j cathepsin D,!486! and soluble thiol
protease, !1251 Although inhibitors of these enzymes can prevent conversion
of big ET-1, their contribution to ET-1 biosynthesis is not thought to be of
major physiological significance. 11971
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The physiologically relevant ECE is thought to be a membrane-bound,
zinc-containing metalloprotease that is inhibited by the neutral
endopeptidase (NEP) inhibitor, phosphoramidon.!415] The activity of this
ECE is not affected by thiorphan, another NEP inhibitor, or by inhibitors
of the neutral metalloprotease ACE.
1.1.3 Characteristics of cloned endothelin-converting
enzymes
Purification of rat and bovine ECE!405- 553! was rapidly followed by
molecular cloning and characterisation of the enzyme from rat,!633!
bovine!495! and human tissue.!495! This enzyme, ECE-1, has a neutral pH
optimum and is inhibited by phosphoramidon. A second ECE, ECE-2, has
also been cloned. !152! ECE-2 is also inhibited by phosphoramidon, but has
an acidic pH optimum. The distribution of these enzymes also appears to
be different. ECE-1 is widely distributed but not found in neural tissues
which are known to produce mature endothelins.!633! ECE-2, in contrast is
abundantly expressed in neural tissues. !152!
ECE-1 is an integral membrane protein composed of 754 or 758 amino
acids. These two isoforms probably result from alternative splicing of the
ECE gene during transcription. !641! No differences in the activity of the
two isoforms have yet been discovered, with both forms converting big
ET-1 in preference to big ET-2 or big ET-3, although Northern blot
-analysis suggests that the tissue distribution of these isoforms may be
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different. !582! ECE-1 has a short N-terminal cytoplasmic tail, a
hydrophobic transmembrane domain containing a zinc binding motif that
is common to the catalytic domains of many metalloproteases,!197! is
highly glycosylated!506! and has a number of highly conserved cysteine
residues, and recent studies have suggested that ECE-1 might exist as a
disulphide-linked dimer.!495- 579!
ECE-2 is also an integral membrane protein, composed of 787 amino
acids, with 59% overall sequence homology with ECE-1.1152! The
structure of ECE-2 is similar to ECE-1, it has a short N-terminal, a single
transmembrane domain and a large C-terminal containing a zinc-binding
motif in the catalytic domain. It is also highly glycosylated. ECE-2 also
preferentially converts big ET-1.!152! This substrate selectivity suggests
that there may be yet another ECE(s) selective for big ET-2 or big ET-3
still to be discovered.
The major site for big ET-1 conversion still remains to be conclusively
determined.I197! The current consensus is that endogenous big ET-1 is
most likely to be converted during its transit through the intracellular
constitutive secretory pathways, especially within the Golgi apparatus.i197!
This conclusion is consistent with immunohistochemical staining for ET-1
in the cytoplasm of endothelial cells and the reported ability of a low
density intracellular fraction to convert big ET-1 to the mature peptide.!204'
2091 The pH in the secretory granules of the trans-Golgi network is -5.5,
.within optimum pH range for ECE-2.!1521 Formation of ET-1 in the
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secretory vesicles that can recognise transport pathways would also
provide a suitable mechanism to explain the directional release of ET-1
towards the abluminal surface of endothelial cells.!593! However, ECE-1
which has a neutral pH optimum, would not efficiently convert big ET-1
under the acidic conditions found within the secretory granules. Therefore,
the intracellular location of ECE-1 still remains to be determined.
Despite the fact that endogenous big ET-1 is converted relatively
efficiently by intracellular ECE, a proportion of it is still secreted in the
unconverted form, accounting for the big ET-1 detectable in plasma.!339!
Circulating big ET-1 concentrations are below the Km of ECE-1, but it
seems likely that some of the big ET-1, like exogenously administered big
ET-1,!29' 218, 345, 633] can be converted by plasma membrane-bound ECE-
1. It has been suggested that ECE is localised in caveoli, invaginations of
the plasma membrane that are abundant in endothelial and smooth muscle
cells.!40' 579] -phis could provide a mechanism whereby secreted big ET-1
is concentrated for more efficient conversion by ECE-1. Further studies
will show whether big ET-1 can be secreted directly into these caveoli for
physiological ET-1 synthesis.
1.1.4 Endothelin-converting enzyme inhibitors
While phosphoramidon effectively inhibits ET-1 formation, its therapeutic
potential is limited by its low potency and by its lack of selectivity for
.ECE.!197! IC50 values for inhibition of purified ECE-1 by phosphoramidon
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range from 0.35 mM to 0.8 mM, several orders of magnitude higher than
the IC5o for inhibition of NEP.!405> 507] Several strategies have been used
to develop inhibitors of ECE that are more potent than phosphoramidon.
However, they have not yet met with great success and the development of
ECE-inhibitors as potential therapeutic agents is at least several years
behind the development of endothelin receptor antagonists. Furthermore,
even if selective and potent ECE-inhibitors were to be discovered, they
would still have to overcome the problem of accessability should the
intracellular ECE prove to be of more importance physiologically.
1.1.5 Clearance and degradation of endothelin
The plasma half-life of ET-1 in humans is less than 1.5 minutes because of
its efficient extraction by the splanchnic, pulmonary and renal vascular
beds.!188- 536> 6141 Extraction of ET-1 follows binding to cell surface
receptors, which are then internalised, allowing degradation to be carried
out within the cell!16' 1821 perhaps in lysosomes.!317! The observation that
circulating concentrations of ET-1 are increased by a combined ETa/b
receptor antagonist!3161 or by an ETb receptor antagonist,!1781 but not by
ETa selective antagonists suggests that ETB receptors may be involved in
the clearance of ET-1. Low affinity ETb binding sites that might serve this
purpose have been found in arteries and veins.!196> 5581 Soluble proteases
found in endothelial and vascular smooth muscle cells have been
implicated in intracellular ET-1 degradation.!124' 2471 The endothelins can
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also be degraded by NEP, which is associated with venous and arterial
endothelial cell plasma membranes.!3141
1.2 Endothelin Receptors
Specific binding sites for endothelin are classified according to their
relative affinities to the endothelin isopeptides. The ETA is characterised
by its very high (subnanomolar) affinity for ET-1 and ET-2 and its -100-
fold lower affinity for ET-3.!21! The ETb receptor has high and equal
affinity for all three isopeptides.I48 H These binding site characteristics are
reflected in the agonist potency of the isopeptide in isolated tissues,
demonstrating that the binding sites represent functional receptors.!327' 5981
1.2.1 ETa and ETB receptors
Within 2 years of the initial description of endothelin,!635l the genes
encoding the ETA and ETb receptor subtypes that mediate its actions were
cloned and characterised.!21' 48 H The cDNAs encoding the human ETA
and ETb receptors predict 427 and 442 amino acids, respectively, and the
overall identity between the two mature proteins is reported to be between
55% and 64%, depending on the tissue studied.!7' 22, 150, 222] The gjA anc]
ETb receptor genes, located on chromosome 4t234l and 13,!221 respectively
have similar structural organisation suggesting that they originated from a
common ancestral gene.
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As with the endothelin genes, the nontranscribed 5' flanking regions of the
endothelin receptor genes contain a number of regions involved in
regulation of gene transcription. Exogenous factors can act through these
regions to increase receptor transcription. For example, ETA receptor
mRNA is upregulated by insulin!172! and ETB receptor mRNA by ANG
II [256] These mechanisms may be important in regulation of
responsiveness to the endothelins in pathophysiological states. ETe
receptor mRNA is selectively increased in marmosets fed a high
cholesterol diet!150! and following glycerol-induced acute renal failure in
rats.I469! In contrast, endothelin receptor expression is reduced in
atherosclerotic human arteries!625! and in the lungs of rats with pulmonary
hypertension.!640! One of the major factors that reduces endothelin
receptor number is prolonged exposure to ET-1 itself, because of down-
regulation or feedback inhibition of receptor expression,!227! or both of
these in combination. In endothelial cells, ETB receptor expression is
decreased because exposure to high local concentrations of ET-1 reduces
the stability of mRNA molecules rather than reducing transcription. !480!
All the cloned endothelin receptor genes predict a heptahelical membrane
spanning structure, common to members of the G-protein-coupled receptor
superfamily and similar to many neuroreceptors.!70! The transcribed region
of both receptor genes encode sites for post-translational modification that
influence the tertiary structure of the receptor and its linkage to
intracellular messenger systems, including consensus sites for N-
glycosylation, several potential sites for palmitoylation to anchor the
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receptor to the cell membrane, and serine residues that may be substrates
for regulatory phosphorylation by serine threonine kinases.!150> 233, 380,
400] phosphorylation may play a role in the down-regulation of endothelin
receptors that follows prolonged exposure to the endothelin isopetides.!227-
348, 467]
1.2.2 Pharmacological evidence suggesting the existence of
additional receptors
Based on studies of cultured rat anterior pituitary cells,!334] rat PC 12
phaeochromocytoma cells,!483] and cultured human endothelial cells,!638]
the existence of a receptor specific for ET-3 has been suggested. Indeed, a
putative ETC receptor subtype, relatively selective for ET-3, has been
cloned from Xenopus dermal melanophores.!2^0] However, Southern blot
analysis of human DNA revealed the existence of only two endothelin
receptor genes, probably corresponding to the ETA and ETB genes.!477]
Indeed, an analysis of human endothelin genes revealed eight and seven
exons for ETA and ETB genes, respectively, and suggested only one
product from each gene.!22' 234] Additional mammalian endothelin
receptors, if they exist, must be markedly different from both ETA and ETB
receptors.
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1.2.3 Agonists at endothelin receptors
All the endothelin and sarafotoxin peptides possess four cysteinyl residues
that form two disulphide bridges, three polar charged side chains (residues
8-10) and a well-conserved hydrophobic C-terminus (residues 16-21,
Figure 1.3). Examination of the binding characteristics of these peptides
reveals that the ETA receptor has much more rigid structural requiremnts
for ligand binding than the ETB receptor.!15^> 236, 523] Both the amino-
terminal loop structure and the carboxy terminal linear portion with Trp in
position 21 are vital for high affinity ETA receptor binding. In contrast,
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only the linear carboxy terminal and the Trp are essential for high affinity
binding to the ETB receptor.!2681 ET-3 and sarafotoxin S6c can be
considered ETB selective ligands, ET-3 having -2000-fold and sarafotoxin
S6c -30 000-fold selectivity for binding to ETB rather than the ETA
receptor. !6231 Although both of these ligands contain loop and linear
portions like ET-1, they have different amino acid sequences within the
inner loop portion, which might account for their lower affinity at the ETA
receptor.
1.2.4 Endothelin receptor antagonists
Since the first description of compounds that could inhibit the binding or
actions of ET-1 in 1991,!238- 5261 a large number of endothelin receptor
antagonists, peptide and nonpeptide, selective and nonselective, have
become available (Table 1.2).!198'320' 5971
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Peptide antagonists have been obtained by chemical modification of ET-1
itself, or of microbial products with endothelin receptor binding
activity!238- 526! BQ-123 is a cyclic pentapeptide derived from microbial
broth that has relatively high potency for binding to the ETA receptor!239!
Although several ETA antagonists are now available, studies using BQ-123
first confirmed the role of endothelin in a number of pathologies!368! BQ-
788,C243! is a peptide compound that is more selective for inhibition of ET-
1 binding to the ETB receptor. The first nonselective endothelin receptor
antagonists to be described were also peptides!101- 296! TAK-044, is a
cyclic hexapeptide with ~20-fold higher affinity at the ETA compared with
the ETb receptor!267! This compound, unlike many of the other peptide
antagonists, has a relatively long duration of action following intravenous
administration in vivo!241! Although useful as research tools, the potential
of peptides as therapeutic agents may be limited by their short duration of
action, as well as by their lack of oral availability.
Potent nonpeptide antagonists have been developed through optimisation
of compounds isolated from plant extracts!173- 349^ and microbial
brothst403! or screened from chemical libraries!92- 93> 372> 404- 529! SB
209670, a nonselective antagonist, is amongst the most potent of these and
inhibits the actions of ET-1 whether administerd intravenously or
orally!140- 404!
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1.2.5 Distribution and function of endothelin receptors in the
cardiovascular system
In vascular tissue, ETA receptor mRNA is expressed predominantly in
smooth muscle,!21- 232> 636! while ETB receptor mRNA is most abundant
in endothelial cells.!233> 360> 400> 625! These findings are consistent with the
view that constriction of vascular smooth muscle is mediated
predominantly by ETA receptors and that constriction is modified by
release of relaxing factors from the endothelium through stimulation of
ETb receptors (Figure 1.6). Elowever, ETB receptor mRNA is detectable in
vascular smooth muscle cells!43' 118> 328> 6251 and ETB selective agonists
can evoke constriction in vz7ro!369> 503> 54°! and pressor responses in
vivo.!58' 94> 6231 These observations suggest the presence of ETB receptors
that mediate constriction of vascular smooth muscle cells (Figure 1.6).
The relative contributions of ETA and ETB receptors to vasoconstriction is
variable and depends on species and the vessel type studied.!116! ETB
receptors are generally more important in the low pressure venous
circulation.!368! In isolated human blood vessels, it is the ETA receptor
subtype that primarily mediates constriction in large calibre arteries,!1161
but recent studies show that the relative functional role of ETB receptors is
greater in small calibre arteries.!127' 556> 577! The balance of receptors may
be altered under pathophysiological conditions. For example, ETB receptor
expression is increased during the change of cultured vascular smooth
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muscle cells from a contractile to synthetic phenotype,!147! in
hypertension!431 and under the influence of ANG II.!256!
1.2.6 Distribution and function of endothelin peptides and
receptors in the kidney
The kidney is an important organ for endothelin synthesis, and ET-1 is
produced by endothelial,!3331 mesangial,!32' 237> 278> 280> 478! glomerular
epithelial!261' 4071 and medullary collecting duct cells.!272"275' 279!
Although studies in rats and cell cultures also demonstrated ET-3
production in mesangial cells and glomerular epithelial cells,!274! no ET-3
production in the human kidney has been demonstrated.!257>259!
Mesangial endothelin synthesis is regulated by factors and mechanisms
similar to endothelial cells!276' 277> 51 ^ and is stimulated by various
humoral factors involved in glomerular injury, such as thrombin,
transforming growth factor 13 (TGF- B) and ANG II.!479] In general,
mesangial cell endothelin production is increased by activation of PKC and
reduced by activation of protein kinase A or cGMP.!276! Interestingly,
endothelin can auto induce its own production by stimulation of ETb
receptors on mesangial cells.!246] The regulation of endothelin synthesis by
medullary cells is still largely unknown, although osmolarity and water
balance are thought to play a significant role.!279> 50°!
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The human kidney, as in the dog, is rich in ETg receptors and these
predominate at least two-fold over ETa receptors with the ETA receptor
being mainly confined to the vasculature.!68' 258> 383i However, the ETA
receptor predominates in the rat kidney with renal vasoconstriction
predominantly mediated by ETb receptors, !12 f 616i As a consequence of
the inter-species variations in renal endothelin receptor function, caution
should be taken when extrapolating the results from animal experiments to
humans.
Endothelin may act both in an endocrine (endothelin derived from the
systemic circulation) as well as in an autocrine/paracrine manner
(endothelin derived from the kidney itself). Infusions of ET-1 may mimic
the former mode of action, while the autocrine/paracrine actions can only
be evaluated by studying tissue expression of endothelin and the effects of
intrarenal endothelin receptor antagonists.
Administration of low dosages of ET-1 in humans that increase plasma
concentrations two-fold produce sustained renal vasoconstriction.!442' 524>
614i From in vitro studies, it appears that the reduction in renal blood flow
is caused by constriction of the glomerular afferent and efferent arterioles,
and the arcuate and interlobar arteries.!30' 145> 269> 288] In addition, ET-1
can reduce ultrafiltration coefficient by mesangial contraction. !311
Administration of ET-1 in humans also consistently induces sodium
retention!59' 252> 442> 5241 even at very low doses of ET-1 that do not affect
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renal blood flow, GFR or the renin-angiotensin system. 14421 In contrast,
studies in the isolated perfused rat kidney have consistently shown a
natriuretic effect.!160> 4331 Similarly, several rat studies report a natriuretic
effect of low dose systemic administration of ET-1, despite a fall in GFR
and renal blood flow.!208' 4321 This natriuresis may be due to stimulation
of atrial natriuretic peptide (ANP)!373! or pressure natriuresis secondary to
a higher blood pressure during endothelin infusion.!269] These findings
suggest that the actions of endothelin on sodium excretion depend on a
balance between sodium retaining and natriuretic factors. In humans, it
appears that the predominate effect of small increases in plasma endothelin
concentration is sodium retention.
The physiological importance of possible autocrine actions of endothelin
in the kidney are still unclear. Studies using intrarenal administration of
endothelin receptor antagonists have shown no significant effect on renal
blood flow and sodium excretion!119>437> 5591 under basal conditions while
one study demonstrated an increase in renal blood flow and sodium
excretion.!67^ As yet, there have been no studies of the actions of
endothelin receptor antagonism on renal sodium handling in humans.
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1.3 Endothelin in the Pathophysiology of Cardiovascular
and Renal Disease and the Clinical Potential of
Endothelin Receptor Antagonists
There are many endothelin receptor antagonists either in, or shortly to be
entering, clinical development (Table 1.2). Some are peptidic in nature and
only likely to be suitable for short term use, whereas others are orally
active and may, therefore, have wider applications in the treatment of
cardiovascular disease. Some are ETA selective, whereas others are
combined ETa/ETb antagonists. As vascular smooth muscle ETA and ETb
receptors can both mediate vasoconstriction in humans!-17' 577i there may
be some advantages from blocking both of these receptors. However, there
may be some benefits from leaving the endothelial ETb receptor, which is
known to mediate vasodilatation, unaffected. Indeed, there is some
evidence that the endothelial and smooth muscle ETb receptors can be
distinguished pharmacologically!595] so it may be possible to develop
agents with appropriate selectivity.
A pathophysiological role for the endothelins has been postulated in a wide
number of diseases!219' 471] -p^g secti0n specifically examines the
evidence implicating ET-1 in the pathophysiology of cardiovascular




Over the last 20 years, it has become well established that the vascular
endothelium plays a fundamental role in the regulation of cardiovascular
function. !588! Endothelial cells produce both vasodilating substances such
as prostacyclin,!361' 3631 NO,!421- 4221 C-type natriuretic peptide
(CNP)!284> 285! and endothelium-derived hyperpolarising factor!589] as
well as vasoconstricting substances such as thromboxane Ai!363! and
endothelin.!635! Hypertension is characterised by increased peripheral
vascular resistance!430! and may, therefore, be associated with a
generalised dysfunction of either an endothelium-dependent vasodilator!17'
362, 583] or vasoconstrictor system!635! or both. Both NOf216> 448> 449> 584!
and endothelin!218! have been shown to contribute to the maintenance of
basal vascular tone and have, so far, been the major focus of research
activity into endothelial dysfunction in hypertension. In this section I will
consider the evidence supporting a generalised dysfunction of the
endothelium in hypertension and why modulation of endothelial function
may be an attractive therapeutic concept in the treatment of hypertension.
NO is synthesised from L-arginine by a family of nitric oxide synthases
(NOS).!421! The isoform present in endothelial cells is calcium-
dependent, !297! constitutively expressed!297! and is modulated by several
stimuli including shear stress!69- 501! and hormones,!612! as well as by
receptor activation by agonists such as acetylcholine (ACh), bradykinin
'and substance P (Figure 1.7).!494! Basally produced NO is important in the
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regulation of vascular tone!584! and blood pressure!215' 448' 4491 as well as
in inhibition of platelet aggregation.!4431 NO also inhibits mitogenesis and
proliferation of vascular smooth muscle cells (Figure 1.8).n 87]
It has been proposed that a deficiency of endogenous NO would lead to
impaired vasodilatation and a rise in peripheral vascular resistance leading
to hypertension.!17' 362> 5851 The antiplatelet!443] and antiproliferative
actions! 1871 of NO may also be connected with the consequences of
sustained hypertension such as vascular hypertrophy, atherosclerosis,
stroke and myocardial infarction. The evidence for this hypothesis is based
on experiments using animal models of hypertension as well as in studies
in patients with essential hypertension.
Several studies using both large conduit and resistance arteries taken from
different animal models of hypertension have demonstrated impaired
endothelium-dependent dilatation to ACh, but not to endothelium-
independent NO donors such as sodium nitroprusside (SNP) or glyceryl
trinitrate, in vitro. !7^> 131-133, 235, 315, 321, 322, 508, 626, 632, 645] Chronic
administration of inhibitors of NO synthesis, such as L-
monomethylarginine (L-NMMA) and NG-nitro-L-arginine methyl ester (L-
NAME), produce a hypertensive response in both normotensive
animals!23- 448. 449] humans.!2151 Conversely, treatment with L-
arginine prevents the development of hypertension in salt-sensitive Dahl
rats and spontaneously hypertensive rats.!86! Studies in patients with
'essential hypertension have demonstrated a blunted decrease in forearm
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blood flow induced by L-NMMA compared with normotensive
controls.!73' 323i Furthermore, several studies have also demonstrated
impaired endothelium-dependent vasodilatation to ACh in the forearm
circulation of patients with essential!228- 312> 423-428, 546-550] ancj
secondary hypertension. !550! Paradoxical vasoconstrictor responses to ACh
are enhanced in epicardial coronary arteries and vasodialatation to ACh is
impaired in the coronary microcirculation (especially if left ventricular
hypertrophy is present). !146> 573> 574> 6481 It has been suggested that the
response to NO in hypertensive animals and patients may be masked by the
concomitant release of vasoconstrictor prostaglandins as an apparently
impaired relaxation to ACh is normalised by cotreatment with inhibitors of
cyclooxygenase.!130- 547! However, different mechanisms may be
simultaneously involved since L-NMMA does not inhibit the
vasodilatation to ACh in hypertensive patients suggesting a defect in the L-
arginine-NO pathway.!4251
This evidence appears to present a strong case for a generalised defect in
endothelial NO production. However, not all in vitro studies using vessels
taken from hypertensive animals!18- 19> 575! and humans!19! have
demonstrated impaired relaxation to ACh. Also, not all studies in have
demonstrated impaired vasodilatation to ACh in the forearm circulation of
hypertensive patients.!78- 96! Some of these differences may be in part
explained by the use of different vessels taken from different animal
models of hypertension and the selection of hypertensive patient
•populations. Nevertheless, several potential problems with the use of ACh
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as a tool for investigating endothelial function have been highlighted and
caution must be taken when interpreting the results of studies using ACh
as an endothelium-dependent agonist.!191 However, the existence of a
dysfunctional endothelium in hypertension is further supported by the
demonstration of impaired relaxation to other endothelium-dependent
agonists, such as substance P and bradykinin, in both hypertensive
animals!235! and humans. 1146> 263> 4241
Recent work has shown that the activity of NO synthase is increased in
mesenteric arteries taken from spontaneously hypertensive rats (SHR)
compared with normotensive controls!3 841 and the plasma concentration of
nitrate, the oxidative product from of NO, is higher in stroke-prone SHR
than in normotensive rats,!385! suggesting that there is no deficiency of NO
synthesis in this animal model of hypertension. However, the capacity of
the vascular smooth muscle to respond to NO is not impaired as shown by
the normal response to organic nitrates.!1301 These findings suggest that
there must be some factor preventing endothelium-derived NO from
eliciting normal vasodilator responses in this animal model. Oxidative
stress has been implicated in the pathophysiology of some cardiovascular
conditions!381' 402> 56°! and interestingly, it has recently been demonstrated
that the release of NO from isolated resistance vessels is improved in the
stroke-prone SHR in the presence of superoxide dismutase.!576! Thus an
increase in the production of oxidative radicals, such as superoxide, or a
fall in the superoxide dismutase activity may cause an increase in the
degradation of NO. These findings suggest the exciting possibility that
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endothelial dysfunction in hypertension may be reversed by administration
of antioxidatants, raising the prospect of novel therapeutic approaches to
the treatment of essential hypertension. Indeed, antioxidants have already
been found to reverse endothelial dysfunction in hypercholesterolaemic
patients!192] as wep as lowering the incidence of cardiovascular events and
mortality in patients with ischaemic coronary artery disease.!532!
Antihypertensive drugs which have a beneficial effect on endothelial
function by direct action on the L-arginine-NO system, or indeed
antihypertensive agents with antioxidant actions, may have additional
benefits in the treatment of hypertension. Such agents could be more
effective in further reducing the vascular consequences of high blood
pressure, such as atherosclerosis and smooth muscle hypertrophy, and
could potentially further reduce the incidence of associated cardiovascular
events, such as stroke and myocardial infarction.
In their original paper, Yanagisawa and colleagues!635! suggested that
disturbances in the control of endothelin production could contribute to the
pathogenesis of hypertension. In addition to its vasoconstrictor and pressor
effects, ET-1 has positively inotropic!244! and mitogenic!512! properties,
has an antinatriuretic action,!442' 524! increases central!325- 390] anc]
peripheral sympathetic activity, !545> 6291 and stimulates generation of renin,
ANG II,!444! aldosterone!110! and adrenaline.!63! Furthermore, ET-1
potentiates, at threshold and subthreshold concentrations, contractile
responses to other vasoconstrictor substances such as noradrenaline and
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serotonin.t637] It would, therefore, appear to be entirely appropriate to
examine the potential for ET-1 to be involved in the pathophysiology of
hypertension. Knockout gene experiments are unrevealing in this regard.
ET-1,!294! ET-3,!44! ETa!90! and ETb!44! knockouts all cause severe
developmental disturbances, which shows the importance of the
endothelins in growth and development, but is not helpful concerning their
physiological effects in cardiovascular regulation.
Plasma endothelin concentrations are not raised in animal models of
hypertension unless malignant hypertension or renal dysfunction are
present.!282! However, because ET-1 is preferentially secreted
abluminally!593- 643! locally increased production may not necessarily
result in raised plasma endothelin concentrations. Indeed, increased
immunoreactive endothelin concentrations have been reported in both
aortic and mesenteric arteries of DOCA-salt hypertensive rats, despite
normal plasma endothelin concentrations, suggesting that increased
vascular generation of ET-1 may be involved in some forms of
hypertension. !301J
In vitro studies using resistance arteries taken from animal models of
hypertension have shown either increased!9!] or decreased!132! vascular
sensitivity to ET-1. Systemic doses of ET-1 in vivo have greater pressor
effects in SHR than in Wistar-Kyoto rats!356! and in renovascular
hypertensive than normotensive rabbits!459!. The interpretation of these
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results is difficult given the propensity for vascular hypertrophy to non-
specifically enhance responses to vasoconstrictors.
Endothelin-specific antibodies!406! and the selective ET^ antagonists BQ-
1231138] ancj FR139317!174! have been shown to lower blood pressure in
animal models of hypertension. Chronic administration of BQ-123 has
been reported to prevent the development of stroke and renal abnormalities
in stroke-prone SHR!389!. Non-peptide combined ETa/ETb receptor
antagonists SB 2096701404] and Ro 46-2005!92! lower blood pressure in
SHR and conscious normotensive salt depleted monkeys respectively.
Although some studies have reported a reduction of blood pressure only in
hypertensive animals, it must be remembered that the absolute effects of
antihypertensive agents are proportionately greater the higher the
pretreatment blood pressure. Few studies have been of sufficient power to
justify the interpretation that endothelin receptor antagonists lower blood
pressure only in hypertensive animals.
Plasma endothelin concentrations are not raised in patients with essential
hypertension and normal renal function,!114' 218! although very high
concentrations are found in severe and malignant hypertension!642!
probably as a result of impaired renal clearance. Increased plasma
endothelin has been reported in the presence of normal renal function in
patients with pre-eclampsia.!167! Plasma endothelin was also increased in
two patients who developed hypertension with the skin tumour haemangio-
•endothelioma.!639! Tumour cells showed increased expression of ET-1
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mRNA and increased staining for the peptide. Blood pressure returned to
normal in both cases after tumour resection and recurrence of the tumour in
one of the patients was associated with a further rise in blood pressure and
plasma endothelin.
Sensitivity to ET-1 in vitro appears to be decreased in resistance arteries
taken from hypertensive patients!490! but increased in the capacitance
vessels of hypertensive patients in vz'vo.!213! These latter vessels do not
develop hypertrophy. Thus, it is possible that increased sensitivity to, and
not necessarily increased production of, ET-1 may be involved in the
pathophysiology of hypertension, indicating an abnormality at the receptor
or post-receptor level.
Hypertension is associated with the development of several cardiovascular
diseases, including angina pectoris, myocardial infarction, peripheral
vascular disease and cerebrovascular disease. It is possible that the
vasoconstrictive properties of ET-1 could contribute to myocardial
ischaemia and that the proliferative effects of ET-1 could contribute to
vascular and cardiac hypertrophy and the atherosclerotic process (Figure
1.8). Indeed, plasma endothelin concentrations are raised in advanced
atherosclerosis!308!, and expression of ET-1 mRNA is increased in the
vascular smooth muscle of atherosclerotic human arteries.!625!
Furthermore, increased tissue endothelin immunoreactivity has been
reported in the active atherosclerotic lesions associated with unstable
-angina. !649! With the multitude of drugs already available to treat
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hypertension, a new class of antihypertensive agents may seem
unnecessary. However, endothelin receptor antagonists may prove more
effective than current therapies in preventing or reversing some of the
important complications that are little affected by current therapy, such as
myocardial infarction. !106! In a recent multicentre study, bosentan, a
combined ETa/ETb receptor antagonist, has been reported to lower blood
pressure in patients with essential hypertension. !29°! Further longer term
studies with outcome data are now eagerly awaited.
1.3.2 Unstable angina and myocardial infarction
The sarafotoxins, potent vasoconstrictor peptides isolated from snake
venom with close structural similarity to the endothelins, cause death from
myocardial ischaemia and infarction secondary to coronary
vasoconstriction.!555! Exogenously administered ET-1 also produces
myocardial ischaemia!293] by causing coronary vasoconstriction. Plasma
endothelin concentrations!590! and myocardial ET-1 binding sites!313] are
increased during reperfusion following ischaemia in animals. Interestingly,
in animal models of myocardial infarction, ECE inhibitors!203!,
monoclonal antibodies against ET-1 !601!, selective ETa antagonists!202!
and combined ETa/ETb antagonists!600! have been reported to reduce
myocardial infarct size.
In humans, plasma endothelin is raised in acute myocardial infarction and
unstable angina,t358! suggesting a possible pathophysiological role for ET-
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1, whereas patients with stable angina do not have raised plasma
endothelin.!446! The higher the plasma endothelin in myocardial
infarction!413! and unstable anginal619! the worse the prognosis. Plasma
endothelin concentrations on the third day after myocardial infarction
significantly related to mortality,!413! and plasma endothelin
concentrations at 9 weeks after hospitalisation with unstable angina or non
Q-wave myocardial infarction significantly related to the incidence of
further cardiovascular events.!619! Patients undergoing fibrinolysis during
the acute phases of myocardial infarction have been shown to have reduced
plasma endothelin compared with patients who did not have early
reperfusion.!302! As previously discussed, the increased tissue endothelin
immunoreactivity in active atherosclerotic plaques causing unstable
angina!649! suggests a possible local role for ET-1 in the associated
vasospasm.
The use of endothelin receptor antagonists in acute myocardial infarction
may be of clinical benefit. First, they may limit infarct size and thereby
reduce or slow the progression to heart failure. Second, they may reduce
the incidence of further ischaemic events or the need for revascularisation.
Third, they may prevent remodelling after infarction, possibly in a similar
fashion to ACE inhibitors. However, given the wide range of drugs
currently available for the treatment of myocardial infarction, and the likely
diminishing returns with additional therapy, companies may be wary of
developing endothelin receptor antagonists in this indication.
Coronary sinus ET-1 levels are raised during and immediately after
percutaneous transluminal coronary angiography (PTCA)!551]. Although,
ET-1 could be involved in the ischaemia, acute vasospasm, and abrupt
vessel closure related to PTCA, these complications are uncommon and
readily reversible with conventional therapy. The main weakness of PTCA
is the relatively high later risk of restenosis. Clinical restenosis occurs in up
to 30% of patients within the first year following the procedure!347] and is
characteristically associated with vascular smooth muscle proliferation.
Although there is currently no experimental evidence that endothelin
antagonists reduce experimental restenosis, it is conceivable, given the co-
mitogenic actions of ET-1, that prolonged treatment with an oral
endothelin antagonist might be useful. Similar arguments are relevant to
graft occlusion after coronary artery bypass grafting.
1.3.3 Varaint angina
Prinzmetal's or variant angina, first described in 1959,!440] is characterised
by chest pain developing at rest, frequently in the early morning, and
associated with ST elevation on the electrocardiogram. The pain is usually
relieved by glyceryl trinitrate. Coronary spasm has been demonstrated at
angiography in patients with this condition, as well as the absence of fixed
stenotic lesions.!129]
Patients with variant angina are known to have endothelial dysfunction
•affecting the L-arginine-NO system!441] and, as a powerful vasoconstrictor
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of human!637] and canine!293] coronary arteries, ET-1 has been implicated
in the pathophysiology of this condition.!319] ET-1 also potentiates the
coronary vasoconstriction induced by serotonin and noradrenaline in
isolated human arteries.!637] Patients with variant angina have elevated
plasma endothelin concentrations during provocation of coronary
vasospasm!341] and one study has also found basal plasma concentrations
of endothelin to be elevated.!241 Interestingly, there is an increased
prevalence of primary Raynaud's disease and migraine in patients with
variant angina!35 E 409i and, as discussed later, ET-1 has also been
implicated in the pathophysiology of these vasospastic disorders.
It appears, therefore, that ET-1 has a pathophysiological role in variant
angina, either as a mediator of coronary vasospasm or by sensitising the
vasculature to other vasoconstrictors. In either case, endothelin receptor
antagonists might prove useful in the management of this condition.
1.3.4 Heart Failure
Many definitions of congestive heart failure (CHF) exist but highlight only
selected features of this complex syndrome.!563! Patients with CHF are
typically breathless or fatigued, either at rest or during exertion, develop
ankle swelling and have objective evidence of major cardiac dysfunction at
rest.!563] Neuroendocrine activation occurs in patients with CHFt171> 563l
and elevation of plasma concentrations of noradrenaline, renin, ANG II and
'aldosterone are related to the severity and prognosis of heart failure.!54j]
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However, in individual patients these predictors are inaccurate and difficult
to interpret because diuretics, vasodilator agents and ACE inhibitors alter
plasma concentrations in a complex fashion.!563' 587] indeed, plasma renin
activity is not raised in patients with left ventricular dysfunction without
CHF not treated with diuretics.!171] Furthermore, plasma renin activity is
stimulated in patients with CHF treated with diuretics despite symptomatic
improvement, decreased sympathetic activity and decreased plasma
natriuretic peptide concentrations.!587]
Intravenous ET-1 raises blood pressure, increases peripheral and coronary
vascular resistance, and decreases cardiac output,!352] despite having
positive inotropic!166] and chronotropic!244] actions. ET-1 also reduces
renal blood flow and GFR, in association with a reduction in sodium
excretion, an increase in plasma renin-aldosterone activity, and increased
plasma concentrations of ANP, vasopressin and aldosterone.!352] ET-1
may, therefore, be involved in the pathophysiology of CHF as part of the
neurohumoral response to cardiac failure!535] and its actions would
certainly contribute to the vicious circle of haemodynamic decline
associated with this condition.
Plasma endothelin concentrations are raised in animal models of CHF!8°]
and in patients with CHF.!346] In patients, the increase in plasma
endothelin concentration correlates closely with the degree of
haemodynamic and functional impairment, !420> 61J] with higher
concentrations predicting a greater likelihood of death or need for cardiac
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transplantation.!420! Although impaired renal function and decreased
clearance of ET-1 may be involved in generating high plasma endothelin
concentrations, raised plasma concentrations of big ET-l!420> 61 ^ suggest
that increased production may also contribute. Also, ET-1 release by
cultured cells is increased in the presence of ANG II and vasopressin,
plasma concentrations of which are elevated in CHF.n 51]
The ETa receptor antagonist, BQ-123, and the ECE inhibitor,
phosphoramidon, cause arterial vasodilatation when infused into the
forearm circulation of patients with stable CHF already on treatment with a
loop diuretic and a maximal dose of an ACE inhibitor. !218! In comparison
to healthy subjects, vasodilatation to BQ-123 tended to be reduced, and to
phosphoramidon increased in patients with CHF, consistent with
upregulation of ETb mediated vasoconstriction. More recent studies with
ET-1 and the ETg specific agonist, sarafotoxin S6c, are also consistent
with this hypothesis!2181. ANG II concentrations are increased in CHF and,
interestingly, ANG II has been shown to down-regulate total endothelin
binding sites!466! but up-regulate ETb receptor mRNA!256!. Given that
ETb receptors can mediate vasoconstriction,!217! it may be that smooth
muscle ETb receptors have greater functional significance in CHF.
Encouragingly, recent studies have shown that administration of systemic
doses of the combined ETa/ETb antagonist, bosentan, to patients with
severe chronic heart failure produces sustained systemic, pulmonary and
peripheral venous vasodilatation, and improved cardiac performance,
'without causing reflex tachycardia.!271! These haemodynamic effects show
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a similar pattern to those seen with ACE inhibitors and so justify the
further clinical development of combined ETa/ETb antagonists for the
treatment of CHF. Vasodilatation has proved to be the most effective of the
recent therapeutic approaches to CHF!102> 562] and, therefore, the results of
longer term clinical studies of endothelin receptor antagonists in CHF
patients must be awaited with interest.
1.3.5 Primary pulmonary hypertension
Primary pulmonary hypertension (PPH) is a rare condition of unknown
aetiology. It mainly affects young people, causes progressive shortness of
breath, and most of those affected are dead within 4 years of diagnosis.!72'
484] jhe condition is characterised by endothelial injury and by
proliferation of pulmonary arterial smooth muscle.!72! Although smooth
muscle proliferation may be the major cause of luminal narrowing in this
condition,!387! a role for vasoconstriction has also been proposed.!630!
Indeed, some patients do have favourable haemodynamic and symptomatic
responses to vasodilators such as isoproterenol, hydralazine and
nifedipine.!484!
Depending on the state of vasomotor tone, endothelin isopeptides can
cause either pulmonary vasoconstriction or vasodilatation.!41! Under basal
conditions ET-1, -2 and -3 contract pulmonary vascular rings!570' 628! and
increase pulmonary vascular resistance in the perfused vascular beds of
/
several species.!23h 570] However, when vascular tone is already high, as
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in the foetus, or has been raised pharmacologically, these peptides induce a
dose-related pulmonary vasodilatation.t570- 6281 The constrictor response is
mediated by the ETa receptor, whereas the dilator response is ETg
mediated. !411 ET-1 also stimulates DNA synthesis and proliferation of
pulmonary artery smooth muscle cells.!2491 In fawn-hooded rats (FHR), a
strain which spontaneously develops pulmonary hypertension, plasma
endothelin concentrations are not elevated.!53 ^ However, tissue endothelin
concentration are two-fold higher and preproET-1 mRNA expression is
three-fold higher in whole lung homogenates from FHR compared with
controls. Interestingly, preproET-1 mRNA expression is increased in FHR
even before the development of pulmonary hypertension. Furthermore,
neither endothelin nor preproendothelin mRNA concentrations are raised
in adult control rats with an equivalent amount of pulmonary hypertension
due to chronic hypoxia.!531] These findings suggest that raised endothelin
production may be directly involved in the pathogenesis of PPH and not
just a secondary phenomenon.
ET-1 produces concentration-dependent vasoconstriction under basal
conditions of human pulmonary arteries!2101 and stimulates the
proliferation of pulmonary artery smooth muscle cells.!646] This
proliferation appears to be mediated by the ETa receptor, because it is
inhibited by the selective ETa receptor antagonist, BQ-123.!646!
Expression of ET-1 mRNA is increased in vascular endothelial cells of
patients with PPH, with a strong positive correlation between the intensity
J
of ET-1-like immunoreactivity and pulmonary vascular resistance.!191]
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Unlike the FHR, patients with PPH, and those with pulmonary
hypertension due to other causes, have increased circulating endothelin
concentrations which might reflect changes in production or clearance of
endothelin by the lung.!191! However, only patients with PPH have high
arterial, compared with venous concentrations, suggesting that only these
patients have increased pulmonary production of endothelin.!191]
Therefore, increased endothelin synthesis may contribute to the elevated
pulmonary vascular resistance observed in this condition.
Direct assessment of the functional importance of endothelin in PPH
awaits studies with endothelin receptor antagonists or ECE inhibitors.
These agents could, potentially, reduce the progression of both structural
and functional narrowing of pulmonary arteries. Given that ET-1 can cause
ETg receptor mediated vasodilatation in conditions of raised pulmonary
vascular tone it may be that selective ETa antagonists will prove more
useful than combined ETa/b antagonists in this condition.
1.3.6 Raynaud's disease
Raynaud's disease!447! is a common condition in colder climates. It is
characterised by the development of episodic ischaemia, usually in exposed
extremities and associated with exposure to cold, hormones, drugs and
emotional stimuli.H 08] Although many treatments are available for patients
with Raynaud's disease, none is effective in the majority of subjects.!141'
•6271 Currently, the pathophysiology of Raynaud's disease remains
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unresolved. However, there is an association between Raynaud's disease
and other vasospastic conditions, including migraine and variant
angina,!351- 409] suggesting that there may be a vascular defect common to
these conditions. In the rabbit ear artery, responses to ET-1 are temperature
dependent and, under physiological conditions, the vasoconstriction to ET-
1 is attenuated by an increase in endothelial NO production during
cooling.!364] A defect in endothelium-dependent dilatation in the veins of
patients with Raynaud's disease has been reported,!46] suggesting that the
defect is widely expressed in blood vessels. Overproduction of ET-1,
reduced production of endothelium-dependent vasodilator substances, or a
combination of these effects, may account for the vasospasm seen in
Raynaud's disease.
Clinical studies have shown that plasma endothelin increases rapidly
during the cold-pressor test in healthy subjects, peaking at four minutes
after immersion of the arm in cold water.!180] Cold provocation tests in
patients with Raynaud's disease have shown an exaggerated increase in
endothelin concentrations in venous blood draining from the cold-
challenged arm, compared with both the control arm and with responses in
healthy control subjects.!647] Elevated basal plasma endothelin
concentrations have been reported in Raynaud's patients between
vasospastic episodes consistent with increased production.!647] During
basal conditions, resistance arteries taken from patients with Raynaud's do
not appear to have abnormal sensitivity to ET-1.!521] This suggests that any
.abnormality in the endothelin system in Raynaud's disease is a result of
59
increased ET-1 production or increased sensitivity to ET-1 during a
vasospastic event.
These results, taken as a whole, appear to support a role for ET-1 in the
pathophysiology of Raynaud's disease. However, there have so far been no
confirmatory studies using endothelin antagonists. Endothelin antagonists
would need to be more effective or better tolerated than the current drugs
of choice, the calcium channel blockers nifedipine and diltiazem,!141] if
they are to achieve widespread use in the treatment of Raynaud's disease.
1.3.6 Subarachnoid haemorrhage
The development of delayed cerebral vasospasm within the first two weeks
after subarachnoid haemorrhage (SAH) is responsible for much of the
morbidity and mortality associated with this condition.!25' 499] has
been implicated in mediating SAH-induced vasospasm. ET-1 is a potent
vasoconstrictor of isolated cerebral arteries!26^ and its effects are
potentiated after SAH.!1 E Plasma endothelin levels are raised in a canine
model of SAH!634! and injection of exogenous ET-1 into the cerebrospinal
fluid (CSF) of dogs reproduces the vasospasm that occurs following
SAH.!26! Furthermore, both thrombin and oxyhaemoglobin, which are
present in high concentrations in SAH, are known to induce ET-1
release.!344- 493,635]
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Inhibition of the enzymatic conversion of big ET-l to ET-1 by
phosphoramidon reduces the vasospasm seen in a dog model of SAH,134°1
as does administration of monoclonal antibodies to ET-1 C6343. Selective
ETa antagonists BQ-123,192! BQ-485l245i and FR1393171388! have also
been shown to reduce vasospasm in animal models of SAH. The mixed
ETa ETb antagonist, Ro 46-2005, markedly reduces the cerebral
vasoconstriction seen in a rat model of SAH without lowering systemic
blood pressure. 1921 This finding is of great significance because the major
potential complication of nimodipine, the currently preferred drug
treatment for SAH,1I371 and for any other vasodilator used in the treatment
of SAH, is hypotension sufficient to compromise cerebral perfusion.
Plasma and CSF endothelin concentrations are significantly raised in
patients after SAHl336> 4"1 and the plasma levels of endothelin are highest
in those patients who develop vasospasm. 15421 Thus, it appears that ET-1
may be implicated in the pathophysiology of delayed vasospasm following
SAH in humans. Endothelin antagonists may have great potential in the
management of SAH and clinical studies with these agents must be awaited
with great interest.
1.3.7 Ischaemic stroke
The evidence of a pathophysiological role for ET-1 in ischaemic stroke is
much more limited than in SAH. Increased plasma and CSF concentrations
-of endothelin are seen in animal models of stroke.i42> 622i Although there
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have been few studies with endothelin receptor antagonists, both the
selective ETa and the combined ETa/ETb receptor antagonists, BQ-
123tl62] and SB 209670,!4041 have been shown to protect against
ischaemia-induced neuronal degeneration in a gerbil stroke model. Plasma
endothelin is also raised in humans after ischaemic stroke,!6521 suggesting
a possible pathophysiological role for endothelin in this condition.
Elowever, considerably more experimental evidence from animal models is
required before clinical trials with endothelin antagonists are likely to be
embarked on in this indication.
1.3.8 Migraine
Migraine headache is a very common condition characterised by a
persistent unilateral headache of moderate to severe intensity frequently
accompanied by nausea, vomiting and photophobia and sometimes
associated with an aura. I2231 The prevalence of migraine ranges widely,
depending on the diagnostic criteria used. However, using the International
Headache Society Classification,l223l the 1-year-period prevalence of
migraine is ~10%.!445] 5-Hydroxytryptamine (5-HT) appears to play an
important role in the pathophysiology of migraine!170] and 5-HT agonists
have proved of major therapeutic value in its treatment.!193 > 510> 615]
Studies have shown local cerebral hypoperfusion during migraine attacks,
especially those associated with an aura.!300- 392> 63H This hypoperfusion
'can last for several hours after the onset of the pain and can be followed by
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hyperperfusion. The vasoconstriction associated with the first phase of a
migraine attack could be attributed, at least in part, to the release of
vasoactive substances, such as the endothelins. Indeed, plasma endothelin
has been found to be elevated during migraine headaches.t157, 181] plasma
endothelin has not been found to be raised between attacks, or in patients
with episodic or chronic tension headaches!1811, suggesting that the rise in
endothelin is specific to migraine and not merely a response to headache.
Therefore, it appears possible that endothelin has a role in the
pathophysiology of migraine either directly or by mediating the effects of
5-HT. Alternatively, endothelin may be produced as a result of brain
ischaemia!652! or changes in vascular shear stress!353! and hence be a
secondary phenomenon.
It has been proposed that dural blood vessels play a central role in
headache pathogenesis.!43*1 Indeed, both the ergot alkaloids!474! and
sumatriptan!7 ^ block peripheral small fibre-dependent neurogenic
inflammation within the dura mater in a rat model. Endothelin receptor
antagonists have also been shown to block neurogenic inflammation,!65!
providing additional support for the view that these agents may be useful in
the treatment of migraine headaches. However, a small trial with the
combined ETa/b receptor antagonist, bosentan, has failed to show any
improvement in migraine symptoms!343! and enthusiasm for the clinical
development of endothelin receptor antagonists in this condition appears to
have waned.
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1.4.1 Acute renal failure
Acute renal failure (ARF) secondary to renal ischaemia is characterised by
intense renal vasoconstriction and severe depression of renal function that
may necessitate haemodialysis.!522' 58°! The renal vasculature is very
sensitive to the actions of endothelin. When infused at doses that have
little vasoconstrictive effect, ET-1 inhibits sodium reabsorption by its
actions on the ETa receptor in the rat,!189! and by its actions on the ETg
receptor in the dog!67!. A possible autocrine role for endothelin in the
regulation of body volume status and water reabsorption has been
proposed.!279! At higher doses, exogenous ET-1 causes potent and long
lasting vasoconstriction similar to that seen in ARE,!164- 504! together with
a reduction in renal blood flow, GFR and urine production.!30' 262] jn the
rat, the renal vasoconstriction to ET-1 is mediated by the ETg
receptor,!1891 whereas in the dog, renal vasoconstriction appears to be
mediated by the ETa receptor.!67!
As a consequence of the inter-species variations in renal endothelin
receptor function, caution should be taken when extrapolating the results
from animal experiments to humans. The human kidney, as in the dog, is
rich in ETq receptors and these predominate at least two-fold over ETa
receptors, which are limited mainly to the vasculature. !258! On this basis,
the dog may be a better model of human ARF than the rat.
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Renal ischaemia and reperfusion increases immunoreactive ET-1 binding
affinity,!95] ETa and ETg receptor numbers on the renal vasculature, !382>
470] mRNA expression!165] and plasma and urine immunoreactive
ET-1 in rats.!504! In the rat, anti-endothelin monoclonal antibodies prevent
renal vasoconstriction following ischaemia induced ARF.!504] This has
been confirmed with the selective ETa antagonist, BQ-123!83> 189' 354] and
the combined ETa/ETb antagonists Ro 46-2005!92! and TAK-044.!295! In
the dog, BQ-123 has no effect on the reduction in GFR produced by
ischaemia.!67' 537] Although renal vasoconstriction in the dog is mainly
ETa receptor mediated!258], the combined ETa/ETb antagonist, SB
209670, does attenuate this reduction in GFR.!67] This suggests that
endothelin may be involved in the pathophysiology of ARF in the dog by
actions other than vasoconstriction, possibly through its actions on the
renal tubules, mediated by the ETb receptor. !671
In humans, plasma immunoreactive ET-1 concentrations are significantly
elevated in ARF.!571] There is currently no effective drug therapy for
ARF!580] and, from the accumulating animal evidence, endothelin receptor
antagonists show great potential in this condition. From the work done on
dog models of ARF and the similarities in receptor distribution between
dog and human kidneys combined ETa/ETb receptor antagonists may be
more useful in the treatment of ARF than selective ETa or ETb
antagonists.
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Endothelin has also been implicated in the acute renal dysfunction and
hypertension associated with nephrotoxic agents such as cyclosporin!168'
2871 and X-ray contrast media.!33 Jl With the increasing use of cyclosporin
in immunosuppressive drug regimens, endothelin receptor antagonists may
have an expanding potential role in the treatment of cyclosporin
nephrotoxicity.
1.4.2 Chronic renal failure
Under physiological conditions, the actions of endothelin on the
glomerular microcirculation may help to maintain perfusion pressure.
However, the sustained reductions of GFR and renal blood flow observed
during administration of ET-1 in humans!442> 5241 may endanger oxygen
supply within the kidney.I4101 Such vascular effects may contribute to renal
injury in chronic renal failure (CRF), a condition characterised by
markedly raised plasma endothelin concentrations in both animal
models!376' 6441 and humans.!128> 28^> 329> 439, 462, 475, 505, 538, 599]
mechanism by which plasma endothelin concentrations are raised is still
unclear with both increased production and decreased clearance of
endothelin having been implicated. Furthermore, it has been suggested that
these high endothelin concentrations may contribute to the increased
vascular tone and the high incidence of cardiovascular mortality in this
condition.!123' 6071
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In addition to impairing renal haemodynamics, endothelin may also cause
renal injury by stimulating excessive cell proliferation and/or extracellular
matrix formation. There is accumulating evidence that endothelin is
involved in the pathogenesis of proliferative glomerulonephritis. ET-1 is a
potent mitogen and partly mediates the proliferative effects of several
cytokines,!33' 281> 3911 as well as activating and being chemotactic for
monocytes which can in turn secrete ET-1.16' 3351 Furthermore, endothelin
receptor antagonists reduce mesangial cell proliferation in experimental
mesangial proliferative glomerulonephritis! 1751 and decrease renal injury in
murine lupus nephritis. !3781 In addition, renal ET-1 mRNA levels are also
elevated in kidneys from mice with an autosomal recessive form of
polycystic kidney disease.!3751
There are also several lines of evidence suggesting that endothelin may
contribute to the excessive accumulation of extracellular matrix
components and fibrosis. Endothelin can increase renal cell fibronectin and
collagen production, tissue inhibitor of metalloproteinases levels, and
release of cytokines that stimulate matrix accumulation.!414' 4721
Glomerular ET-1 and endothelin receptor mRNA levels correlate with the
degree of glomerular sclerosis in rats with puromycin nephrosis.!3791
Endothelin receptor antagonists have also been shown to decrease matrix
accumulation in experimental models of nephritis.!175' 379] Several studies
have noted increased renal endothelin production in streptozocin diabetic
rats.!176- 177> 3661 Furthermore, chronic treatment with an endothelin
.receptor antagonist attenuates increases in glomerular mRNA levels of
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collagen, laminin, tumour necrosis factor-a, TGF-|3, platelet-derived
growth factor, and basic fibroblast growth factor in diabetic rats.!377]
However, endothelin receptor blockade does not appear to affect the degree
of fibrosis in chronic cyclosporin nephrotoxicity.!286] It would therefore
appear that the extent of involvement of endothelin in matrix accumulation
and fibrosis depends on the underlying disease process.
Once substantial renal scarring exists, there is typically an inevitable
progression towards end-stage kidney disease.!309> 45°] This process
involves gradual glomerular sclerosis and interstitial fibrosis, and occurs
regardless of the initial renal insult. There is now evidence that endothelin
contributes to this progressive renal deterioration. Most studies, but not
all,!572] have reported increased renal endothelin production in
experimental animals or humans with reduced renal mass.!418- 552> 5571
Furthermore, ETa receptor blockade has been shown to reduce glomerular
injury in progressive renal failure in rats.!49] However, interpretation of
this study is confounded by the blood pressure lowering effect of
endothelin antagonism, an effect that has been shown to reduce renal
fibrosis in severely hypertensive rats.!408] Hence, endothelin may
contribute directly or indirectly (through blood pressure elevation) to
fibrosis when renal function is severely and irreversibly compromised.
There are now sufficient theoretical reasons as well as accumulating
experimental animal evidence to warrant the further evaluation of
•endothelin receptor antagonists in the treatment of chronic renal failure.
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However, ACE inhibition has been shown in several studies, in both
diabetic!183' 207> 240> 255' 31U and non-diabetic patients,l337- 561J to slow
the progression of renal impairment in CRJF and endothelin antagonists
would have to demonstrate additional benefits to these agents. As yet there
are no studies examining the actions of endothelin antagonism in CRF or in
healthy subjects.
1.5 Conclusions
Endothelin antagonists have proved extremely useful in extending the
understanding of cardiovascular physiology and for providing new insights
into the pathophysiology of cardiovascular disease. A broad body of
experimental and clinical evidence now exists to support the clinical
development of drugs that block the production or actions of endothelin for
use in cardiovascular medicine. There is particularly good evidence to
support their development in conditions associated with chronic
vasoconstriction, such as hypertension and heart failure, as well as in
vasospastic conditions, such as subarachnoid haemorrhage and Raynaud's
phenomenon. To date, most of the work has been with endothelin receptor
antagonists. With the recent cloning of ECE-1, it is likely that selective
ECE inhibitors will soon be developed, and these may also prove to have
properties of benefit in the treatment of cardiovascular disease. It is still
not clear whether combined ETa and ETg antagonists have therapeutic
advantages over selective ETa antagonists, as both these receptors can
.contribute to ET-1 induced vasoconstriction in humans. Theoretically, the
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combination of an ETa receptor antagonist with a smooth muscle selective
ETb receptor antagonist would be most effective because they it would
leave dilator ETq receptors unblocked. However, antagonists with this
selectivity are still awaited. Currently, combined ETa and ETB receptor
antagonists appear to have the widest potential for clinical application and
several such agents are currently being assessed in phase I trials. These
drugs represent a novel therapeutic approach to a fundamental and newly
discovered vasoconstrictor mechanism and the results of the clinical trials
will be awaited with considerable interest.
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1.5 Table Legends
Table 1.1 Factors that influence ET-1 biosynthesis




Figure 1.1 Endothelium-derived vasoactive substances
The vascular endothelium is a source of relaxing and contracting factors
and has been the target of several of the most succesful pharmacological
interventions in cardiovascular medicine, including nitrates, aspirin and
ACE inhibitors.
Figure 1.2 Endothelin
Endothelin-1 is a 21-amino acid peptide with 2 intra-chain disulfide
bridges linking paired cysteine residues.
Figure 1.3 Endothelins and sarafotoxin S6c
Structures of the endothelin isopeptides and sarafotoxin S6c. The filled
circles indicate the amino acids that differ from those of ET-1.
Figure 1.4 Endothelin synthetic pathway
The gene encoding ET-1 on chromosome 6 contains 5 exons and 4
intervening intron sequences. Once translated, an amino terminal sequence
(amino acids 1-17) is cleaved on secretion of the prepro peptide from the
.nucleus. Big ET-1 is formed through proteolysis of pro ET-1 by dibasic
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pair endopeptidase enzymes, then mature ET-1 is formed through cleavage
of big ET-1 at Try21-Val22 by a specific endothelin converting enzyme.
Figure 1.5 Big endothelin-1 and C-terminal fragment
Big ET-1 is cleaved at Try^-Val22 by a specific endothelin converting
enzyme to form ET-1 and the C-terminal fragment of big ET-1. In certain
conditions associated with raised plasma concentrations of ET-1,
measuring plasma concentrations of big ET-1 and/or C-terminal fragment
may help distinguish increased production of ET-1 or decreased clearance
of ET-1 as the cause of the raised ET-1 concentrations.
Figure 1.6 Vascular effects of endothelin and its receptors
Endothelin produced by endothelial cells acts on two receptors: ETa and
ETb- Both these receptors are located on smooth muscle cells and mediate
smooth muscle contraction by increasing intracellular calcium. The ETb
receptor is also found on on endothelial cells and mediates smooth muscle
vasodilatation by releasing NO and vasodilator prostanoids such as
prostacyclin.
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Figure 1.7 Constitutive release of NO
Agonists such as acetylcholine, shear stress, bradykinin, adenosine
diphosphate (ADP) or substance P increase intracellular calcium activating
NO synthase. NO activates guanylate cyclase in smooth muscle cells
increasing intracellular cGMP and lowering cytosolic calcium resulting in
smooth muscle relaxation. NO also inhibits platelet aggregation by similar
actions on platelet guanylate cyclase.
Figure 1.8 Actions of nitric oxide and endothelin in the pathogenesis
of atherosclerosis
Endothelial injury plays an initial role in the increased adherence and
migration of monocytes into the subendothelial space. Once in the arterial
intima monocytes are activated to macrophages. Uptake of oxidised low
density lipoprotein by the macrophages leads to foam cell formation and
together with smooth muscle cell proliferation and platelet adhesion leads
to the formation of lipid-laden plaques. The rupture of these plaques,
together with the associated thrombosis and vasospasm, leads to vascular
occlusion and myocardial infarction or stroke. The main actions of ET
appear to facilitate, whereas the actions of endothelial NO mainly inhibit,
the atherogenic process. High plasma concentrations of endothelin are
associated with a worse outcome after myocardial infarction.
74
Table 1.1
Factor Effect Cellular signal Gene promoter element





LDL Increase PLC/PKC AP-1
Insulin Increase PLC/PKC AP-1
ANG II Increase PLC/PKC AP-1
Vasopressin Increase PLC/PKC AP-1








Selectivity Compound Company Comments
BQ-123 Banyu cyclic pentapeptide
BQ-153 Banyu linear tripeptide
BQ-485 Banyu linear tripeptide
FR-139317 Fujisawa pseudo-tripeptide
TTA-386 Takeda synthetic hexapeptide
PD151242 Parke-Davis pseudo-tripeptide
50-235 Shionogi caffeoyl ester




ETb BQ-788 Banyu tripeptide
RES-701-1 KyowaHakko 16 amino acid cyclic peptide















Ciba-Geigy irreversible binding, unstable



































Stimuli e.g. hypoxia, shear stress, circulating hormones
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Inhibition of platelet aggregation and adhesion
Inhibition of monocyte adhesion
Inhibition of smooth muscle proliferation and migration
Figure 1.8




2.1.1 Venous occlusion plethysmography and arterial
administration of vasoactive agents
2.1.2 Aelliig Technique
2.1.3 Combining systemic drug administration with local studies
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2.2.1 Single blood pressure measurements
2.2.2 Twenty-four hour blood pressure monitoring
2.3 Impedance Cardiography
2.4 Measurement of Renal Function
2.4.1 Effective renal plasma flow
2.4.2 Glomerular filtration rate
2.4.3 Renal sodium handling
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•y 2.5.4 Endothelin (Studies 1 & 8)
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2.5.9 Plasma TAK-044 (Studies 3 & 4)




When studying the physiology of human blood vessels, in vivo techniques
offer distinct advantages over in vitro techniques: in vivo, the vessels are
exposed to physiological pressure and have physiological dimensions; they
are bathed in the physiological medium of blood and exposed to local and
circulating vasoactive and growth factors; they have intact nervous
mechanisms; and they have not been exposed to a general anaesthetic
agent or to potentially significant vessel trauma or hypoxia.
One substantial disadvantage of most human studies of blood vessels in
vivo is that systemic doses of drug are used. This can cause effects on other
organs such as the brain, heart and kidneys, as well as influence
neurohumoral reflexes through change in systemic haemodynamics. Using
such methods, the direct vascular effects of drugs cannot readily be
interpreted in humans. In animals, to avoid these confounding influences,
locally active doses of drugs have been infused into single regional
vascular beds, such as the mesentery or hindlimb. Similar local infusion
techniques have been available for some years to study the vascular
pharmacology of resistance and capacitance vessels in humans,!10' 12, 104,
463, 617] buf- their power as tools in the study of cardiovascular physiology
and pharmacology has only recently been widely appreciated.
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2.1.1 Venous Occlusion Plethysmography
Principle
Venous occlusion plethysmography has been used to measure limb blood
flow for over 80 years.!224! Although air and water plethysmographs have
been replaced by externally applied gallium/indium-in-Silastic and
mercury-in-Silastic strain gauge devices,!218' 386] the underlying principle
remains the same. A proximal limb cuff is inflated rapidly to greater than
venous pressure but lower than arterial pressure, so that initially, when
venous return is halted but arterial inflow continues unimpeded, the
increase in limb volume with time gives a measure of blood flow. In strain
gauge plethysmography, changes in limb circumference, and hence limb
volume, are detected as a change in electrical resistance of the gauge.
Because limb circumference and not volume is measured by the strain
gauge technique, a measure of blood flow per unit volume of tissue (ml"
'mhf'lOO ml tissue) is obtained. Limb volume must be measured
separately in order to obtain an absolute measure of blood flow, though for
many studies this is not necessary. The mathematical principles underlying
this technique have been reviewed. !154> 6181 Although early studies often
involved the lower limb, the studies described in this thesis are confined to
the forearm vascular bed.
Technique
Subjects are made to feel relaxed resting supine in a comfortable, quiet,
draught-free environment maintained at a constant temperature between 22
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and 26°C so as to minimise variability in blood flow and blood pressure
and maximise the reproducibility of the results. The arms are maintained
resting comfortably, above the level of the central venous pressure and
with venous emptying unimpeded, so that venous pressure cannot rise
sufficiently to affect arterial inflow during measurements. The upper arm
cuff is inflated to 40 mm Hg for 10 seconds and then deflated for 5
seconds, a manoeuvre which does not affect arterial inflow or pressure!62!!
and generally provides analysable linear tracings (Figure 2.1).!200> 618! At
high flow rates, a shorter inflation period and a longer deflation period are
needed to ensure adequate venous emptying. Recordings of forearm blood
flow are made repeatedly over 3-minute periods. Voltage output from a
dual-channel Vasculab SPG 16 strain gauge plethysmograph (Medasonics
Inc) is transferred to a Macintosh personal computer (Performa 475, Apple
Computer Inc, Cupertino, CA) using a MacLab analogue digital converter
and Chart software (version 3.2.8; both from AD Instruments, Castle Hill,
NSW, Australia). Calibration is achieved using the internal standard of the
Vasculab plethysmography units.
During measuements, hand blood flow is excluded by wrist cuffs inflated
to 220 mm Hg. Flow only stabilises after 60 seconds of cuff inflation!266!
so thses cuffs must be inflated for 60 seconds longer than the period of
measurement. Hand ischaemia limits the time of any one period of
measuremenmt to -10 minutes. Venous occlusion plethysmography has
been shown to be a reliable!153! and reproducible technique in individual
■Subjects.!458!
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Compared with muscle blood flow, skin blood flow varies more markedly
with temperature and emotion. 151 It also has a different physiology and
exhibits different responses to drugs. Compared with the forearm, the hand
is primarily made up of skin. In addition, the tissues of the hand cannot
stretch in the same way as those of the forearm, and inclusion of the hand
during forearm blood flow measurements can result in non-linear and
unmeasurable flows.!6181 Therefore, hand blood flow is excluded during
measurements of forearm blood flow. Even with hand exclusion, it should
be recognised that blood flow to skin contributes to total forearm blood
flow,!107- 651] accounting for -25% of flow <6 ml.l00ml."1min"1 and as
much as 50% of higher flows.
Arterial administration
The first descriptions of arterial cannulation to assess responses of skeletal
muscle to local drug administration were provided by Barcroft and
colleagues!12' 39] ;n 1946. They infused adrenaline into the femoral artery,
although now most workers use the brachial artery route. They noted the
major advantage of this technique over systemic administration, which is
that it can be used to examine the direct effects of a drug on the resistance
vessels without eliciting effects mediated through actions on other organs
or by stimulation of neurohumoral reflexes. These unwanted effects can be
avoided by giving doses that do not have systemic actions, which is
feasible because the blood flow to the forearm at rest is low (-50 ml.min"1)
compared with the cardiac output (5000 ml.min"1). Hence, doses 100- to
1000-fold lower than those active systemically are effective within the
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upper limb circulation. Assuming that drugs are used for short periods, or
are short-lived, their effects are restricted to the infused limb. The opposite
arm can then act as a contemporaneous control for the experimental arm
receiving drug (Figure 2.1), taking account of any minute-to-minute
changes in blood flow that affect both arms, such as due to emotion or
minor changes in basal state.!50' 199] In general, although the forearm is
obviously only one of several resistance circuits, effects in the circulation
to forearm muscle are commonly predictive of those found in other major
systemic resistance beds, such as the mesentery and the kidney, t604!
Technique
Drugs are infused via a Welmed PI000 syringe pump (Welmed Clinical
Care Systems), with the total rate of infusion maintained constant
throughout at 1 ml.min"1, through a cannula sited in the brachial artery at
the elbow under local anaesthesia with lignocaine (Astra Pharmaceuticals
Ltd, Herts, UK). The discomfort associated with this procedure is usually
no greater than that associated with placement of a venous cannula. Very
fine steel needles (27 SWG: Cooper's Needle Works, Birmingham, UK)
mounted on a 16-gauge epidural cannula (Portex Ltd) were used in these
studies. They were regularly checked for 'flashback' of blood at intervals
during the studies to ensure correct placement. These needles have been
found to be safe and atraumatic, consistent with the safety of long-term
siting of larger brachial and radial artery cannulae in clinical practice.!186>
367] The technique is also extremely well tolerated allowing studies to be
.repeated at 1- to 2- week intervals up to 6 times in the same subjects.!2181
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Some researchers use cannulae of a size sufficient to allow direct
measurement of arterial blood pressure. However, these are less well
tolerated, and difficult to justify ethically. Except in unusual
circumstances, the combination of intermittent non-invasive measurement
of blood pressure, either at the brachial or digital artery, with measurement
of blood flow in the control arm is sufficient for safety purposes and to
exclude a systemic drug effect.
In these local infusion studies, particularly with potent vasoconstrictors, it
is critical to carefully consider, and be guided by, the data from animal
pharmacology studies. Although critical closure is theoretically possible in
resistance vessels maintaining constant transmural pressure in the face of
an increasing tension secondary to administration of a vasoconstrictor
agent,1271 this has not been observed in practice even with major
reductions in local blood flow caused by ANG III50! and ET-1.1211] It
should be noted that, where pharmacological considerations have been
taken into account, vasoconstrictors have proved remarkably safe in the
forearm, avoiding the potential hazards that might be associated with
studies undertaken in other vascular beds, such as the coronary circulation,
or with systemic administration.
Separate issues relate to the infusate. It is important to use the appropiate
vehicle as the time control for the active drug, particularly if the pH of the
infusate has to be non-physiological in order to dissolve the drug or if one
component of the vehicle might might have vasoactive properties. To
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avoid these problems, physiological (0.9%) saline is used to dissolve
agents for arterial infusion. It is also critical to avoid the use of
hyperosmolar solutions for infusion as these can cause substantial
vasodilatation.!35' 4191 Where posssible, infusate flow of >lml.min"' and
changing infusate flow rate should be avoided, because this can make a
measurable contribution to total blood flow, especially during the infusion
of vasoconstrictors. Clearly, some drugs cannot be given, even at locally
active doses, in humans because of the potential for toxicity. However, if
particular concerns exist about local vascular inflammatory effects of the
infusate from intravenous studies in animals or humans, specific testing in
the rabbit ear artery!27°1 can be helpful.
Analysis ofResponses
In a fasted subject resting comfortably in the supine position in a quiet,
warm, temperature-controlled environment, blood pressure and forearm
blood flow remain stable for several hours.!6041 Although there may be
small fluctuations in blood flow associated with changing levels of
alertness, these affect both arms simultaneously, so blood flow in the
control arm can serve as a contemporaneous control for drug effects in the
infused arm. In general, the effects of external stimuli on drug responses,
and the inter-subject variability in drug effects, are minimised by
describing the drug effect as the percentage change from baseline of blood
flow in the infused arm as a ratio of the same percentage change in the
control arm. This method uses all the information obtained from flow
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measurements, and serves to minimise the effects of variations in blood
flow caused by minor external factors. !50> 20°!
The validity of this method for handling the data is dependent on arterial
pressure remaining stable during the experiment, in which case changes in
blood flow provide a reliable measure of drug effect on the contractile state
of the smmoth muscle. Some workers use flows and pressures to calculate
changes in vascular 'resistance', although with a non-newtonian fluid, a
distensible vascular system and pulsatile flow, this derived parameter
offers no particular advantaged604]
If significant changes in arterial pressure do occur, the results must be
interpreted with considerable caution because the contractile state of the
smooth muscle is not independent of distending pressure, depending on the
balance between passive stretch caused by the increased pressure and the
evoked contraction of the circular smooth muscle (autoregulation). There
is much variability between subjects in the response of the forearm
vascular bed to changes in arterial pressure!460! and no simple way of
distinguishing the autoregulatory response from the direct effect of a drug.
Lower Body Negative Pressure (LBNP): Sympathetic Function in
Resistance Vessels
Application of a small degree of negative pressure to the lower body (10-
15 mm Hg) causes venous pooling within the legs leading to unloading of
.low-pressure cardiopulmonary baroreceptors.!3! This generates a selective
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increase in sympathetic activityt5411 of the efferent nerves serving the
upper limbs, and produces -20% reduction in forearm blood flow without
affecting arterial pressure or heart rate.!498! This technique can be used to
examine the influence of drugs on peripheral sympathetic function and,
where required, can be coupled with assessment of venous noradrenaline
overspill or with direct measurements of sympathetic nerve activity.
2.1.2 The Aellig Technique
Principle
Several methods exist for studying venous responses in the upper limb.!8!
It is possible to study compliance in deep forearm veins using venous
occlusion plethysmography and such studies have been performed during
intra-arterial infusion to assess simultaneously the effects of drugs on the
arteries and veins.i85' 135> 338l Venous compliance can also been assessed
in single dorsal hand veins, a technique which has been widely applied
using the method of Aelligd10! This technique measures the internal
diameter of the vein while maintaining its distension through inflation of
an upper arm cuff to a constant low level of pressure. Contraction of the
venous smooth muscle can be detected by a reduction in internal diameter.
One limitation of this methodology, but also a strength, is that under
resting conditions in healthy subjects these veins have no intrinsic
toned103- 6061 They, therefore, have to be pre-constricted to study dilator
agents and thus, responses may depend on the constrictor agent chosen.
•Noradrenaline is generally preferred, being the physiological mediator of
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sympathetic tone in these vessels.!5'1 It should also be remembered that
there are may differences between the responses in the deep and superficial
veins. However, only the cutaneous limb veins participate in venomotor
reflexes,t4> 6501 so responses in hand veins should reflect responses of that
component of the venous system which is most important in physiological
regulation of venous capacitance and cardiac preload. Given also the
relative ease with which hand veins can be studied, these are now widely
used in preference to the deep veins.
Technique
For reproducible results in hand vein studies, subjects are studied under the
same general conditions as for forearm studies, except that they can rest
semi-recumbant, with the hand to be studied supported above the level of
central venous pressure by means of an arm rest. A dorsal hand vein
without branching over a length of at least 2 cm is then selected and a
small steel cannula (23-gauge butterfly needle; Abbott, Sligo, Republic of
Ireland) sited in the direction of flow without use of local anaesthesia.
Internal diameter of the dorsal hand vein, distended by inflation of an
upper arm cuff to 30 mm Hg can then be measured by the technique of
Aellig.t10] A magnetised lightweight rod rests on the summit of the infused
vein ~1 cm down-stream from the tip of the infusion cannula. This rod
passes through the core of a linear variable differential transformer
(LVDT; Model 025 MHR,Lucas Schaevitz Inc, Pennsauken, NJ, USA)
supported above the hand by a small tripod, the legs of which rest on areas
of the dorsum of the hand which are free of veins. If venoconstriction
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occurs during cuff inflation, or if the upper arm cuff is deflated with
consequent emptying of the vein, there is a downward displacement of the
lightweight rod. The displacement causes a linear change in the voltage
generated by LVDT, and thus allows determination of the internal diameter
of the vein, after calibration against standard displacements.
As with forearm studies, this technique has the advantage that locally
active doses can be used. The blood flow in a single dorsal hand vein is ~1
ml.min"1, so the doses administered are ~1000-fold lower than are
systemically active. Given the lack of potential for systemic dosing and the
relative constancy of vein size, most investigators do not use a control vein
as with the control arm in forearm studies.
Value ofHand Vein Studies
There are a number of reasons for wishing to study veins. First, the venous
system has an important influence on cardiac output in its own right, and
has been reported to be abnormal in several conditions, including
borderline!149' 473] an(j established hypertension,!213] acute myocardial
infarction,!46*1 and chronic renal failure.!206! This raises the possibility
that abnormal venous responses may contribute directly to the
pathophysiology of a number of vascular diseases. Second, in diseases
primarily associated with abnormalities in resistance or conduit vessels,
such as essential hypertension,!159! and Raynaud's disease,!46! similar
abnormalities are found in the hand veins. Third, studies of responses to
vasoconstrictors in resistance beds may be confounded by the presence of
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vascular hypertrophy,! 1691 whereas the process does not appear to occur, at
least in hypertension,!148' 213! within the hand veins. Fourth, because
human dorsal hand veins have no intrinsic tone in rested subjects,!103' 6061
tone can be induced with any number of venoconstrictor agents and then
the effects of dilators examined. If another drug is co-infused and reverses
induced tone then one can presume it is acting against the venoconstrictor
mechanism involved in generating tone.
Exact concentrations of drug are not obtained in vein studies because vein
size, but not blood flow, is measured. However, concentrations can be
roughly calculated, at least to the nearest order of magnitude, based on a
flow of ~1 ml.min"1. Differences in basal vein flow between patients and a
control group might affect responses in hand veins. However, unless
forearm blood flow is also different between the groups, there is no reason
to believe that this should influence responses. In any case, studies have
shown that increasing the rate of drug infusion by up to 100%, but keeping
the dose infused constant, does not alter dorsal hand vein responses to a
number of agents. !10> 1031
2.1.3 Combining Systemic Drug Administration with Local
Studies
Although the forearm and hand vein techniques are generally at their most
powerful in a mechanistic sense when drugs are administered locally, they
.can usefully be combined with systemic drug administration in studies.
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The situation is simplest, as with aspirin, where the systemic drug does not
have haemodynamic effects, although the techniques can also be used with
vasoactive drugs.
2.2 Blood Pressure Measurements
2.2.1 Single Blood Pressure Measurements
A semiautomated noninvasive oscillometric sphygmomanometer (Takeda
UA 751, Takeda Medical Inc, Tokyo, Japan) was used to make duplicate
measurements of blood pressure in the noninfused arm, which were then
averaged. This system has been well-validated against intra-arterial blood
pressure measurements, ordinary auscultation and semi-automatic devices
using the microphone detection of Korotkoff sounds for the registration of
blood pressure.t62°l
2.2.2 Twenty-four Hour Blood Pressure Monitoring
Twenty-four hour ambulatory blood pressure monitoring was performed
using Spacelabs 90207 monitors. The Spacelabs were set to take readings
every 30 minutes and to deflate in 8 mm Hg bleed steps. These monitors
have been evaluated according to the protocol of the British Hypertension





Impedance cardiography (bioimpedance) is a simple, accurate and non¬
invasive method for measuring cardiac output and function. Essentially, a
constant sinusoidal current is applied between electrodes placed on the
neck and lower chest and changes in the bioimpedance to the current are
related to cardiac events and blood flow. The major change involved is
reduction in impedance (Z) during left ventricular ejection. The first
derivative of this impedance cardiogram (dZ/dt) includes inflections which
are timed with cardiac events such as aortic valve opening and closure and
peak systolic aortic flow and the maximum change in dZ/dt (dZ/dt{max})
is related to peak aortic flow.!359! By measuring the intervals between the
impedance reflections and those on the ECG it is possible to derive systolic
time intervals (STIs) such as the pre-ejection period (PEP) and ventricular
ejection time (VET). These and the ratio PEP/VET, are related to left
ventricular performance and have often been used in the non-invasive
assessment of drug effects.[34> 76> 6131
The impedance cardiogram has also been used to determine stroke volume.
Using a model in which the chest is considered to consist of two parallel
conductors (blood and thoracic tissues), and making several loose
assumptions about the relationship between the impedance cardiogram and
aortic blood flow, Kubicek et a/,!291! devised a plethysmography formula
for estimating stroke volume from the extent of the systolic thoracic
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impedance change. While the formula produced acceptable estimates of
stroke volume and cardiac output both at rest and with exercise in healthy
volunteers, the method was sometimes inaccurate, especially in patients
with cardiovascular diseased134' 3591
More recently Sramek and Bernstein have described an empirical
modification to Kubicek's original formula!56] and combined this with a
sophisticated computer algorithm to produce a very simple and cheap
method for measuring stroke volume. Several studies have shown that the
new method is more accurate in the clinical setting than was Kubicek's.!20>
55, 194, 248, 394, 482, 525, 564]
Technique
Impedance measurements were made using a Non-invasive Computerised
Cardiac Output Monitor (NCCOM) 3, series 6 (Biomed Medical
Manufacturing, Irving, California) impedance cardiograph. A constant
sinusoidal alternating current (2.5 mA RMS, 70 kHz) was applied between
electrode pairs placed on the lateral aspects of the neck and lower chest.,
and the voltage associated with this was detected by two inner sensing
electrode pairs placed 5 cm from the corresponding current injecting
electrodes and parallel to the current path. Self adhesive Ag/AgCl
electrodes (Red Dot 3M, Minneapolis USA) were used. This voltage was
relayed to an amplifier within the apparatus. An impedance (Z) signal was
produced using Ohms law and differentiated to give the dZ/dt signal. A
microprocessor incorporated in the apparatus uses algorithms to produce
/
on-line measurements of basal impedance (Z0), peak rate of change of
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impedance (dZ/dt{max}), and VET. Stroke volume and cardiac output are
calculated on-line by the microprocessor using the Sramek-Bernstein
formula:
Stroke volume = L3.dZ/dt{max}.VET / Z0.
where L is the thoracic length, estimated from the patient's height and
weight using a normogram.!56!
Using this method, both absolute cardiac output and changes in cardiac
output measured by bioimpedance agree closely with thermodilution
measurements, and the within-subject coefficient of variation is lower with
bioimpedance.t482' 5641
2.4 Measurement of Renal Function
2.4.1 Effective Renal Plasma Flow
Principles
The classic clearance technique for the determination of effective renal
plasma flow (ERPF) is based on the application of the Fick principle to the
disappearance of an indicator substance from blood passing through the
kidneys and its subsequent appearance in the urine, t520! If the indicator is
neither synthesised or nor metabolised in the kidney, its rate of appearance
.in the urine equals its rate of extraction from the blood.
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/?-Aminohippurate (PAH) is thought to undergo essentially quantitative
renal tubular excretion at plasma concentrations below 25 mg.f1, and its
renal clearance under these conditions has been established as the standard
measure of the ERPF for -50 years.i52> 84> 5191 The original method for
estimating the renal clearance of PAHl519! has stood the test of time well
and it is calculated from the urinary excretion rate and plasma
concentration at steady state following an appropriate intravenous loading
dose and constant infusion. However, significantly reduced values of PAH
extraction have been observed in patients with renal disease.I54- 64> 5861
Therefore, determination of the actual extraction ratio' by measuring
simultaneous renal arterial and venous concentrations of PAH is necessary
whenever a precise value for renal plasma flow is required. In these
studies, PAH clearance was estimated both after active treatment and
placebo, with the data expressed as placebo-corrected changes from
baseline in order to overcome this problem.
2,4.2 Glomerular Filtration Rate
Principles
The gold standard for the assessment of GFR is the urinary clearance of
inulinl518! or polyfructosan.l53! These agents are inert and do not bind to
plasma proteins. They distribute in extracellular fluid, are freely filtered by
the glomerulus, and are neither reabsorbed nor secreted by renal
tubules, i310! The rate of appearance of these substance in the urine,
-therefore, equals its rate of filtration by the glomerulus.
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The original method for estimating GFR.!520! has stood the test of time
well and it is calculated from the urinary excretion rate and plasma
concentration at steady state following an appropriate intravenous loading
dose and constant infusion.
2.4.3 Renal Sodium Handling
Principles
Lithium clearance has been proposed as a valuable method for estimating
the proximal reabsorption of sodium.!565! This approach is based on the
assumption that lithium is reabsorbed in the proximal renal tubule to the
same extent as sodium and water, and that lithium is neither reabsorbed
nor secreted in the distal tubule. !565! This conclusion is is supported by
experimental data obtained in animals with micropuncture technique,!22T
509, 567] ]n humans by non-invasive methods.!528' 5681 Although under
certain experimental conditions such as extremely low sodium intake!566!
or frusemide-induced diuresis,!528! a small fraction of lithium reabsorption
may take place within the distal nephron, lithium clearance appears to
represent under most clinical situations a useful indicator of proximal
tubular reabsorption.!565! This technique has been largely used to analyse
the renal tubular handling of sodium in patients with normal renal
function.!77-144> 212> 230> 527> 61°!
In patients with impaired renal function, a reduction of GFR is
accompanied by an equivalent reduction in lithium clearance.!89' 254> 569!
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This is consistent with the delivery of tubular fluid from the end of the
proximal tubule falls in parallel with the decrease in GFR.!89> 254> 569i
Thus, in the presence of mild to moderate renal failure (GFR>50 ml.min"1)
the fractional proximal and distal reabsorption of sodium are
unchanged!89] and lithium clearance can be used to investigate tubular
sodium handling in these patients.
2.4.4 Protocol
In each study, subjects received oral lithium carbonate (Camcolit: 250 mg
sustained release) before each study day (~14 hours before baseline
measurements), to assess proximal tubular reabsorptive capacity of
sodium. This dose of lithium is physiologically inert.!144] A 24 hour
collection of urine was performed by all subjects from 7:00 AM on the day
before each study day. At 7:30 AM on the study day, subjects drank 450
ml of water before attending the clinical research centre at 8:00 AM. On
arrival subjects were given 5 ml.kg"1 water to to drink and two cannulas
were placed in the antecubital fossa of the non-dominant arm for infusion
of PAH (Merck, Hoddeston, UK) / polyffuctosan-S (Inutest; Laevosan
GmbH, Linz, Austria) and the study agent. A third cannula was placed in
the antecubital fossa of the opposite arm for blood sampling and the
subjects remained supine thereafter except when passing urine. Priming
doses of PAH (0.45 g) and polyfructosan-S (3.5 g) were diluted in 100 ml
of 0.9% saline and infused over 15 minutes (8:30 AM), followed by a
maintenance infusion of PAH (8.3 g.l"1) and polyfructosan-S (lOg.F1) in
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0.9% saline at 120 ml.hr"1. After an equilibration period of 75 minutes,
blood samples were drawn at the beginning and at the end of accurately
timed 30 minute clearance periods. An appropriate volume of water was
drunk by the subjects after all urine collections to maintain a stable water
balance throughout the rest of the study. Two baseline periods preceded
intravenous infusion of the study agents dissolved in 50 ml 0.9% saline
over 15 minutes, followed by 4 further collection periods.
2.5 Plasma Assays
All venous blood samples were collected into chilled tubes, centrifuged at
1500 g for 20 minutes at 4°C and stored at -80°C until assay. All assays
were done in single batches.
2.5.1 Measurement of Plasma Aldosterone
Venous blood samples for plasma aldosterone concentrations were
collected into lithium heparin tubes and plasma aldosterone was measured
using a solid-phase (coated tube) radioimmunoassay from unextracted
serum using a commercially available kit (Coat-a-Count; Diagnostic
Products Corporation, Los Angeles, CA). The intra-assay CV is <8.3%.
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2.5.2 Measurement of Plasma Angiotensin II
Venous blood samples were taken into EDTA/o-phenanthroline to inhibit
converting enzyme and angiotensinase enzymes. H431
The method for radioimmunoassay of ANG II is described in described in
detail in Morton, 1985.1370! In brief, samples were extracted by passage
through Sep-pak CI8 cartridges (Waters Associates, Milford, MA). The
cartridges were pretreated with methanol (5 ml) and then water (5 ml).
Plasma (5 ml) was then passed through the cartridge under gentle vacuum.
After washing with water (5 ml), ANG II was then eluted from the column
with aqueos 20% methanol (2 ml). The extracts were dried and redissolved
in Tris buffer (50 mmol.T ; pH 7.5) for assay. The recovery from plasma of
added ANG II was 95%. The intra-assay CV is 10%.
2.5.3 Radioimmunoassay of Atrial Natriuretic Peptide
Blood samples (10 ml) were collected in chilled tubes containing EDTA as
anticoagulant and enough Trasylol to give a final concentration of 50
Kallikrein inhibitor units.ml"1.!454]
The method for radioimmunoassay of ANP is described in detail in
Richards, 1987.1454! In brief, ANP was extracted from 4 ml plasma on
Sep-pak CI8 reverse phase columns. Sep-Paks were pre-activated with 5
'ml methanol and washed with 5 ml distilled water prior to application to
107
the acidified (0.25 ml 2N HCl.mF1 of plasma) plasma. Acidified plasma
was centrifuged (1000 g, 4°C, 10 minutes) prior to its application to the
Sep-paks. The Sep-pak cartridges were then washed with 0.1%
trifluoroacetic acid (TFA; 3x5 ml) and the adsorbed peptide was eluted
with 2 ml 60% acetonitrile (v/v) 0.1% TFA into plastic tubes. The extracts
were dried down under compressed air, and reconstituted in 0.5 ml buffer
(100 mmol.r1 sodium phosphate, pH 7.4, containing 50 mmol.F1 NaCl,
0.1% w/v BSA, 0.1% w/v Triton x-100 and 50 kallikrein inhibitor units/ml
Trasylol). Recovery of peptide form the Sep-paks was >80%.
Antibodies to a-hANP were raised in New Zealand white rabbits
(Peninsula Laboratories). Reconstituted plasma extract (100 ml), antibody
in buffer (100 ml)at a dilution of 1/10 000, and 2 pg 123I-a-hANP in 50 ml
of the buffer were incubated at 4°C for 24 hours. Separation of free and
bound ligand was achieved by mixing with 1 ml dextran-coated charcoal.
The mixture was immediately centrifuged for 20 minutes at 2°C and the
free label was counted. Cross-reaction of the antibody with a variety of
synthetic ANP sequences (5-28 hANP, 7-28 hANP, atriopeptins I, II, III
and rat ANP) was >90%. No significant cross-reactions with bradykinin,
arginine vasopressin, angiotensins I and II or adrenocorticotrophic
hormone (ACTH) have been reported with this method. The intra-assay
CV was 3.9%.
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2.5.4 Endothelin (Studies 1 & 8)
Samples for endothelin assay were collected into tubes coated with EDTA
and plasma endothelin was assayed using a commercially available kit
(Endothelin-1 Radioimmunoassay, Peninsula Lab, Belmont, CA) as
previously described,11001 except samples were extracted using acetic
acid.t464] This method gives an extraction recovery of ET-1 of 89%. The
intra-assay CV is <6% and the cross-reactivity of this assay with ET-1, ET-
2, ET-3 and big ET-1 is 100, 7, 7 and 10% respectively.
2.5.5 Radioimmunoassay for Endothelin (Studies 3 & 4)
Immunoreactive endothelin was extracted from acidified plasma using
Sep-pak CI8 silica columns. Duplicate extracted samples and standards
were incubated with rabbit polyclonal antibody raised against ET-1 (ITS
Production B.V., Wijchen, The Netherlands; in 100 ml distilled water and
123I-ET-1 (ITS; 100 ml) was added, and tubes were incubated for 18 hours
at 4°C. Donkey anti-rabbit gamma globulin bound on solid-phase (ITS;
100 ml) was added, and tubes were incubated for 30 minutes at room
temperature. The amount of radioactivity in the antibody-bound fraction
was determined by gamma counting for 3 minutes. The recovery of added
ET-1 was 84%. Intra- and inter-assay CVs were 2.4% (n=6) and 4.2%
(n=5), respectively. The sensitivity of this assay is 2 pg.ml"1 endothelin.
Cross-reactivity of the assay with ET-1, ET-2, ET-3 and big endothelin-1
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is 100, 52, 96, and 7%, respectively. This assay does not cross-react with
TAK-044.
2.5.6 Endothelin (Study 5)
Plasma endothelin was measured by radioimmunoassay (New England
Nuclear Endothelin 1,2 kit) as previously described. i464l The sensitivity of
this assay is 2.2 pg.mE1 immunoreactive ET. Cross-reactivity of this assay
with ET-1, ET-2, ET-3 and big ET-1 is 100%, 53%, 4% and 70%
respectively. The normal range for this assay is 12-28 pg.ml"1.
2.5.7 Radioimmunoassay for Endothelin, Big Endothelin-1 and
the C-terminal fragment of Big Endothelin-1 (Studies 6 &
7)
Sample preparation
After being thawed, 5 ml plasma samples were acidified by adding 1 ml
hydrochloric acid 2 M, and clarified by centrifuging for 15 minutes at 2000
g at 4°C. The resulting supernatants were applied to activated supernatants
500 mg Spe-ed CI8 (14% carbon coverage) disposable mini-columns
using a vacuum manifold (Applied separations, Laboratory Impex Ltd,
Middx.). Unbound materials were washed from the mini-columns with a
vacuum manifold with a 5 ml 0.1% TFA and discarded. Immunoreactive
C-terminal fragment was eluted with a subsequent 2 ml of 80% methanol,
0.1% TFA and immunoractive endothelin and big ET-1 were separately
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eluted with a subsequent 2 ml of 80% methanol, 0.1% TFA. Eluates were
evaporated to dryness in polypropylene tubes using a Savant sample
concentrator (Life Sciences International (UK) Ltd. Basingstoke, Hants).
Radioimmunoassay
Plasma immunoreactive endothelin, big ET-1 and C-terminal fragment
were determined by radioimmunoassay using rabbit antisera raised against
the C-termini of endothelin (ET-l(15.2i) and big ET-1(31.38). Plasma extracts
were reconstituted in assay buffer (50 mM sodium phosphate, 0.25%
bovine serum albumin (BSA), 0.01% Tween 20, 0.05% sodium azide, pH
7.4) and incubated in duplicate with diluted antisera overnight at 4°C.
hollowing a further overnight incubation with ~10,000 c.p.m./tube tracer
(125I_ET-1 or 125I-big ET-1, Amersham International pic, Amersham,
Bucks), bound counts were separated using Amerlex-M reagent
(Amersham International pic) and radioactivity determined in a gamma
counter (Canberra Packard, Pangboume, Berks). Immunoreactivity was
calculated by reference to standard curves (0.5 - 1000 fmol/tube) of
authentic ET-1 (Peptide institute, Scientific Marketing Associates. Barnet,
Herts) or Novabiochem Ltd, Nottingham)., or big ET-1 (Peninsula
Laboratories Ltd, St Helens Lanes). For both assays, ED50 values were 20-
25 fmol/tube, inter- and intra-assay coefficients of variation were <13% in
the range 6-30 fmol/tube and the sensitivities of detection (defined as 2
standard deviations above zero standard) were <1.25 fmol/tube. The
recoveries of ET-1, big ET-1 and C-terminal fragment were 57.5%, 39.8%
and 76.6%, respectively (n=4).
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The mature endothelin RIA cross-reacted 100% with ET-1, ET-2 and ET-3
as expected as the immunogen contained the 7 C-terminal residues of ET-1
common to all 3 mature ET isoforms. Cross-reactivity with ET-1(1_20), big
ET-1(22-38)j big ET-1, big ET-2 and big ET-3 were <0.02%. The big ET-1
RIA showed <0.007% cross-reactivity with the mature endothelins, big
ET-2 and big ET-3, and cross-reacted 143% with big ET-l(22-38) thus
allowing the quantification of C-terminal fragment following fractionation.
Neither of the assays showed any detectable cross-reactivity (<0.000002%)
with TAK-044. Furthermore, TAK-044 did not interfere with either assay
as indicated by superimposable standard curves at concentrations five
orders of magnitude greater than the serum TAK-044 levels achieved. No
cross-reactivity was detected (<0.005%) at the highest concentrations
tested with unrelated vasoactive peptides such as ANG II, ANP and a-
calcitonin gene-related peptide.
2.5.8 Measurement of Plasma Active Renin by an Antibody
Trapping Technique
The antibody trapping technique relies on incubating plasma with renin
substrate at concentrations sufficient to ensure zero-order kinetics.
Reaction velocity is therefore proportional to renin concentration. The
ANG I generated is 'trapped' with ANG I antibodies present in high
concentration. External calibration against the International Standard
Renint350! allows results to be expressed in enzyme concentration units
rather than velocities.
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This technique is described in detail in Millar et aid350! In brief, 35 ml of
plasma was incubated at 37°C for 30 minutes with 55 ml of a premixed
solution consisting of ox or sheep renin substrate, buffer (3 mmold"1
Tris/HCl), pH 6.9, 0.005 mmolT1 EDTA) and antibody at appropriate
(predetermined by titration) trapping concentration. The ratio of the
premixed components was 8:2:1. The enzyme reaction was terminated by
dilution and cooling, obtained by the addition of 1.4 ml of ice-cold buffer
(0.25 molT1 Tris/HCl, pH 7.4, 0.01% human serum albumin; HSA),
followed at once by trace 125I-ANG I (20 pg, 5000 - 10 000 cpm). The
radioimmunoassay for ANG I was completed by further incubation at 4°C
for 48 hours. Separation of free and bound ligand was achieved by addition
of Dextran-coated charcoal (150 ml). The intra-assay CV for this assay is
3.4%.
Standard curves for ANG I were prepared by serial dilution of Ile5-ANG I
in 35 ml buffer (0.25 mold"1 Tris/HCl, 7% HSA) from 1000 - 16 pg per
tube in duplicate. Tubes containing no ANG I were also included. Fifty-
five ml of antibody-substrate-buffer was added and tubes were then treated
identically as unkowns.
2.5.9 TAK-044 (Studies 3 & 4)
TAK-044 was extracted from sodium acetate (pH 5) buffered serum by
methanol/acetic acid-conditioned Varian Certify II cartridges and was
measured by HPLC. Eluates were evaporated to dryness under vacuum at
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40°C, and the dry residues were taken up in 200 ml of 39% acetonitrile.
Chromatographic separation was achieved by column-switching technique
using two Alltech CI8 HPLC columns with Gilson model 307 HPLC
pumps. The first mobile phase comprised 40% acetonitrile and 60% 0.01
mold"1 KH2PO4/O.OO5 mold"1 tetrabutylammonium bromide, pH 3.8. The
second mobile phase comprised 45% acetonitrile / 1% acetic acid / 54%
water. Detection was achieved by fluorimetry (excitation, 286 nm;
emission, 348 nm) with Hitachi F-1050 fluorescence detectors. The limit
of quantification of this assay, defined as the lowest quantifiable amount of
compound at which the loss of precision was 10% and the accuracy was
between ± 20%, was 5 ng.ml"1 of TAK-044.
2.5.10 TAK-044 (Studies 5, 6 & 7)
TAK-044 was extracted from buffered (Merck 9437; pH 5) plasma by
methanol/buffer-preconditioned Bakerbond SPE cartridges and was
measured by HPLC. Eluate was evaporated to dryness under nitrogen at
40°C, and the residue reconstituted in 100 pi water. Chromatographic
separation was achieved using two Merck LiChrospher columns with
Hewlett Packard 1090 HPLC pumps. The first mobile phase comprised
40% acetonitrile and 60% 6 mmol.l"1 KH2PO4/3 mmol.l"1
tetrabutylammonium bromide. The second mobile phase comprised 52%
acetonitrile/0.5% acetic acid/47.5% water. Detection was achieved by
fluorimetry (excitation, 286 nm; emission 348 nm) with Jasco 821
fluorescence detectors. The limit of quantification of this assay, defined as
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the lowest quantifiable amount of compound at which the loss of precision
was -15% and the accuracy was ± 15%, was determined to be 2.1 ng.ml"1.
2.5.11 Plasma Adrenaline and Noradrenaline
Plasma adrenaline and noradrenaline concentrations were measured by
dual-electrode coulometric detection after separation on a reverse phase
HPLC column as previously described. !517l A simple solvent extraction
system was used for the selective and quantitative isolation of adrenaline
and noradrenaline.!517] The limits of detection were.<5 pg per injection for
both adrenaline and noradrenaline with a coefficient of variation of 2% for
adrenaline and 1.6% for noradrenaline. The average recovery of




Figure 2.1 Forearm blood flow measurements
Simultaneous measurements of blood flow in both cannulated and control
arms, during brachial artery infusion of physiological saline followed by
angiotensin II in the cannulated arm. Flows are given by the gradient of the
increase in forearm volume with time during inflation of upper arm cuffs
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Neutral endopeptidase (EC 3.4.24.11; enkephalinase; NEP) is a plasma
membrane-bound zinc metalloprotease that was initially isolated from
renal epithelial brush border cells and cleaves peptide substrates at the
amino side of hydrophobic amino acids.11551 It catalyses the degradation of
a number of endogenous vasodilator peptides, including atrial natriuretic
peptide (ANP),!533! brain natriuretic peptide,12981 C-type natriuretic
peptide,!264! substance Pt515! and bradykinin,!155! as well as
vasoconstrictor peptides including ET-ll2l and ANG II.!155! In addition to
degrading vasoactive peptides to inactive breakdown products, NEP can
also convert big ET-1 to the active peptide, ET-1.!374! Therefore, the
physiological actions of NEP in vivo will be the balance of its effects on
the breakdown of vasodilators and vasoconstrictors, and on the synthesis
of ET-1 from big ET-1 (Figure 3.1).
NEP is inhibited by several agents, including candoxatrilatl113],
thiorphan!496! and its prodrug, sinorphan,!201! and phosphoramidon.!155!
ANP has potent natriuretic! 12°1 and vasodilator properties,!112' 605! and
inhibits activity of the renin-angiotensin-aldosterone system by reducing
both renin!66! and aldosterone!28! release. Therefore, increasing the
circulating concentrations of ANP through inhibition of NEP is an
attractive therapeutic approach to a number of cardiovascular diseases such
as hypertension and heart failure.!539! However, although NEP inhibitors
-increase circulating ANP concentrations in man, and cause the expected
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natriuresisj57' 20'> 393> 4551 they do not generally lower blood pressure in
normotensive subjects.!201- 397- 455- 4571 Indeed, both candoxatril!15! and
candoxatrilat!371! have been reported as raising blood pressure in
normotensive subjects. Although NEP inhibitors have been reported to
lower blood pressure in patients with essential hypertension,!16 E 306> 401>
452, 453, 456, 544, 578] this finding has not been universal.!57' 158> 397- 45E
51 ->] Thus, the therapeutic value of NEP inhibitors in hypertension remains
uncertain. In patients with heart failure, these agents do not reduce
afterload although they do reduce pulmonary capillary wedge pressure,
presumably due to natriuresis.!253> 3931
If the predominant substrates for vascular NEP were vasodilator peptides,
then local inhibition of this enzyme should cause peripheral vasodilatation.
However, in previous studies using brachial artery administration of the
NEP inhibitor, thiorphan, a modest vasoconstriction had been
observed!218' 3181 suggesting accumulation of vasoconstrictor peptides
such as ANG II or ET-1. Therefore, in the present study, the effects of
brachial artery administration of a structurally different NEP inhibitor,
candoxatrilat, on forearm blood flow were examined to determine whether
the vasoconstriction produced by thiorphan is a class effect of NEP
inhibitors. Whether an accumulation of ANG II was the cause of the
forearm vasoconstriction produced by thiorphan was also investigated by
infusing thiorphan into the brachial artery, in the presence or absence, of
concurrent systemic ACE inhibition. Furthermore, whether accumulation
-of ET-1 was the cause of the forearm vasoconstriction by thiorphan was
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examined by co-infusing an ETA antagonist, BQ-123, together with
thiorphan. The effects of brachial artery administration of thiorphan in a
group of hypertensive patients was also examined to confirm the clinical
relevance of these findings in healthy subjects.
3.2 Methods
3.2.1 Subjects
Twenty-four healthy male subjects, and 6 hypertensive patients (BP >
160/100 mmHg) who had not yet received any treatment, participated in
these studies. None of the subjects received vasoactive or non-steroidal
anti-inflammatory drugs in the week before each phase of the study, and all
abstained from alcohol for 24 hours and from food, caffeine-containing
drinks, and cigarettes for at least 3 hours before any measurements were
made. All studies were performed in a quiet room maintained at a constant
temperature of between 22 and 25°C.
3.2.2 Drugs
Candoxatrilat (Pfizer Central Research, Sandwich, UK) and thiorphan
(Sigma, Poole, UK) were administered intra-arterially dissolved in
physiological saline (0.9%; Baxter Healthcare Ltd). (+)Candoxatrilat (UK-
73,967) was used in this study; this eutomer has twice the potency as a
.NEP inhibitor than the racemate, (±)candoxatrilat (UK-69,578)t38l and is
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the active metabolite of the orally available prodrug candoxatril. The dose
of candoxatrilat (125 nmol.min"1) was chosen to achieve forearm blood
concentrations >50-fold higher than the IC50 (40 nmol.l"1) of
(+)candoxatrilat in vz'/ro.!38] The dose of thiorphan (30 nmol.min"1) used in
this study has been shown to produce -20% reduction in forearm blood
flow when infused via the brachial artery.!218] This dose is known to
achieve local concentrations in forearm blood, following brachial artery
administration, > 10-fold higher than the IC50 of thiorphan (35 nmol.T1) for
NEP in vitro based on a forearm blood flow of 50 ml.min"1.
The peptide ETA antagonist, BQ-123 (Cyclo{—D-Asp—L-Pro—D-Val—L-
Leu—D-Trp—}; American Peptide Company, Sunnyvale, CA, USA) was
administered intra-arterially (100 nmol.min"1) dissolved in physiological
saline. This dose chosen achieves local concentrations in the forearm > 10-
fold higher than the pA2 at the ETA receptor and is known to produce
-40% increase in blood flow when infused via the brachial artery.!218]
The ACE inhibitor, enalapril (Merck, Sharp & Dohme Ltd), was
administered orally in ascending, single, daily doses of 2.5, 5, 10 and 15
mg over a period of 4 days. This ascending dose design was used to
minimize the already low risk of hypotension. On the fifth day, subjects
were admitted to the clinical research centre and, after lying supine for 30
minutes, they received 20 mg enalapril orally at 8:30 AM. The final dose
of 20 mg was chosen because it reduces plasma concentrations of ANG II
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to a level close to the detection limit of radioimmunoassay 4 hours after
administration.P51l
3.2.3 Intra-arterial administration
The left brachial artery was cannulated under local anesthesia (see Section
2.1.1). The total rate of intra-arterial infusion was maintained constant
throughout all studies at 1 ml.min"1.
3.2.4 Measurements
Forearm Blood Flow
Blood flow was measured in both forearms by venous occlusion
plethysmography using indium/gallium-in-Silastic gauges (see Section
2.1.1).
Blood Pressure
Duplicate measurements of blood pressure in the non-infused arm were
taken, which were then averaged (see Section 2.2.1).
Plasma assays
Forty ml venous blood samples were obtained at intervals for assay of
concentrations of plasma active renin, ANG II, aldosterone, ANP and
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endothelin from both arms. This technique of bilateral venous sampling,
from deep veins in the antecubital fossae, together with intra-brachial
artery infusion of locally active agents has been reported previously. 14361
Samples were collected into chilled tubes, centrifuged at 1500 g for 20
minutes at 4°C and stored at -80°C until assay. All assays were performed
as single batches (see Section 2.5).
3.2.5 Study Design
Four single-blind studies were performed.
Protocol 1: Intra-arterial candoxatrilat
Ten subjects participated in this single-phase, single-blind study. Subjects
rested recumbent throughout. Physiological saline was infused via the left
brachial artery for 30 minutes. Candoxatrilat (125 nmol.min"1) was then
infused for 90 minutes. Forearm blood flow was recorded in both arms
every 5 minutes. Blood pressure was measured at 10 minute intervals.
Protocol 2: Intra-arterial thiorphan and systemic ACE inhibition
Six subjects participated in this two-phase, single-blind, crossover study.
In each phase, subjects were administered orally either increasing single
daily doses of enalapril (as detailed above), or matching placebo. On the
fifth day subjects were admitted to the clinical research centre at 8:00 AM,
and deep veins in both antecubital fossae were cannulated with 18G
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intravenous cannulae (Venflon; Viggo-Spectramed) for blood sampling.
After lying recumbent for 30 minutes (8:30 AM) a venous blood sample
was taken, from the right (noninfused) arm for assays of renin, ANG II,
aldosterone, ANP and endothelin concentrations. Blood pressure was
measured and enalapril 20 mg or placebo was administered at 8:30 AM.
Blood pressure was then measured at 30 minute intervals for 3.5 hours
with the subjects remaining recumbent. At 12:00 AM, physiological saline
was infused via the left brachial artery for 30 minutes. At 12:30 PM,
thiorphan (30 nmol.min"1) was infused for 90 minutes, 4 hours after
administration of the final dose of enalapril or placebo. Before the start of
the thiorphan infusion, a venous blood sample was taken for aldosterone,
renin and clinical biochemistry from the right (noninfused) arm. Blood
samples were also taken from both arms, at the beginning and end of the
period of thiorphan infusion, for measurement of plasma ANG II, ANP and
endothelin concentrations.
Protocol 3: Intra-arterial thiorphan and intra-arterial BQ-123
Eight subjects participated in this randomised three-phase, single-blind
study. Subjects rested recumbent throughout. Physiological saline was
infused via the left brachial artery for 30 minutes. In random order and in
separate occasions, at least one week apart, either thiorphan (30 nmol.min"
') or BQ-123 (100 nmol.min"1) alone, or both in combination were then
infused for 90 minutes. Forearm blood flow was recorded in both arms
every 5 minutes. Blood pressure was measured at 10 minute intervals.
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Protocol 4: Intra-arterial thiorphan in hypertensive patients
Six hypertensive patients participated in this single-phase, single-blind
study. Subjects rested recumbent throughout. Physiological saline was
infused via the left brachial artery for 30 minutes. Thiorphan (30
nmol.min"1) was then infused for 90 minutes. Forearm blood flow was
recorded in both arms every 5 minutes. Blood pressure was measured at 10
minute intervals.
3.2.6 Data Analysis and Statistics
Plethysmographic data listings were extracted from the Chart data files and
forearm blood flows calculated for individual venous occlusion cuff
inflations using a template spreadsheet (Excel 4.0; Microsoft Ltd) as
described in Section 2.1.1.
Data are shown as mean ± standard error of the mean (SEM) in the figures
and as mean ± SEM with 95% confidence intervals in the tables for the
effects of NEP inhibition. Forearm blood flows were examined by repeated
measures analysis of variance (ANOVA) using Statview 512+ software
(Brainpower Inc, Calabasas, Ca, USA) for the Apple Macintosh personal
computer. The overall forearm blood flow response to intra-arterial
candoxatrilat and thiorphan are described in the text as the area under the
curve (AUC)i342! and as individual maximum responses (max).
Haemodynamic and assay measures where analysed by ANOVA and
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Student's /-test were appropriate! 131 using Statview 512+ software
(Brainpower Inc, Calabasas, CA, USA) for the Apple Macintosh personal
computer.
3.3 Results
Protocol 1: Intra-arterial candoxatrilat
Brachial artery infusion of candoxatrilat did not alter systolic, diastolic or
mean arterial pressure (86 ± 2 to 90 ± 2 mm Hg) or heart rate (63 ± 3 to 64
± 3 beats per minute). Also, blood flow in the noninfused arm did not alter
significantly following infusion of candoxatrilat, confirming that drug
effects were confined to the infused arm. Brachial artery infusion of
candoxatrilat caused a slowly progressive forearm vasoconstriction, with
blood flow decreasing by a mean (AUC) of 12 ± 2% and maximum of -28
± 3% (p=0.001; Figure 3.2) during the 90 minute infusion.
Protocol 2: Intra-arterial thiorphan and systemic ACE inhibition
There were no significant differences between plasma urea, electrolytes
and creatinine concentrations at the start of the thiorphan infusion during
the placebo and enalapril phases. Heart rate and mean arterial pressure
were not significantly different at the start of thiorphan infusion in either
phase, and did not change during the intra-arterial infusion of thiorphan in
-dither phase (Table 3.1).
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Plasma active renin concentrations were higher after 4 days of treatment
with enalapril than with placebo. Plasma active renin concentration
increased further 4 hours after administration of 20 mg enalapril, with no
change during the placebo phase (Table 3.1). Plasma ANG II concentration
tended to be lower after 4 days of enalapril, although this difference
between phases did not reach statistical significance (Table 3.2; p=0.09).
Plasma ANG II concentrations did not change significantly during the
placebo phase in either the infused or non-infused arms. Four hours after
administration of 20 mg enalapril, there was a substantial reduction in
plasma ANG II concentration (Table 3.2). Plasma ANG II concentration
did not change further during the 90 minute thiorphan infusion in the
enalapril phase in either the infused or non-infused arms (Table 3.2).
Venous aldosterone concentration was lower after 4 days of enalapril than
after 4 days of placebo (Table 3.2). During both phases, aldosterone
concentration tended to decrease after four hours of supine posture.
However, this decrease was only significant after 20 mg enalapril when
compared to basal (Table 3.2).
Neither oral enalapril nor intra-arterial thiorphan had any effect on plasma
ANP or plasma endothelin concentrations in either the infused or non-
infused arms (Table 3.2).
Basal forearm blood flow in the infused arm tended to be lower during the
enalapril phase than the placebo phase, although this was not statistically
significant (2.9 ± 0.4 and 3.7 ± 0.4 ml. 100 mf'.min"1 respectively; p=0.12).
Blood flow in the noninfused arm did not change significantly following
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infusion of thiorphan, confirming that drug effects were confined to the
infused arm. Brachial artery administration of thiorphan caused a slowly
progressive forearm vasoconstriction, with blood flow decreasing during
both the enalapril phase (mean 17 ± 6%; max 33 ± 7%; p=0.05) and
placebo phase (mean 13 ± 3%; max 24 = 2%; p=0.006). The reductions in
blood flow were similar during either phase (p=0.6; Figure 3.3).
Protocol 3: Intra-arterial thiorphan and intra-arterial BQ-123
Brachial artery administration of BQ-123 alone caused a progressive
forearm vasodilatation (mean 33 ± 3%; max 47 ± 9%; p=0.0001) whereas
thiorphan caused a slowly progressive vasoconstriction (mean -14 ± 1%;
max -22 ± 4%; p=0.0001). Coinfusion of BQ-123 and thiorphan caused a
vasodilatation (mean 32 ± 2%; max 48 = 6%; p=0.0001)which was not
different from that observed with BQ-123 alone (p=0.98; Figure 3.4).
Protocol 4: Intra-arterial thiorphan in hypertensive patients
In hypertensive patients, brachial artery administration of thiorphan caused
a slowly progressive forearm vasoconstriction (mean -10 ± 2%; max -20 ±
3%; p=0.0001). This was not significantly different from that observed in
the healthy volunteers in the third study (p=0.39; Figure 3.5).
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3.4 Discussion
These studies have shown that the specific NEP inhibitors, candoxatrilat
and thiorphan, cause slowly progressive vasoconstriction when given by
direct brachial artery infusion to healthy subjects and patients with
essential hypertension. The vasoconstriction caused by thiorphan was not
reversed by systemic ACE inhibition but was abolished by endothelin
receptor antagonism. These findings are unlikely to be due to other actions
of these agents because both candoxatrilafi113> 393> 4961 and thiorphanf345-
41!] are highly specific for NEP. Furthermore, the finding that two
structurally independent inhibitors of NEP produce vasoconstriction
strongly suggests that this is a class effect of NEP inhibition on human
resistance vessels. It is possible that different effects may be obtained in
other blood vessels, although responses in forearm resistance vessels are
generally thought to be broadly representative of those in other vascular
beds.i103' 604] These findings have potential implications both for the
physiological role of NEP and for the therapeutic use of NEP inhibitors.
Although it was initially thought that the most important site of natriuretic
peptide metabolism by NEP was the kidney, t53 31 candoxatrilat is just as
effective in reducing clearance of ANP in nephrectomized animals,i37l
implying other, non-renal, sites of action. NEP is now known to be
expressed in blood vessels, by both endothelial195] and vascular smooth
muscle cells.H42] Despite the clear evidence for vascular generation and
'metabolism of natriuretic peptides, these studies have demonstrated that
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local NEP inhibition causes vasoconstriction rather than vasodilatation.
This finding implies that, under physiological conditions, vasoconstrictor
peptides, such as ANG II and ET-1, are more important substrates for
vascular NEP than dilator substances, such as the natriuretic peptides and
bradykinin (Figure 3.1). However, the finding that brachial artery
administration of thiorphan produces forearm vasoconstriction in the
presence of substantial systemic ACE inhibition implies that ANG II
accumulation is not responsible for the observed vasoconstriction. In
addition, ANP blocks activity of the renin-angiotensin system by reducing
renin release!66! and blocking aldosterone secretion,!28! so ANG II
generation is likely to be decreased by NEP inhibition.
The vasoconstriction to candoxatrilat and thiorphan was slowly
progressive, which is more in keeping with an effect of ET-1 than ANG II,
based on the known rate of onset of forearm vasoconstriction after brachial
artery infusion of these peptides.!88! This is supported by a recent study in
which systemic oral doses of candoxatril in healthy men, produced an
increase in both systolic blood pressure and venous plasma endothelin
concentration.!15! In another recent study, systemic administration of
candoxatrilat in healthy subjects produced a significant increase in systolic
blood pressure.!371! However, because this rise was prevented by
pretreatment with enalapril, it was suggested that the increase in blood
pressure was caused by potentiation of ANG II. These findings do not
support this conclusion. Indeed, in this study thiorphan produced arterial
vasoconstriction in the presence of systemic ACE inhibition, despite ANG
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II concentrations being very low. Furthermore, no increase in ANG II
concentrations was detected in venous blood draining the infused arm
during the placebo phase of this study suggesting that NEP inhibition does
not cause an accumulation of ANG II.
No significant fall in blood pressure after 20 mg enalapril orally was
detected despite the very low concentrations of ANG II produced.
However, this study was not designed to specifically measure changes in
systemic haemodynamics. The hypotensive effect of enalapril would be
expected to have been greatest when subjects were being prepared for the
intra-arterial stage of the study. This involved subjects standing to pass
urine and having the blood pressure cuff repositioned over the rapid
inflation cuffs required for forearm plethysmography, as well as insertion
of an intra-arterial needle.
In this study, enalapril had no effects on plasma ANP concentrations. This
is in agreement with other published reports.t81' 136' 37 ^ Intra-arterial
thiorphan did not produce a detectable increase in ANP concentrations in
venous blood draining the infused arm. However, any changes in local
ANP concentrations are likely to be small and may have been below the
sensitivity of the assay. In addition, not all studies of acute NEP inhibition
have demonstrated an increase in ANP concentrations.i15> 158> 3"1 ANP
may also be metabolised by an aminopeptidase which is insensitive to
thiorphan. t412^ Although incomplete local NEP inhibition is possible, this
is highly unlikely because the doses of both candoxatrilat and thiorphan
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used were chosen to achieve local blood concentrations in the forearm
>50-fold and > 10-fold higher higher than the IC50 of (+)candoxatrilat and
thiorphan respectively for ANP in vitroX38i
Consistent with earlier work!581!, systemic ACE inhibition with enalapril
had no effect on plasma endothelin concentrations. In addition, intra¬
arterial thiorphan did not increase plasma endothelin concentrations in
samples collected from the infused arm. However, endothelin produced by
endothelial cells is preferentially secreted abluminally!593] and inhibition
of local endothelin degradation may not have resulted in increased plasma
endothelin concentrations. Furthermore, any measurable increase in plasma
endothelin concentrations is likely to be rapidly reduced through tissue
receptor binding.!436i Therefore, the absence of any detectable rise in
plasma endothelin does not exclude local accumulation of the peptide and
it is still possible that decreased ET-1 breakdown is the cause of the
vasoconstriction produced by NEP inhibitors.
ET-1 mediates vasoconstriction primarily by effects on the vascular
smooth muscle ETA receptor.!1161 The selective ETA receptor antagonist,
BQ-123 abolishes the vasoconstriction produced by thiorphan. This
provides strong evidence that accumulation of ET-1, resulting from an
inhibition of its degradation, mediates the vasoconstriction caused by local
NEP inhibition. Nevertheless, it is also possible that accumulation of an as
yet undiscovered vasoconstrictor may contribute to the observed
^vasoconstriction, although its abolition by BQ-123 makes this unlikely.
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In clinical trials, NEP inhibitors have been shown to cause a natriuresis
and diuresis.!201' 393] However, a reduction in blood pressure has not been
clearly demonstrated in normotensive subjects!201- 399, 455, 457]
studies have even reported an increase in blood pressure!15' 371] despite the
potent vasodilator actions of the natriuretic peptides.!112- 539> 6051 Also,
several studies on hypertensive patients!57- 138, 398, 451, 514] have not
demonstrated a reduction in blood pressure. Furthermore, a recent study in
patients with CHF showed that candoxatrilat further increased systemic
vascular resistance in these patients.!2651 These results help to explain this
apparent contradiction. The haemodynamic effects of systemic NEP
inhibition will depend on the balance between its cardiac, renal and
vascular actions. These studies have shown that local NEP inhibition
causes forearm vasocontriction in healthy subjects and, of greater clinical
relevance, that this effect is also occurs in untreated essential hypertensive
patients. Thus, peripheral vasoconstriction may play an important role in
counteracting the anti-hypertensive actions of NEP inhibition.
This study shows that the vasoconstriction produced by NEP inhibitors
may be mediated by ET-1 or other vasoconstrictor peptides. Given that
systemic NEP inhibition has been shown to increase venous endothelin
concentrations,! 151 it is possible that the combination of NEP inhibition
and endothelin antagonism may be useful therapeutically. Indeed,
phosphoramidon, a combined endothelin-converting enzyme and NEP
inhibitor, is known to produce substantial vasodilatation when infused
.intra-arterially in humans,!218> 3181 and can lower blood pressure in
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normotensive and hypertensive rats.i345! Nevertheless, even without
reducing blood pressure, NEP inhibition may offer therapeutic benefits in
hypertension and heart failure. For example, infusion of ANP causes
sympathoinhibition in man.i15! In addition, NEP inhibitors appear to
possess favourable anti-mitogenic effects in models of left ventricular
hypertrophyi365] and atherosclerosis.P92l Such effects would need to be
counterbalanced against potential mitogenic actions of ET-l.i197i
In conclusion, local inhibition of NEP causes slowly progressive
vasoconstriction in healthy subjects and essential hypertensive patients,
suggesting that the predominant physiologic substrates for vascular NEP
are vasoconstrictor peptides. The slowly progressive nature of the
vasoconstriction together with the finding that it is not blocked by systemic
ACE inhibition, but is abolished by endothelin antagonism, supports
accumulation of ET-1 as the cause. Vasoconstriction produced by NEP
inhibitors may help to explain some of the apparently contradictory




Table 3.1 Systemic haemodynamics after oral enalapril and intra¬
arterial thiorphan
Heading Heart rate, blood pressure, plasma active renin and
aldosterone concentrations (mean ± SEM) before (8:30 AM; basal) and 4
hours after (12:30 PM) oral administration of placebo or enalapril 20 mg.
Footnote CI indicates confidence intervals.
*p = 0.05 vs. basal (8:30 AM)
f p = 0.05 vs. placebo phase
{ p = 0.005 vs. placebo phase
Table 3.2 Plasma concentrations of vasoactive hormones after oral
enalapril and intra-arterial thiorphan
Heading Plasma ANP, ANG II and endothelin (ET) concentrations
(mean ± SEM) taken from the infused and non-infused arms (see main text
for details) before (basal; 8:30 AM) and 4 hours (12:30 PM) after oral
administration of enalapril 20 mg, and after 90 minutes intra-arterial
infusion of thiorphan 30 nmol.min"1 (2:00 PM; 5.5 hours after enalapril 20
mg orally). 95% confidence intervals are shown in brackets.
Footnote *p = 0.05 vs. basal (8:30 AM)
tp = 0.005 vs. placebo
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3.6 Figure Legends
Figure 3.1 Actions of neutral endopeptidase
The enzyme neutral endopeptidase 24.11 (NEP) catalyses the metabolism
of the vasoconstrictor peptides ET-1 and ANG II, as well as the
metabolism of several vasodilator peptides, including bradykinin (BK),
atrial, brain and C-type natriuretic peptides (ANP, BNP and CNP
respectively) and substance P (SP). NEP is also involved in the enzymatic
conversion of big ET-1 to its active form, the vasoconstrictor peptide, ET-
1. The balance of effects of NEP inhibition on vascular tone will,
therefore, depend on whether the predominant substrate(s) degraded by
NEP are vasodilators or vasoconstrictors and in the extent of NEP
involvement in the processing of big ET-1.
Figure 3.2 Intra-arterial candoxatrilat
Effect of brachial artery administration of the NEP inhibitor, candoxatrilat
(125 nmol.min"1 for 90 minutes), on forearm blood flow in 10 healthy,
male volunteers. Candoxatrilat produced a slowly progressive
vasoconstriction confined to the infused forearm (p=0.001).
Figure 3.3 Intra-arterial thiorphan and systemic ACE inhibition
Effect of brachial artery administration of the NEP inhibitor, thiorphan (30
nmol.min"1), on forearm blood flow after oral placebo (o) or oral enalapril
'(•) in 6 healthy, male volunteers (see text for details). Thiorphan produced
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a slowly progressive vasoconstriction both during the placebo (p=0.05) and
enalapril phases (p=0.01), with no significant difference between the two
phases (p=0.6).
Figure 3.4 Intra-arterial thiorphan and BQ-123
Effect of brachial artery administration of the NEP inhibitor, thiorphan (o;
30 nmol.min"1), the endothelin receptor antagonist, BQ-123 (•; 100
nmol.min"1) and coinfusion of both agents (□) on forearm blood flow.
Thiorphan produced a slowly progressive vasoconstriction (p=0.0001)
whereas BQ-123 caused a slowly progressive vasodilatation (p=0.0001).
Co-infusion of BQ-123 and thiorphan produced a vasodilatation
(p=0.0001) not significantly different from that produced by BQ-123 alone
(p=0.98).
Figure 3.5 Intra-arterial thiorphan in hypertensive patients
Effect of brachial artery administration of the NEP inhibitor, thiorphan (30
nmol.min"1), on forearm blood flow in 6 hypertensive patients. Thiorphan






























































































































































































8:30 AM 13.0 ± 3.4 (4.4 to 21.7)
12:30 PM 14.8 ±3.6 (4.7 to 24.9)
2:00 PM 21.8 ±5.5 (7.8 to 35.8)
8:30 AM 15.2 ± 2.3 (9.2 to 21.1)
12:30 PM 13.0 ±3.1 (5.0 to 21.0)
2:00 PM 17.2 ±2.6 (10.6 to 23.8)
8:30 AM 12.7 ± 2.5 (6.2 to 19.2)
12:30 PM 12.6 ±2.6 (6.0 to 19.1)
2:00 PM 7.8 ± 1.8 (3.4 to 12.2)
8:30 AM 7.4 ± 1.2 (4.2 to 10.6)
12:30 PM 1.7 ± 0.3*t (0.8 to 2.5)
2:00 PM 1.5 ± 0.4*f (0.5 to 2.6)
8:30 AM 3.8 ± 0.3 (3.0 to 4.6)
12:30 PM 3.7 ±0.4 (2.6 to 4.6)
2:00 PM 4.3 ±0.5 (2.9 to 5.7)
8:30 AM 4.1 ± 0.2 (3.5 to 4.7)
12:30 PM 3.8 ±0.2 (3.3 to 4.4)




21.5 ±7.9 (1.2 to 41.8)
18.6 ±3.6 (9.3 to 28.0)
N/A
17.1±3.1 (9.2 to 25.0)
21.5±5.3 (7.9 to 35.0)
N/A
10.0 ± 1.9(5.2 to 14.8)
8.2 ±3.3 (4.7 to 11.7)
N/A
1.6 ± 0.4*t (0.6 to 2.7)
1.5 ± 0.4*t (0.6 to 2.4)
N/A
4.3 ± 0.3 (3.6 to 4.9)
3.6 ±0.5 (2.3 to 4.1)
N/A
3.9 ±0.4 (3.7 to 4.6)












Thiorphan (30 nmol.min _1)
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Big endothelin-3 constricts forearm resistance vessels but not














Of the three endothelins, ET-1 appears is the major isoform produced by
the vascular endothelium and is therefore likely to be the most important
isoform in terms of cardiovascular function. ET-1 is produced from an
inactive 38-amino acid intermediate form, big ET-1, by selective cleavage
21 22of the Trp -Val bond in the carboxy-terminal of big ET-1 catalysed by
an endothelin-converting enzyme (ECE).!471! In humans, ET-2 and ET-3
are also formed by corresponding intermediates, big ET-2 and big ET-
3.1471i Immunoreactive big ET-2, ET-3 and big ET-3 have also been
detected in human plasma!190' 3391 and prepro ET-3 mRNA has been
detected in blood vessels,!5941 suggesting that blood vessels might
synthesize and respond to other isopeptides in addition to ET-1.
Two ECEs have so far been cloned in man, ECE-l!495! and ECE-2.!152!
Both ECE-1 and ECE-2 convert big ET-1 in preference to big ET-2 and
big ET-3.!152' 6331 This substrate specificity suggests that there may be yet
undiscovered ECE(s) selective for big ET-2 or big ET-3. Previous work
has demonstrated that exogenously administered big ET-1 vasoconstricts
human forearm resistance vessels!2181 but not human capacitance
vessels!2141 in vivo. Because circulating blood contains no significant ECE
activity,!602] these findings suggest that forearm resistance vessels contain
an ECE able to cleave luminally presented big ET-1 to the mature peptide.
However, it is not known whether human resistance or capacitance vessels
■contain an ECE able to generate ET-3 from big ET-3. These studies were
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designed to investigate the potential existence of such an ECE by infusing
big ET-3 into the brachial artery and dorsal hand vein of healthy volunteers
and assessing constrictor responses by measuring forearm blood flow and
dorsal hand vein diameter.
4.2 Methods
4.2.1 Subjects
A total of eight healthy male subjects between 22 and 35 years of age
participated in these studies. Four subjects participated in both studies. No
subject received vasoactive or non-steroidal anti-inflammatory drugs in the
week before each phase of the study, and all abstained from food for 4
hours, and from alcohol, caffeine containing drinks and cigarettes for at
least 12 hours before any measurements were made. All studies were
performed in a quiet room maintained at a constant temperature between
24 and 26°C.
4.2.2 Drugs
Pharmaceutical grade ET-3 (Peninsula Laboratories, Europe) and big ET-3
(Peninsula Laboratories) were administered. A single dose of each peptide
was used in individual studies because the slow-onset and long-lasting
action of the endothelin isopeptides precludes the use of repeated doses in
a single study to examine conventional dose relationships.t88l The peptides
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were dissolved in physiological saline (0.9%; Baxter Healthcare Ltd,
Thetford, UK).
Intra-arterial Administration
The left brachial artery was cannulated under local anaesthesia as
described in Section 2.1.1. The total rate of intra-arterial infusion was
maintained constant at 1 ml.min"1.
Intravenous Administration
A 23-gauge butterfly needle attached to a 16-gauge epidural catheter was
sited in a selected dorsal hand vein, without the use of local anaesthesia, in
the direction of flow as described in section 2.1.2. Patency was maintained
by infusion of physiological saline. The total rate of intravenous infusion
was maintained constant at 0.25 ml.min"1.
4.2.3 Measurements
Forearm blood flow
Blood flow was measured in both forearms by venous occlusion
plethysmography!604] using mercury-in-Silastic strain gauges as described
in Section 2.1.1.
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Dorsal Hand Vein Diameter
Dorsal hand vein diameter was measured by use of the Aellig technique as
described in Section 2.1.2.
Blood Pressure
A well-validated semi-automated noninvasive oscillometric
sphygmomanometer was used to make duplicate measurements of blood
pressure in the noninfused arm (see Section 2.2.1).
4.2.4 Study Design
Forearm Resistance Bed Protocol
Subjects were studied on four separate occasions, and rested recumbent
throughout each study. Strain gauges and upper arm cuffs were applied,
and the left brachial cannula was sited. Saline was infused for 30 minutes,
during which three measurement of forearm blood flow were made at (-25,
-15 and -5 minutes). Blood pressure was measured immediately after each
forearm blood flow measurement, thereby avoiding any effect on forearm
blood flow measurements of the venous congestion caused by this
procedure. t429l In random order and on separate occasions separated by at
least 7 days, subjects received 90 minute brachial artery infusions of ET-3
at 5 and 10 pmol.min"1 and big ET-3 at 50 and 100 pmol.min"1. The lower
dose of ET-3 was chosen based on previous work showing in vivo that 5
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pmol.min"1 of ET-3 causes slow-onset vasoconstriction in human forearm
resistance vessels, reducing blood flow by ~20%d217] The higher dose of
ET-3 (10 pmol.min"1) was chosen with the intention of causing a greater
forearm vasoconstriction and reducing blood flow to a similar extent to
ET-1 (-40%).I88' 2181 The doses of big ET-3 were chosen with the
intention of producing a measurable forearm vasoconstriction even with
only 5-10% conversion to ET-3. Although no in vivo studies in human
resistance vessels with big ET-3 have been reported, previous work with
big ET-1 has shown that 50 pmol.min"1 of big ET-1 produces a
vasoconstriction comparable to 5 pmol.min"1 of ET-1.1218! Forearm blood
flow was measured at 5 minute intervals during the infusion of the study
agents. Blood pressure was measured at 30, 60 and 90 minutes after the
start of the infusion.
Hand Vein Protocol
Subjects were studied on three separate occasions separated by at least 7
days, in random order/Subjects rested semi-recumbent throughout each
study. The dorsal hand vein cannula and the LVDT were sited. Saline was
infused for 30 minutes, during which vein diameter was measured every 5
minutes. Then, on three separate occasions, saline, ET-3 or big ET-3 were
infused for 90 minutes, with measurement of vein diameter every 5
minutes. The choice of dose of ET-3 was based on previous work showing,
in vivo, that 5 pmol.min"1 ET-3 causes slow-onset venoconstriction of ~5-
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10%.P05] xhe choice of dose of big ET-3 was based on previous work
with big ET-ld214!
4.2.5 Data Analysis and Statistics
Plethysmographic data listings were extracted from the Chart data files,
and forearm blood flows were calculated for individual venous occlusion
cuff inflations by use of a template spreadsheet (Excel 4.0; Microsoft Ltd)
as described in Section 2.1.1.
Basal vein diameter was calculated as the mean of the last three
measurements before the start of the study infusion, expressed in
millimetres. Because basal vein size varies between subjects, responses are
expressed as a percentage change in vein size from basal in order to reduce
the inter-subject variability as described in Section 2.1.2.
Data are shown as mean values, with 95% confidence intervals (CI) shown
in the text and SEM in the figures. Data were examined by a repeated
measures analysis of variance (ANOVA) with statistical testing of overall
significance by Scheffe's F test (ANOVA) using Statview 512+ software




Basal blood pressure, heart rate, forearm blood flow, and vein diameter
were similar on the different study days, and there was no significant
difference in basal blood flow between the infused and noninfused
forearms (Table 4.1). Blood pressure, heart rate, and blood flow in the
noninfused arm, did not change significantly after infusion of any study
agent, confirming that drug effects were confined to the infused arm (Table
4.1).
Forearm Resistance Bed Protocol
ET-3 at 5 pmol.min"1 caused a significant forearm vasoconstriction, with a
-20% reduction in forearm blood flow at 90 minutes (CI: -40 to -1%;
P=0.009 vs. baseline; Figure 4.1). ET-3 at 10 pmol.min"1 also significantly
reduced forearm blood flow by -20% after 90 minutes (CI: -33 to -8%;
P=0.001 vs. baseline; P=0.69 vs. ET-3 at 5 pmol.min"1; Figure 4.1).
Big ET-3 at 50 pmol.min"1 caused a significant forearm vasoconstriction,
with a -22% reduction in forearm blood flow at 90 minutes (CI: -38 to -
5%; P=0.009 vs. baseline; P=0.88 vs. ET-3 5 pmol.min"1; P=0.73 vs. ET-3
10 pmol.min"1; Figure 4.1). Big ET-3 at 10 pmol.min"1 also significantly
reduced forearm blood flow by -18% after 90 minutes (CI: -29 to -8%;
P=0.001 vs. baseline; P=0.44 vs. Big ET-3 at 50 pmol.min"1; P=0.65 vs.
ET-3 5 pmol.min"1; P=0.21 vs. ET-3 10 pmol.min"1; Figure 4.1).
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Hand Vein Protocol
There was no significant change in vein diameter in the control session,
with a change from basal after infusion of saline for 90 minutes of +2%
(CI: -6 to +10%; P=0.66; Figure 4.2). Intravenous infusion of big ET-3 did
not cause any vasoconstriction, with a change in vein size at 90 minutes of
-2% (CI: -12 to +8%; P=0.43; Figure 4.2). In contrast, a 10-fold lower dose
of ET-3 caused progressive venoconstriction of-9% at 90 minutes (CI: -12
to -6%; P=0.04) which was significantly different to the response to saline
(P=0.001) and big ET-3 (P=0.008).
4.4 Discussion
These clinical studies have shown that both ET-3 and its precursor big ET-
3 cause forearm vasoconstriction. They have also shown that ET-3
constricts human hand veins whereas big ET-3 does not. These findings
have important implications for the existence and distribution of an ECE
capable of converting big ET-3 to the mature peptide and are similar to
those obtained for big ET-1.
These studies have shown that intra-arterial infusion of ET-3 causes
vasoconstriction of forearm resistance vessels confirming an earlier
report.!217] However, the vasoconstriction to ET-3 (5 pmol.min"1) is
considerably less than that seen with the nonselective ETA and ETb agonist
ET-1 (5 pmol.min"1).!218] This held true even when the concentration of
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ET-3 infused was doubled to 10 pmol.min"1. However, it is difficult to
extrapolate these results to quantify the relative contribution of each
receptor subtype in mediating the vasoconstrictor effects of endogenous
endothelin. Further comparative studies with selective ETA and ETB
antagonists may help clarify this issue.
It is highly unlikely that big ET-3 had a direct vasoconstrictor action given
its very low affinity for endothelin receptors.!471] Therefore the
vasoconstriction caused by big ET-3 is likely to have resulted from
conversion to ET-3. These studies, therefore provide direct evidence for
the existence of an ECE capable of converting big ET-3 to ET-3. As both
ECE-1 and ECE-2 convert big ET-1 in preference to big ET-3!197] this
study also provides indirect evidence for the existence of another ECE in
forearm resistance arteries. The slow onset and sustained actions of the
endothelin isopeptides precluded the use of repeated doses in a single study
to examine conventional dose-relationships. Therefore, the proportion of
exogenously administered big ET-3 converted to ET-3 cannot be
determined from this study.
There does not appear to be any ECE activity present in human hand veins
because no venoconstriction to big ET-3 was found despite using a dose
ten-fold higher than a dose of ET-3 sufficient to cause -10%
venoconstriction. However, it is possible that an ECE may be present in
these vessels but not in a location to convert exogenously (intra-luminal)
big ET-1 or big ET-3. Only responses to a single dose of ET-3 were tested
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because the slow onset and sustained actions of ET-3 preclude the use of
repeated doses in a single study to examine conventional dose-response
relationships. !6041 Hand vein size did not alter during saline infusion,
confirming that these veins are completely relaxed under these
experimental conditions.!214!
The lack of effect of big ET-3 in human hand veins contrasts with the
forearm vasoconstrictor actions of the same dose of big ET-3 administered
via the brachial artery. It could be argued that this difference between hand
veins and forearm resistance vessels is a result of the reduced time infused
big ET-3 is in contact with the hand vein (~1 cm in length) under study.
This may be too small to allow adequate biochemical conversion of big
ET-3. This would appear to be unlikely given that similar studies have
shown that ANG I constricts human hand veins, this effect being blocked
by an ACE inhibitor, demonstrating the presence of ACE in these
vessels.1051 There is only a small difference in constrictor potency
between ANG I and ANG II in hand veins, similar to the observations with
angiotensin peptides in the forearm resistance bed.!105!
The lack of conversion of big ET-3 coincides with finding with the lack of
effect of big ET-1 in human hand veins!214! despite forearm
vasoconstrictor actions of the same dose of big ET-1.!218! Thus ECE
activity for big ET-1 appears to have a similar vessel distribution to ECE
activity for big ET-3.
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The endothelin system of peptides have been implicated in the
pathophysiology of several cardiovascular diseases.I197] Although the
major emphasis to date has been in the clinical development of endothelin
receptor antagonists, the search for a pathophysiologically relevant ECE
and potent ECE inhibitors to prevent endothelin production continues.!415'
5791 There is a current controversy as to whether combined ETA and ETb
receptor antagonists are preferable to selective ETA antagonists which
leave vasodilator ETb receptors unblocked.!609] Given that ET-3 is a
relatively selective agonist at ETb receptors, it could be potentially
beneficial for a clinically useful ECE inhibitor not to block big ET-3
conversion. The identification of the ECE responsible for big ET-3
conversion is, therefore, important.
In conclusion, these results show that human forearm resistance vessels
have the capacity to convert exogenous big ET-3. In contrast, human hand
veins appear to lack the capacity to convert exogenous big ET-3 and
suggest that these capacitance vessels exhibit little or no ECE activity.




Table 4.1 Blood pressure and heart rate before and after local
infusions of vasoactive agents and basal forearm blood
flows and hand vein diameters
Mean arterial pressure (MAP) and heart rate (HR) before and after 90
minute infusion of sodium chloride (SAL), big endothelin-3 (big ET-3)
and endothelin-3 (ET-3). Basal hand vein diameter and forearm blood flow
in the infused arm are also shown.
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4.6 Figure Legends
Figure 4.1 Intra-arterial ET-3 and big ET-3
Changes in forearm blood flow following infusion of endothelin-3 (5
pmol.min"1 O; 10 pmol.min"1 •) and big endothelin-3 (50 pmol.min"1 □;
100 pmol.min"1 ■). Significant vasoconstriction occurred after infusion of
both peptides at both doses.
Figure 4.2 Intravenous ET-3 and big ET-3
Changes in hand vein diameter following infusion of sodium chloride
(0.9% w/v O), endothelin-3 (5 pmol.min'1 •) and big endothelin-3 (50


























































































































Actions of systemic endothelin receptor blockade on















The physiological relevance of endogenous generation of endothelin in the
control of blood pressure has been unclear. If basal generation of
endothelin contributes to resistance vessel tone, then drugs that inhibit the
generation or actions of endothelin would be expected to cause
vasodilatation and decrease blood pressure and might have potential
therapeutic value in diseases associated with sustained peripheral
vasoconstriction such as hypertension and chronic heart failure. However,
results of animal studies using ECE inhibitors and endothelin receptor
antagonists have been contradictory. Some have shown no apparent effect
of antiendothelin therapy on blood pressure in normotensive animals. !87>
139, 163, 184, 185, 239] However, most of the studies have not been designed
primarily to test this hypothesis, with the result that they may have lacked
statistical power to confidently exclude a hypotensive effect. In addition, in
some, blood pressure was not measured for sufficient time after dosing to
detect the expected slow-onset hypotensive effect of antiendothelin
therapy. Other studies have shown that endothelin blockade apparently
reduces blood pressure only in hypertensive animals,!45' 3891 leading to
suggestions that ET-1 has a pathological rather than a physiological role.
However, there were similar percentage decreases in blood pressure in
normotensive and hypertensive animals in these and other studies,!45' 345>
389] suggesting that endothelin plays a similar role in hypertensive and
normotensive animals. The lack of a significant effect of antiendothelin
therapy on blood pressure in normotensive animals may be due to the
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relative imprecision of measurements of small changes in blood pressure.
Other studies have shown that ECE inhibitors and endothelin receptor
antagonists do decrease blood pressure in normotensive animals.i92' 229>
345, 438, 591] These positive studies have usually examined haemodynamic
responses for several hours after drug administration, thereby taking into
account the known slow reversal of ET-1 induced vasoconstriction by
antiendothelin therapy. [5961
Recent work has demonstrated that brachial artery infusion of the ECE
inhibitor phosphoramidon and the ETa receptor antagonist, BQ-123 causes
progressive forearm vasodilatation. I2181 These effects of phosphoramidon
and BQ-123 on forearm blood flow indicate a physiological role for basal
generation of ET-1 in maintenance of vascular tone. Elowever, homeostatic
mechanisms often obscure the blood pressure effects of quite large changes
in resistance vessel tone, with the results that changes in blood pressure
may be quite small in relation to the effects of a drug on peripheral
resistance.12151 The magnitude of any potential effect of systemic
endothelin blockade on haemodynamics in healthy human subjects have
not previously been reported. Therefore, the haemodynamic effects of
systemic administration of TAK-044, a combined ETa/b receptor




Two groups of five healthy male subjects, between 21 and 60 years of age
and within 15% of ideal body weight were recruited. No subject received
vasoactive or nonsteroidal medication in the week before or during the
study. In addition, subjects abstained from alcohol for 48 hours, from
caffeine containing drinks and cigarettes for at least 24 hours, and from
food for at least 10 hours before any measurements were made.
5.2.2 Drugs
TAK-044 is a cyclic hexapeptide (cyclo{D-a-aspartyl-3-{4-
phenylpiperazin-1 -yljcarbonyl} -L-a-aspartyl-D-2-(2-thienyl)-glycyl-L-
leucyl-D-tryptophyl} disodium salt; molecular weight 972) that potently
antagonises 12;>I-ET-1 binding at both ETA (IC5o=0.08 nmol.E1) and ETb
(IC5o=120 nmol.l"1) receptors in vitroP-^l] TAK-044 also blocks
constriction of isolated coronary vessels to ET-1 (ETA and ETB agonist)
and sarafotoxin S6c (ETB agonist), i267! Specificity of TAK-044 for
endothelin receptors has been shown in vitro in porcine coronary arteries in
which it does not affect vasoconstriction to histamine, serotonin,
acetylcholine, U-46619, and potassium and in which it is without direct
vasoactive effects even at concentrations of 100 pmol.r'i600] Specificity
.has also been shown in vivo, where systemic pretreatment of rats with
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TAK-044 at 10 mg.Kg"1 does not alter pressor or depressor responses to
phenylephrine, ANG II, nitroglycerine and acetylcholine.!241] In contrast,
TAK-044 dose-dependently blocks the pressor response to bolus doses of
ET-1 and sarafotoxin S6c in rats with 90% blockade apparent at a dose of
10 mg.Kg"1, the effects of which persist for 3 hours.!241' 60°] For the
clinical studies in humans, doses of TAK-044 ranging between 10 and 100
mg were chosen. This dose range was based on the animal evidence of
specificity and efficacy at doses from 0.1 to 10 mg.Kg"1 and also the safety
profile of TAK-044 in toxicological studies (information on file, Takeda
Euro R&D Centre GmbH). Pharmaceutical grade TAK-044 for parenteral
use was obtained from Takeda Euro R&D GmbH and was dissolved in
physiological saline (0.9%; Baxter Healthcare Ltd). The placebo was
dextrose (50 mg), also dissolved in physiological saline. For intravenous
administration of TAK-044, an antecubital vein was cannulated at least 1
hour before dosing. TAK-044 or placebo was dissolved in physiological
saline and infused at 200 ml.hr"1 for a period of 15 minutes (total volume
50 ml). This cannula was not used for blood sampling.
5.2.2 Measurements
Systemic haemodynamics
Blood pressure and heart rate were measured with semiautomated
oscillometric monitors (see Section 2.2.1). Cardiac function (stroke
volume, cardiac output, and heart rate) were measured with a noninvasive
bioimpedance methodology (see Section 2.3).
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Side-effect assessments
The following assessments were performed to detect potential adverse
effects: 12-lead ECGs, visual analogue scale (for sedation), urinalysis,
clinical chemistry screen (liver enzymes, electrolytes, creatinine, blood
urea, protein), and haematology screen (full blood cell count, white blood
cell differential count).
Pharmacokinetic and endothelin assays
Fifteen ml venous blood samples were obtained at intervals for assay of
serum TAK-044 (see Section 2.5.9) and plasma immnuoreactive
endothelin (see Section 2.5.5).
5.2.4 Study Design
Two groups of five subjects were recruited to a double-blind, ascending
dose, crossover study with a randomised placebo phase. Group 1 subjects
were studied on 5 occasions, receiving placebo and 10, 100, 500 and 1000
mg TAK-044, with 7 days between phases. Group 2 subjects were studied
on four occasions, receiving placebo and 30, 250 and 750 mg TAK-044,
with 7 days between phases. The ascending-dose design allows the
evaluation of the safety and tolerability of TAK-044 at lower doses before
proceeding to higher doses and entailed that the study day for groups 1 and
2 occur on different days of the same week for the first four weeks of
dosing. For example, in the first week, subjects in group 1 received either
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placebo or 10 mg on Monday and group 2 subjects received placebo or 30
mg on Wednesday.
In each study phase, subjects were admitted to the research unit the day
before dosing and fasted from 11 PM. At least 1 hour before dosing, an
antecubital venous cannula was sited in each arm for administration of
TAK-044 and blood sampling. Subjects received a 15 minute intravenous
infusion of TAK-044 or placebo at ~9 AM and, apart from voiding, were
not permitted to stand until 4 hours after dosing. Haemodynamic
measurements were made and blood samples were obtained for TAK-044
and endothelin concentrations before and after dosing (see Figures 5.1
through to 5.4). Sedation was assessed and 12-lead ECGs were recorded
before and after dosing. Blood and urine samples were obtained before and
24 hours after dosing. Subjects were fasted until 4 hours after dosing, when
they received a light meal. An evening meal was provided 10 hours after
dosing. Subjects were discharged 24 hours after dosing.
5.2.5 Data Presentation and Statistical Analysis
Mean arterial pressure was calculated as diastolic blood pressure plus one
third pulse pressure. Data for stroke volume and cardiac output were
corrected for body surface area, calculated according to a standard
normogram, to provide measures of stroke and cardiac indexes. Total
peripheral resistance was calculated as mean arterial pressure divided by
cardiac index and expresed in arbitrary units (AU). For the systemic
haemodynamic data, the change from the last measurement before dosing
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was calculated at each time point and corrected for the changes that
occurred at the same time point after placebo.
Pharmacokinetics of TAK-044 were analysed by use of SIPHAR software
(version 4, SIMED). The following parameters were calculated: AUC,
Cmax, and elimination half-life. Plasma immunoreactive endothelin
concentrations were analysed in a similar manner, with AUC and Cmax
being calculated.
Absolute values are presented as mean ± SEM. Placebo-corrected
haemodynamic changes from baseline were arithmetically averaged over
the 24 hours measurements were made, with uniform weighting given to
each time point, and are shown in the tables with 95% CIs. Data were
analysed statistically by repeated measures ANOVA. Factors included in
the ANOVA were subject, dose of TAK-044, time point, and dose-time
point interaction. Therefore, the adjusted dose group means from the
ANOVA were compared with the null hypothesis, for all time points
combined, by a two-sided t test. In addition, dose-response trends were
assessed statistically by the technique of linear contrast. Linear contrast
analyses trends between groups of subjects that are categorised
quantitatively, using variances derived from the ANOVA. Each linear
contrast was calculated as the sum of the mean of each group multiplied by
a coefficient that represented that group's dose (adjusted so that the sum of
all coefficients equals zero)i465l Statistical testing of the linear contrast
involved calculation of its SEM using the pooled estimate of variance from
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the ANOVA, with the t statistic given by the linear contrast divided by this
SEM. Simple regression analysis was used to explore whether there was a
correlation between plasma endothelin and haemodynamic changes.
Statistical analyses were performed by use of the software package SAS
(version 6.07, SAS Institute Inc).
5.3 Results
One subject withdrew from group 1 after the second phase for non-study
related reasons and was not replaced; he did not receive placebo and was,
therefore, not included in the analysis. All other subjects completed the
study protocols. TAK-044 was well tolerated, with no difference between
placebo and TAK-044 phases in the prevalence of the minor symptoms.
There were no serious adverse events in this study, and no clinically
significant abnormalities were detected on safety monitoring (urinalysis,
haematology, clinical chemistry, ECG, and sedation scores).
Baseline haemodynamic parameters did not differ between study days
(Table 5.1). Compared with placebo, all doses of TAK-044 reduced blood
pressure, with the hypotensive effect apparent within 30 minutes, maximal
between 1 and 6 hours, and persisting to 24 hours at the higher doses
(Figures 5.1 & 5.2). For example, after the 30 and 1000 mg doses, mean
arterial pressure was reduced at 4 hours by 8 and 18 mm Hg from baselines
of 75 and 72 mm Hg respectively. Diastolic and mean arterial pressures
were reduced by all doses; systolic pressure was significantly decreased by
all doses except 750 mg.
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Heart rate was significantly increased by TAK-044 at all doses except 30
and 100 mg; this increase persisted to ~8 hours for doses >250 mg (Figures
5.1 & 5.2). Most doses of TAK-044 significantly increased stroke and
cardiac indexes (Figure 5.2). Total peripheral resistance index was
significantly and substantially reduced at all doses and this effect was
sustained for up to 24 hours (Figures 5.1 & 5.2). For example, after the 30
and 1000 mg doses, total peripheral resistance index was reduced at 4
hours by 378 and 665 AU from baselines of 1628 and 1605 AU,
respectively. There were significant dose-related trends on linear contrast
testing for heart rate, stroke index, cardiac index, and total peripheral
resistance, although not for blood pressure (Figure 5.2).
TAK-044 increased plasma immunoreactive endothelin concentrations in a
dose-dependent manner, with significant increases at all doses except 10
mg (Table 5.2). For example, after 1000 mg, plasma endothelin
concentrations increased from 3.3 to 35.7 pg.mf1 within 30 minutes.
Compared with the sustained haemodynamic effects of TAK-044,
increases in plasma endothelin were maximal within 30 minutes and
waned rapidly, even at the highest doses (Figure 5.3). Even so, there was a
significant correlation between the increase in plasma endothelin and the
change in total peripheral resistance in both group 1 (r=-0.15; P=0.03) and
group 2 (r=-0.16; P=0.02). In group 2 only, plasma endothelin was also
correlated with change in systolic (r=-0.19; P=0.005) and mean arterial
(r=-0.16; P=0.02) pressures. TAK-044 plasma concentrations increased
dose-dependently (Figure 5.4); the terminal half-life was short (30 to 60
minutes) and tended to increase with dose (Table 5.2).
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5.4 Discussion
This study is the first report of the effects of systemic endothelin receptor
blockade in healthy humans. This study has shown that a 15 minute
infusion of the endothelin ET^g receptor antagonist, TAK-044, decreased
systolic blood pressure (by -4%), diastolic blood pressure (by -18%) and
total peripheral vascular resistance (by -26%) over a 24 hour period.
Systemic ET^ receptor blockade also increased circulating
immunoreactive endothelin (by up to 1000%). These findings have
implications for the physiological role of endothelin generation, the
pharmacology of endothelin receptor antagonists, and their ultimate
therapeutic relevance.
Previous work has shown that brachial artery administration of an ECE
inhibitor or an ETA receptor antagonist causes local forearm
vasodilatation.f218l The finding here that systemic administration of an
ETvg receptor antagonist causes peripheral vasodilation and hypotension
confirms that endogenous generation of endothelin plays a fundamental
physiological role in the maintenance of blood pressure in humans.
Physiological role of endothelin in regulation of blood
pressure
As noted earlier, animal data on the haemodynamic effects of systemic
endothelin receptor antagonism are apparently contradictory. Studies in
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humans have previously shown that brachial artery administration of of an
ECE inhibitor or ETA antagonist causes local forearm vasodilation,
suggesting that basal vascular generation of endothelin contributes to
vascular toned218! This current study demonstrates that systemic
administration of an ETa/b antagonist causes peripheral vasodilation and
hypotension confirming that endogenous generation of endothelin plays a
fundamental physiological role in the maintenance of blood pressure in
humans.
Pharmacology of endothelin receptor antagonists
TAK-044 decreased MAP and increased heart rate and cardiac index,
resulting in a substantial decrease in calculated peripheral resistance. The
greater reduction in diastolic as opposed to systolic pressure in consistent
with a primary action of TAK-044 on peripheral resistance. These effects
indicate that the resistance vessels are the major site of action after
endothelin ETa/b receptor blockade with TAK-044. In spontaneously
hypertensive rats, a 6 hour infusion of an endothelin ETa/b receptor
antagonist (SB 209670) also decreases blood pressure through an effect on
total peripheral resistance. t14°] However, heart rate tended to decrease in
these animals suggesting other sites of action for endothelin receptor
antagonists. The differences between the results of this present study and
these animal data may reflect differences in species resting blood pressure,
or mode of administration of the antagonist.
174
Vasodilatation and hypotension caused by TAK-044 occurred within 15
minutes and persisted for up to 12 to 24 hours. In contrast to its sustained
haemodynamic actions, the marked increase in plasma endothelin
concentrations caused by TAK-044 was relatively short in duration, and
TAK-044 itself appeared to have a short half-life. In animals, the blood
pressure-lowering effects of ECE inhibitors or endothelin ETA receptor
blockade usually takes several hours to reach maximum,!45> 92> 229> 345>
389, 438, 591] anc] forearm vasodilation to these agents is also slow in
onset.!218] gradual effect is thought to be related to the slow
dissociation of endothelin from its receptor, resulting in persistent
vasoconstriction even after new receptor binding is inhibited. There are
two speculative explanations for the rapid onset of vasodilatation observed
here. First, the rapid effects of TAK-044 may be related to its potency as
an endothelin receptor antagonist, with plasma concentrations being
achieved that were sufficient to reverse, rather than prevent, endothelin
receptor binding. Second, TAK-044 is active at ETb as well as ETA
receptors;!241' 267, 295, 600] there is some evidence that vasoconstrictor
ETb receptors may have a more rapid onset of action than ETA
receptors. !196i
ET-1 has a slow-onset of action and this may partially explain the
sustained vasodilatation caused by ET/vb receptor blockade with TAK-044.
In addition, although TAK-044 had a short half-life (30 to 60 minutes),
TAK-044 concentrations were substantially greater than the IC50 for
.binding to ETA receptors (0.08 ng.mf1)) for at least 12 hours after doses
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>500 mg. Furthermore, it is also possible that TAK-044 concentrations
were above this level for longer periods or at lower doses; however, the
limit of quantification for the TAK-044 assay was 5 ng.ml"1, ~50-fold
greater than the IC50 at ETA receptors. Finally the dissociation between the
pharmacokinetic and pharmacodynamic parameters may reflect entry into
and activity of TAK-044 in another tissue compartment. This might be
within the vasculature or in the central or peripheral nervous system. Entry
into and actions of in other tissue compartments appear to explain the
similar dissociation between actions and plasma concentrations observed
for inhibitors of the renin-angiotensin system!324' 608i
The trend analysis shows that vasodilatation to TAK-044 was dose
dependent. Elowever, given that vasodilatation occurred at almost all
doses, including the lowest (10 mg), it is probable that doses <10 mg may
be effective. Indeed, the pharmacokinetic results, together with the in vitro
pharmacology data discussed earlier, suggest that the initial plasma levels
were probably sufficiently high even after 10 mg to block endothelin ETA
receptors for at least 2 hours. This study also demonstrated a dose response
for the elevation of circulating immunoreactive endothelin by TAK-044. In
addition, peripheral vasodilatation was related to plasma endothelin
concentrations, further supporting a dose-dependent effect on peripheral
resistance.
The increase in plasma immunoreactive endothelin after TAK-044 may
have several components. The radioimmunoasay used detected both ET-1
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and ET-3. Although it also cross-reacted with big ET-1, this was to a
limited degree (7%) and therefore is unlikely to explain the substantial
increases in circulating endothelin concentrations. The increase in
circulating endothelin may have been due to increased generation or
decreased receptor-mediated clearance of endothelin isopeptides.
Decreased clearance of endothelin by ETB receptors appears to be the
likeliest explanation for several reasons. First, in animals, blockade of ETB
receptors, but not of ETA receptors, increases plasma ET-1 and ET-3
concentrations!316] and prolongs the half-life of exogenous l25I-endothelin-
1 .[178] Second, blockade of endothelin receptors increases plasma
endothelin concentrations within 15 minutes,!316] whereas de novo
generation is thought to take several hours.!635] Third, endothelin receptor
blockade does not increase big ET-1 concentrations.!316] The substantial
increase in total immunoreactive endothelin in this study, together with the
animal findings above, suggests that ETB receptor binding is an important
mechanism in clearance of endogenous endothelin peptides.
In conclusion, this study has shown that systemic endothelin ETA and ETb
receptor blockade with the peptide TAK-044 causes sustained and
substantial peripheral vasodilatation and, to a lesser extent, hypotension.
This response suggests a fundamental physiological role for endogenously
generated endothelin in cardiovascular regulation. The sustained
vasodilator actions of TAK-044 in healthy subjects suggest that orally
available endothelin receptor antagonists with a similar profile of action
•may have a valuable therapeutic role in diseases associated with chronic
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peripheral vasoconstriction, such, as essential hypertension, chronic heart
failure and chronic renal failure. However, an intravenous agent such as
TAK-044 could be therapeutically useful in conditions associated with
acute vasoconstriction or vasospasm in which endothelin has been
implicated in the pathophysiology. It would, therefore, be important to
know whether TAK-044 can inhibit peripheral vasoconstriction to
exogenous endothelin as a model of vasospasm. This was one of the aims
of the next study.
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5.5 Table Legends
Table 5.1 Baseline haemodynamic values
Footnote There were no significant differences between baseline
values on the different study days for either group 1 or 2.
Table 5.2 Summary pharmacokinetic parameters for plasma
immunoreactive endothelin concentrations and TAK-044.
Footnote Cmax indicates maximal endothelin concentrations after
dosing: ti/2, terminal half-life of compound; NA, parameters not available
because data were insufficient for calculation.
*P<0.05 vs. placebo; fP<0.005 vs. placebo.
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5.6 Figure Legends
Figure 5.1 Time course of the effects of TAK-044 (1000 mg) on
systemic haemodynamics
Time course of the effects of the highest dose of TAK-044 (1000 mg) on
MAP, HR, SI, CI and SVRI in group 1. TAK-044 significantly decreased
MAP (P0.001) and SVRI (P<0.001) and increased HR (P0.001), SI
(P<0.034), and CI (P0.001); these effects were maximal at 4 hours and
sustained for at least 12 hours. Data shown represent placebo-corrected
changes from predose (change from predose {active} minus mean change
from predose {placebo}).
Figure 5.2 Mean haemodynamic changes over 24 hours after dosing
with TAK-044.
Mean haemodynamic changes (A) over 24 hours after dosing with TAK-
044. For the placebo columns (open), mean change from predose is shown.
For the active treatment columns (stipled), placebo-corrected changes from
predose are shown (change from predose {active} minus mean change
from predose {placebo}). *P=0.05 for comparison with predose; fP=0.05
for linear contrast trend with dose.
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Figure 5.3 Effect of TAK-044 on plasma immunoreactive endothelin
Effect of TAK-044 on plasma immunoreactive endothelin concentrations.
A, Group 1 results after infusion of placebo (♦) and TAK-044 at 10 mg
(□), 100 mg (•), 500 mg (O), and 1000 mg (■). B, Group 2 results after
infusion of placebo (♦) and TAK-044 at 30 mg (□), 250 mg (•), and 750
mg (O). TAK-044 dose dependently increased circulating endothelin
concentrations.
Figure 5.4 Pharmacokinetic profile of TAK-044
Graph showing pharmacokinetic profiles of TAK-044. A, Results after
infusion of TAK-044 at 10 mg (■), 30 mg (O), and 100 mg (•). B, Results
after infusion of TAK-044 at 250 mg (□), 500 mg (•), 750 mg (O) and
1000 mg (■). Results are shown here only for the first 4 hours after dosing,
although pharmacokinetic calculations were based on all time points up to
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6. Study 4
Inhibition of endothelin-1 mediated vasoconstriction by














This study was designed to examine whether it is possible to inhibit ET-1
induced vasoconstriction without causing substantial systemic
haemodynamic effects. ET-1 has been implicated in the pathophysiology
of conditions associated with acute vasoconstriction such as subarachnoid
haemorrhage and acute renal failure (see Section 1.3). In these conditions,
inhibition of ET-1 mediated vasoconstriction would be potentially
therapeutically beneficial, whereas lowering of systemic arterial pressure
might be disadvantageous.
This issue was addressed using a model of ET-1 mediated vasospasm in
the forearm using brachial artery administration of a non-systemic, locally
active dose of ET-1 over a period of 2 hours. Three different doses of
TAK-044 were given systemically and their effect on systemic
haemodynamics, as well as their effectiveness in reversing ET-1 mediated
vasoconstriction was assessed. The direct effects of brachial artery infusion
of TAK-044 were also investigated.
6.2 Methods
6.2.1 Subjects
Eight healthy male subjects, between 18-65 years of age and within 15% of
their ideal body weight were recruited. No subject received vasoactive or
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nonsteroidal medication in the week before or during the study. In
addition, subjects abstained from alcohol for 48 hours, from caffeine
containing drinks and cigarettes for at least 24 hours, and from food for at
least 10 hours before any measurements were made.
6.2.2 Drugs
TAK-044 (see Section 5.2.2) at doses of 30, 250 and 750 mg were chosen.
This dose range was based on the animal evidence of specificity and
efficacy at doses from 0.1 to 10 mg.Kg"1 and also on the safety profile of
TAK-044 on toxicological studies at higher doses (see Section 5.2.2).
Pharmaceutical grade TAK-044 was dissolved in physiological saline
(0.9%; Baxter Healthcare Ltd). The placebo was dextrose (50 mg), also
dissolved in physiological saline.
ET-1 was administered intra-arterially at a dose of 5 pmol.min"1, based on
previous work showing that this dose of ET-1 causes slow-onset
vasoconstriction of human forearm resistance vessels in vzvoi217> 2181
Pharmaceutical grade ET-1 was obtained from Clinalfa AG
(Novabiochem) and dissolved in physiological saline (0.9%; Baxter
Healthcare Ltd) to a final concentration of 5 pmoLmf1.
For intravenous administration of TAK-044, an antecubital vein was
cannulated at least 1 hour before dosing. TAK-044 or placebo was
dissolved in physiological saline and infused at 200 ml.hr"1 over a period of
190
15 minutes (total volume 50 ml). This cannula was not used for blood
sampling. For intra-arterial infusion of ET-1 or TAK-044, the left brachial
artery was cannulated under local anaesthesia (see Section 2.1.1). Patency
was maintained by infusion of 0.9% physiological saline. The total rate of
infusion was maintained constant at 1 ml.min"1.
6.2.3 Measurements
Systemic haemodynamics
Blood pressure and heart rate were measured with semiautomated
oscillometric monitors (see Section 2.2.1). Cardiac function (stroke
volume, cardiac output, and heart rate) were measured with a noninvasive
bioimpedance methodology (see Section 2.3).
Side-effect assessments
The following assessments were performed to detect potential adverse
effects: 12-lead ECGs, visual analogue scale (for sedation), urinalysis,
clinical chemistry screen (liver enzymes, electrolytes, creatinine, blood




Blood flow was measured simultaneously in both forearms by venous
occlusion plethysmography using indium/gallium-in-Silastic strain gauges
(see Section 2.1.1).
Pharmacokinetic and endothelin assays
Fifteen ml venous blood samples were obtained at intervals for assay of
serum TAK-044 (see Section 2.5.9) and plasma immnuoreactive
endothelin (see Section 2.5.5).
6.2.4 Study Design
Eight subjects were recruited to a five-phase, double-blind, randomised,
placebo-controlled crossover study, with at least 7 days between phases.
These studies using forearm blood flow plethysmography were performed
in a quiet clinical research ward maintained at a constant temperature
between 22°C and 25°C. In each phase subjects were admitted to the
research unit at 7:00 AM, and blood and urine samples obtained for safety
assessments before dosing. At least 1 hour before dosing, an antecubital
fossa cannula was sited in each arm for administration of TAK-044 and
blood sampling. In the first four phases, subjects received, in random
order, placebo and 30, 250, and 750 mg TAK-044 IV over 15 minutes, at
~9 AM. Brachial artery cannulation was performed once the infusion of
TAK-044 or placebo had finished, and intra-arterial infusion of ET-1 (5
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pmol.min"1) commenced 60 minutes after the start of TAK-044 dosing and
continued for 120 minutes thereafter (ie, until 180 minutes after TAK-044
dosing). Measurements were made of forearm blood flow (see Figure 6.1)
and blood pressure and cardiac output (-25, -15, -5, +15, +30, +45, +60,
+90, +120, +150, and +180 minutes). Blood samples were obtained at -15,
+15, +60, +120, and +180 minutes for assay of TAK-044 and endothelin
concentrations. In the fifth phase, TAK-044 was infused intra-arterially via
the brachial artery, with subjects receiving 10 mg over 1 hour followed by
100 mg over 1 hour. Measurements were made of forearm blood flow (see
Figure 6.2), blood pressure, and cardiac function (-10 and +120 minutes),
and blood samples were obtained for assay of endothelin (-15, +15, +60,
and +120 minutes). In each phase, subjects remained supine until 3 hours
after dosing and were fasted until 4 hours after dosing, when they received
a light meal. Subjects were discharged 6 hours after dosing.
6.2.5 Data presentation and statistical analysis
Systemic haemodynamic data was analysed as described in Section 5.2.5.
Plethysmographic data listings were extracted from computer data files and
analysed as described in Section 2.1.1. Pharmacokinetics of TAK-044 and
plasma immunoreactive endothelin concentrations were analysed as
described in Section 5.2.5.
Absolute values are presented as mean ± SEM. Placebo-corrected
haemodynamic changes from baseline were arithmetically averaged over
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the 3 hours measurements were made, with uniform weighting given to
each time point, and are shown in the tables with 95% CIs. Data were
analysed statistically by repeated measures ANOVA as described in
Section 5.2.5. Dose-response trends were assessed statistically by the
technique of linear contrast as described in Section 5.2.5. Simple
regression analysis was used to explore whether there was a correlation
between plasma endothelin and haemodynamic changes. Statistical
analyses were performed by use of the software package SAS (version
6.07, SAS Institute Inc).
6.3 Results
As in Study 5, all intravenous doses of TAK-044 significantly decreased
diastolic blood pressure, increased heart rate and cardiac index, and caused
peripheral vasodilatation (Table 6.1), with effects sustained over the three
hour measurement period. There were significant dose-related trends for
systolic blood pressure, mean arterial blood pressure, and total peripheral
resistance (Table 6.1). As in Study 5, plasma immunoreactive endothelin
concentrations were increased in a dose-dependent manner, with
significantly higher Cmax values after 250 mg (22.9 pg.ml"1; PO.OOl) and
750 mg; (37.2 mg.mf1; P<0.0001) compared with placebo (7.8 pg.mf1).
Similarly, there were significant correlations between plasma endothelin
concentrations and changes in cardiac index (r=0.23; P=0.01), diastolic
pressure (r=-0.23; P=0.01), mean arterial pressure (r=-0.21; P=0.006).
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blockade. Although increases in plasma immunoreactive endothelin
correlated with decreases in total peripheral resistance, this association was
relatively weak, with correlation coefficients of -0.2. Changes in
circulating endothelin concentrations probably only reflect antagonism of
the ETb receptor, which in addition to its functional roles, appears to
mediate clearance of circulating ET-1.1178> 316] por a dmg gpA
receptor blocking properties, such as TAK-044, pharmacodynamic effects
may be apparent at concentrations that do not substantially increase
circulating endothelin concentrations, as was the case here. This may help
to explain the different timings of changes in circulating endothelin and
peripheral resistance, as well as the rather weak correlation between these
parameters. In this study, forearm vasoconstriction to ET-1 at 1 to 3 hours
after dosing with TAK-044 was used to test endothelin receptor blockade.
Vasoconstrictor responses to locally infused ET-1 were completely
inhibited by all three doses, consistent with the similar haemodynamic
responses to these doses. This model is safer than using intravenous
infusion of systemic doses of ET-1 to increase blood pressure, particularly
given the sustained and potent nature of vasoconstriction to ET-1. Given
that both ETa and ETB receptors mediate vasoconstriction to ET-1 in the
forearm,P173 blockade of vasoconstriction to ET-1 is likely to reflect
antagonism at both ETA and ETB receptors. Antagonism of ETB receptors
could be tested by brachial artery administration of a selective ETB receptor
agonist, such as sarafotoxin S6c.l217l There are currently no selective ETA
receptor agonists available.
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The potent inhibition of peripheral vasoconstriction to exogenous ET-1, as
a model of vasospasm, by TAK-044 in this study suggests that it could be
of benefit in conditions associated with acute vasoconstriction in which
ET-1 has been implicated. Indeed, in experimental animal models, TAK-
044 has been shown to prevent postischaemic renal failure!295! and limit
myocardial infarct size.!600! The peptide nature of TAK-044, which
requires it to be given intravenously, is not a problem in these acute
conditions which are usually managed in association with intensive
monitoring.
In conclusion, this study shows that intra-arterial infusion of TAK-044
causes local and systemic vasodilatation and that systemic dosing with
TAK-044 at doses of 30, 250, and 750 mg completely inhibited the
vasoconstriction produced by brachial artery infusion of ET-1 for at least





Placebo 30 250 750
SBP*, mm Hg
Baseline value 132 ±24 128 ±16 122 ±15 127 ±12
Mean A over 3 h -3.0 ±3.0 ±2.1 -2.5
95% CI -22.1 to ±16.4 ±0.7 to ±5.3 -0.2 to ±4.3 -4.8 to-0.2
P ... 0.010 0.078 0.034
DBP, mm Hg
Baseline value 75 ± 7 73 ± 6 75 ± 8 73 ± 6
Mean A over 3 h +0.7 -5.8 -6.7 -6.5
95% CI -5.1 to+6.5 -7.2 to-4.5 -8.0 to-5.5 -7.9 to-5.2
P ... <0.001 <0.001 <0.001
Heart rate, bpm
Baseline value 57 ± 7 60 ± 9 61 ±11 62 ±11
Mean A over 3 h +2.7 +1.8 +2.0 +1.4
95% CI -1.6 to+7.0 +0.6 to+3.0 +0.7 to+3.3 +0.2 to+2.6
P ... 0.004 0.003 0.027
Stroke index, ml.m"2
Baseline value 56 ± 4 51 ± 3 55 ±3 2.8 ±0.6
Mean A over 3 h -3.1 +4.4 +2.3 +0.43
95% CI -6.3 to+0.2 +3.3 to+5.5 +1.1 to+3.6 +0.37 to+0.49
P ... <0.001 <0.001 <0.001
Cardiac index, l.min"'.m"2
Baseline value 3.2 ±0.7 3.0 ±0.4 3.2 ±0.4 2.8 ± 0.6
Mean A over 3 h -0.09 +0.39 +0.034 +0.43
95% CI -0.36 to+0.18 +0.33 to+0.45 +0.27 to+0.41 +0.37 to+0.49
P ... <0.001 <0.001 <0.001
SVRI*, AU
Baseline value 2484 ± 838 2472 ±330 2212 ±288 2719 ±701
Mean A over 3 h +70 -329 -286 -485
95% CI -274 to+414 -395 to-263 -359 to-213 -552 to-419
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The previous studies have shown that systemic intravenous administration
of the cyclic hexapeptide combined ETa/b receptor antagonist, TAK-044,
at doses of 10 to 1000 mg, is well tolerated and produces dose-dependent,
long-lasting vasodilatation resulting in decreases of blood pressure and
systemic vascular resistance persisting, at the highest dose, for at least 24
hours. Systemic administration of TAK-044, at doses of 30, 250 and 750
mg abolished vasoconstriction to locally infused ET-1, as a model of ET-1
induced 'vasospasm', for up to three hours.
Endothelin receptor antagonists are currently under clinical development.
Peptide antagonists such as TAK-044 requiring intravenous administration
are better suited for the treatment of acute vasospastic conditions in which
endothelin has been implicated in the pathophysiology. These conditions
include subarachnoid haemorrhage, acute ischaemic renal failure and
myocardial infarction. In these clinical situations intermittent dosing might
have both practical and economic advantages over continuous infusion.
The potential of TAK-044 to inhibit the forearm vasoconstriction
produced by brachial artery infusion of ET-1 for up to 12 hours after




Eighteen healthy male subjects between 19 and 41 years of age participated
in these studies. All had normal baseline results on routine biochemical
and haematological screening tests. None of the subjects received
vasoactive or non-steroidal anti-inflammatory drugs in the two weeks
before the study or during the study period. All of the subjects abstained
from alcohol for 48 hours, from caffeine containing drinks and cigarettes
for at least 24 hours, and from food for 12 hours before the start of the ET-
1 infusion. All studies were performed in a quiet room maintained at a
constant temperature of 24-26°C.
7.2.2 Drugs
The initial dose of TAK-044 studied, 25 mg, was chosen on the basis that
30 mg TAK-044 completely inhibited ET-1 mediated vasoconstriction for
up to 3 hours after administration. Depending on whether or not 25 mg
TAK-044 abolished the vasoconstriction to ET-1, it was intended to study




Eighteen subjects took part in a randomized, placebo-controlled, single-
blind, three-way, crossover study. Subjects were studied on three
occasions, each one week or more apart. They were admitted to the clinical
research centre at 8 PM on the day before the study and were discharged at
1 PM on the study day. On two occasions subjects received TAK-044
either at 12 PM or 4 AM. Sucrose placebo was substituted for TAK-044 at
the other timepoint. On a third occasion subjects received only sucrose
placebo at both timepoints. The first group of 6 subjects (group 1) was
studied using 25 mg TAK-044. Because this dose did not appear to abolish
ET-1 mediated vasoconstriction, groups 2 and 3 were studied using 50 and
100 mg TAK-044 respectively as previously determined. ET-1 was infused
intra-arterially starting at 10 AM and ending at 12 AM. The end of the
infusion corresponding to either 8 or 12 hours after administration of
TAK-044. Ten-millilitre venous blood samples were obtained at 10 AM
and 12 AM for assay of plasma endothelin and five-millilitre venous
samples were obtained at 8 AM, 10 AM and 12 AM for assay of serum
TAK-044. Blood and urine samples were collected for safety assessments
before the start of the study and at the end of the third study phase.
Electrocardiographs were recorded before dosing, at 9:30 AM and before
discharge on every study day.
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7.2.3 Data Presentation and Statistical Analysis
From previous studies using intrabrachial ET-1 infusions done in the
Department of Clinical Pharmacology at Edinburgh University (data on
file), studying six subjects at each dose would have 95% power to detect a
50% reduction in the vasoconstriction produced by ET-1 at the 5% level.
However, studying 6 subjects would lack the power to detect smaller
differences in ET-1 vasoconstriction. Therefore, the a priori decision to
pool the data from all 18 subjects was taken. Combining the responses
from all 18 subjects, would give 90% power of detecting a 25% decrease at
the 5% level. Power calculations were done using Graphpad Instat
software (GraphPad Software, San Diego, CA, USA).
Data are described as mean ± SEM, with 95% CI where appropriate.
Haemodynamic data are presented as absolute values and as placebo-
corrected changes from baseline (12 PM). Data were examined by repeated
measures ANOVA using Stat View 512+ software (Brainpower Inc,
Calabasas, CA, USA) for the Apple Macintosh computer. Where the F
value obtained by ANOVA was significant (p<0.05), the Fisher PLSD
(protected least significant difference) multiple comparison test was used
to compare pairs of mean values.
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7.3 Results
TAK-044 was well tolerated, with no difference between placebo and
TAK-044 phases in the prevalence of minor symptoms. There were no
serious adverse events during the study, and no clinically significant
abnormalities were detected on safety monitoring (urinalysis,
haematology, clinical chemistry and electrocardiograph).
Mean arterial pressure showed a tendency to decrease after infusion of
TAK-044 (Figure 7.1). However, this decrease was only significant in
group 2 after 50 mg TAK-044 (maximum decrease: -10 ± 4 mm Hg;
p=0.005). Similar trends were noted for systolic and diastolic pressures.
Heart rate (Figure 7.1) increased only after dosing with 100 mg TAK-044
at 12 PM (maximum increase: 8 ± 3 beats per minute; p=0.03). There were
no differences between phases in any of the haemodynamic parameters
measured at the start of the intra-brachial ET-1 infusion at 10 AM (Table
7.1). Mean arterial pressure and heart rate did not change during infusion
of ET-1 (Figure 7.1). Administration of TAK-044 did not cause an
increase in immunoreactive endothelin concentrations after 8 or 12 hours
compared with placebo (Table 7.2).
In group 1, TAK-044 plasma concentrations were not higher than the limit
of quantification of the assay (2.1 ng.ml"1) at any time in any of the
subjects. In group 2, TAK-044 was detectable in >50% of subjects only at
8 AM and only after administration of TAK-044 at 4 AM. In group 3,
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TAK-044 was detectable at 8 AM after administration of TAK-044 at 12
PM and 4 AM. TAK-044 was also detectable in plasma at 10 AM after
administration of TAK-044 at 12 PM (Table 7.2). The inter-subject
variation for this assay was high at >50%.
There were no differences between any of the phases in absolute forearm
blood flows at the start of the intra-brachial ET-1 infusions (Table 7.1).
Blood flow in the non-infused arm did not change significantly during
infusion of ET-1 in any of the phases. Brachial artery infusion of ET-1
caused significant slowly-progressive local forearm vasoconstriction.
Infusion of ET-1 reduced forearm blood flow over 120 minutes by 30 ±
5% (p=0.0001 vs. basal), 30 ± 4% (p=0.0001) and 28 ± 5% (p=0.013) after
placebo groups 1, 2 and 3 respectively (Figure 7.2; Table 7.3). TAK-044 at
all three doses and administered at both timepoints tended to blunt the
vasoconstriction caused by ET-1 but these effects failed to achieve
statistical significance (Figure 7.2; Table 7.3). However, when the
responses from all three groups were combined, vasoconstriction to ET-1
was reduced by TAK-044 administered 8 and 12 hours previously (Figure
7.3; Table 7.3), when compared with placebo.
7.4 Discussion
The combined endothelin ETa/b receptor antagonist, TAK-044, given as a
15-minute intravenous infusion, attenuated peripheral vasoconstriction to
exogenous ET-1 by ~ 30% for up to 12 hours after administration. This
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inhibition occurred at a time when plasma concentrations of TAK-044
were below the limit of quantification of the assay and plasma
concentrations of endothelin were not elevated. These findings have
important implications for the clinical development of endothelin receptor
antagonists.
A simple and reliable pharmacodynamic index of endothelin receptor
blockade would be useful for the clinical development of endothelin
receptor antagonists. Forearm vasoconstriction to intra-brachial
administration of ET-1 is highly reproducible!88' 217i and this model may
be safer than using systemic intravenous infusions of ET-1 to increase
blood pressure, given the sustained and potent nature of vasocontriction to
ET-1, especially in the coronary, renal and cerebral circulations.!434' 442i It
is possible that endothelin receptor antagonism may produce different
effects in other blood vessels. Elowever, responses in forearm resistance
vessels are generally thought to be broadly representative of those in other
vascular beds.!103- 604i
The vasoconstriction produced by intra-arterial ET-1 in this study was
consistent with other published reports.!88' 2171 The results demonstrate
that bolus doses of TAK-044 up to 100 mg can still inhibit ET-1 mediated
forearm vasoconstriction by -30% for up to 12 hours after administration.
However, this contrasts with complete inhibition for up to 3 hours of ET-1
mediated vasoconstriction by TAK-044 30 mg and suggests a marked time
dependence for this inhibitory action. This was a small study with
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insufficient power to exclude a dose dependent effect and, therefore,
studies with larger doses would be needed to show whether greater
inhibition of ET-1 induced vasoconstriction could be achieved. However,
the finding that 25 mg TAK-044 seemed to be as effective as 50 and 100
mg TAK-044 suggests that 25 mg may achieve maximum inhibition at this
late stage after systemic administration and that increasing the dose of
TAK-044 further might not produce greater inhibition of ET-1 mediated
vasoconstriction. Therefore, if an inhibition >30% is required, more
frequent dosing (3 to 6 hourly) or a continuous infusion, may be needed.
Clinical trials with endothelin receptor antagonists, including TAK-044,
are currently in progress. These should indicate the doses required for
clinical effect and the forearm model can then be used to determine
effective doses of other endothelin receptor antagonists. The effects of
repeated dosing with TAK-044 on ET-1 mediated vasoconstriction are not
yet known and it is possible that a cumulative inhibition might be achieved
in this manner if the clearance mechanisms for TAK-044 were to become
saturated. These issues remain to' be addressed.
Although increases in plasma endothelin concentrations have been shown
to correlate with some of the haemodynamic changes observed, these
associations were relatively weak, with correlation coefficients of -0.2.
Furthermore, changes in circulating endothelin concentrations are likely to
reflect only antagonism of the ETg receptor!27 E which, in addition to its
functional roles, appears to mediate clearance of circulating ET-1.!178' 316]
For a drug with ETa and ETb receptor blocking activity, such as TAK-
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044, effects on systemic haemodynamics may be apparent at
concentrations that do not substantially increase circulating endothelin
concentrations, as was the case in the previous studies (Studies 3 & 4).
Similarly, here it was found that plasma endothelin concentrations were
not raised 12 hours after administration of TAK-044 despite continuing
inhibition of ET-1 mediated vasoconstriction.
TAK-044 was not detected in any of the volunteers 12 hours after
administration of any of the doses. These findings are in close agreement
with the previous studies (Studies 3 & 4) in which the plasma half-life of
TAK-044 was 30 to 60 minutes. However, the IC50 for TAK-044 at ETa
receptors is 0.08 ng.ml"1 ~ 25 fold below the limit of quantification of the
assay (2.1 ng.mf1). It is, therefore, possible that circulating TAK-044
remains present in plasma at concentrations sufficient to inhibit the
vasoconstriction produced by exogenous ET-1 at 12 hours. It is also
conceivable that TAK-044 binds tightly to endothelin receptors and
remains bound for several hours in a similar manner to ET-I.P27] Indeed,
in intact cells ET-1 appears only to become dissociated from its receptors
following receptor internalisation.l332! Thus, prolonged receptor binding
may explain the sustained inhibition of ET-1 mediated vasoconstriction by
TAK-044. Another possible explanation for the observed inhibition could
be the entry of TAK-044 into another tissue compartment, probably within
the vasculature. A similar situation arises with inhibitors of the renin-
angiotensin system, where entry into and actions in other tissue
compartments appear to explain the dissociation between actions and
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plasma concentrations observed. [324, 608] These possibilities require
further investigation.
The previous studies (Studies 3 & 4) showed that TAK-044 lowers
systemic vascular resistance and blood pressure. The current study was not
designed primarily to assess these measures and factors such as diurnal
variation of blood pressure, disturbed sleep and the measurement of
forearm blood flow may all have interfered with their optimal assessment.
Thus, although the study was placebo controlled, small changes in blood
pressure and heart rate may have been obscured by these factors.
Nevertheless, systolic, diastolic and mean arterial pressure tended to
decrease after administration of TAK-044, to a similar extent to that
reported previously (Studies 3 & 4) and heart rate was increased after
administration of the highest dose of TAK-044. However, in this study
systemic vascular resistance was not measured, the most sensitive index of
peripheral vasodilatation in the previous study (Study 3).
In conclusion, the cyclic hexapeptide, combined ETa/b receptor
antagonist, TAK-044, inhibited local ET-1 mediated vasoconstriction by
-30% for up to 12 hours after administration. This inhibition occurred at a
time when plasma concentrations of TAK-044 were below the limit of
quantification of the assay and plasma concentrations of endothelin were
not elevated. Therefore, in this study, the most sensitive index of effect of
endothelin receptor antagonism was inhibition of ET-1 mediated
vasoconstriction. Although TAK-044 is a peptide, these features may be
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common to non-peptide endothelin receptor antagonists and this study sets
up a marker against which other endothelin receptor antagonists can now
be compared. The long lasting effects of the short lived peptide, TAK-044,
are generally encouraging for the clinical development of endothelin
receptor antagonists and emphasise the valuable contribution that the
combination of local intra-arterial administration of ET-1 and forearm
plethysmography can make to the early clinical evaluation of this novel
class of vasoactive drugs.
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7.5 Table Legends
Table 7.1 Haemodynamics in groups 1, 2 and 3 before intra-arterial
ET-1 infusion.
Footer:
There were no significant differences between baseline values on the
different study days for any of the three groups.
95% confidence intervals are shown in brackets.
Table 7.2 Plasma TAK-044 and plasma endothelin concentrations in
groups 1, 2 and 3.
Footer:
Descriptive statistics for plasma TAK-044 concentrations were calculated
only for the timepoints where >50% of the subjects showed concentrations
>2.1 ng.ml"1, the limit of quantification of the assay.
There were no significant differences between plasma endothelin
concentrations in any of the groups.
Table 7.3 Mean percentage vasoconstriction to 120 minutes intra¬
arterial ET-1 infusion after Placebo and TAK-044 8 and 12
hours earlier.
Footer:
*p=0.01. 95% confidence intervals are shown in brackets.
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7.6 Figure Legends
Figure 7.1 Haemodynamic changes after systemic TAK-044
Placebo corrected changes (A) in mean arterial pressure (MAP) and heart
rate (HR) from baseline (12 PM) following intravenous administration of
TAK-044 at 12 PM (open bars) and 4 AM (shaded bars) for group 1, 2 and
3.
*P=0.05 from baseline.
Figure 7.2 Effect of 3 doses of TAK-044 on forearm vasoconstriction
to locally administered endothelin-1 8 and 12 hours after
Percentage change in forearm blood flow produced by brachial artery
infusion of endothelin-1 (5 pmol.min"1 for 2 hours) following intravenous
administration of TAK-044 at 12 PM (o) and at 4 AM (•) and during the
placebo phase (□) for groups 1, 2 and 3. Standard errors have been omitted
for sake of clarity.
Figure 7.3 Combined results of the 3 doses of TAK-044 on forearm
vasoconstriction to locally administered endothelin-1 8 and
12 hours after
Percentage changes in forearm blood flow for all three groups of subjects
combined, following brachial artery infusion of endothelin-1 (5 pmol.min"1
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for 2 hours from 10 AM to 12 PM) following intravenous administration
of placebo (□) and TAK-044 at 4 AM (•) and at 12 PM (o). Endothelin-1
caused a slowly progressive forearm vasoconstriction during the placebo
phase. TAK-044 (25-100 mg) administered at either 4 AM and 12 PM
(corresponding to 8 and 12 hours before the end of the endothelin-1








































































































































































































































































































































































































































































































































































































































































































































































Actions of systemic endothelin receptor blockade on renal















The kidney has been found to have high concentrations of immunoreactive
endothelin,!272] mainly ET-l.!25^] a variety of cell types in the kidney,
other than vascular endothelial cells, including mesangial and glomerular
as well as renal tubular cells are able to produce endothelin.!277] The
kidney also has a high density endothelin receptors, although the
distibution of receptor subtypes appears to be very variable between
species.!277! In human kidney ETB receptors predominate and are mainly
localised to tubules and collecting ducts.!257] In contrast, the ETA subtype
is largely confined to the smooth muscle of the renal vasculature.!360]
Systemic infusion of exogenous ET-1 in humans increases blood pressure,
systemic and renal vascular resistance and sodium retention, as well as
decreasing renal blood flow and GFR.!442> 5241 However, the actions of
endogenously produced endothelin in the human kidney have not yet been
studied.
In this study, the actions of endogenously generated endothelin on renal
function in healthy subjects were investigated using systemic infusions of
the non-selective endothelin receptor antagonist TAK-044 (see Section
5.2.2). The actions of endothelin antagonism on other vasoactive sodium




Eight healthy male subjects (age range, 41-49 years) participated in this
study. No subject received vasoactive or nonsteroidal anti-inflammatory
drugs in the week prior to each study day, and all were asked to abstain
from alcohol for 24 hours and from food, caffeine-containing drinks, and
cigarettes for at least 16 hours before baseline measurements were made. A
24-hour collection of urine was performed by all subjects beginning at 7:00
AM on the day before each study day. Subjects received a physiologically
inert dose of oral lithium carbonate (Camcolit, 250 mg sustained release;
Norgine, Harefield, UK) before each study day (-14 hours before baseline
measurements) to assess proximal tubular reabsorptive capacity of
sodium.11441
8.2.2 Drugs
The doses of TAK-044 (see Section 5.2.2) studied, 100 and 750 mg mg,
were chosen on the basis of Studies 3 and 4. These two doses are both
known to cause significant haemodynamic effects and are at the lower and
higher ends of the dose range studied.
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8.2.3 Measurements
Blood pressure was measured in the right arm in duplicate using a well-
validated semi-automated oscillometric technique (see Section 2.1).
Cardiac function (stroke volume, cardiac output, and heart rate) was
measured using a noninvasive bioimpedance method (see Section 2.2).
Effective renal plasma flow (ERPF) and GFR were estimated by measuring
the renal clearances of p-aminohippurate sodium (PAH; Merck
Hoddesdon, UK) and polyfructosan-S (Inutest; Laevosan, Linz, Austria),
respectively (see Section 2.4.1). Priming doses of PAH (0.45 g) and
polyfructosan-S (3.5 g) were diluted in 100 ml of 0.9% saline and infused
over 15 minutes, followed by a maintenance infusion of PAH (8.3 g.F1)
and polyfructosan-S (10 g.F1) in 0.9% saline at 120 ml.hr"1. An
equilibration period of 90 minutes allowed plasma concentrations of PAH
and polyfructosan-S to stabilize before baseline collections started.
8.2.4 Plasma Assays
Venous blood samples were collected into heparinized tubes for assay (see
Section 2.5) of plasma polyfructosan-S, PAH, sodium, potassium and
aldosterone concentrations, and plasma osmolality; into EDTA tubes for
assay of plasma immunoreactive endothelin, big ET-1, C-terminal
fragment, plasma active renin and hematocrit (Hct); into plain glass tube
for assay of serum lithium concentrations; into EDTA/sodium
metabisulphate tubes for assay of plasma adrenaline and noradrenaline;
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into EDTA/trasylol tubes for assay of plasma ANP; and into EDTA/o-
phenanthroline tubes for assay of ANG II concentrations. Plasma was
separated and frozen within 15 minutes of sampling. Urine was collected
into plain plastic containers. All samples were stored at -80°C before assay.
8.2.5 Study Design
This was a randomized, single-blind, crossover study comparing 2 doses of
TAK-044, 100 and 750 mg, with placebo (50 g dextrose). Each of the three
phases were separated by at least 7 days. Studies were performed in a quiet
clinical research laboratory maintained at a constant temperature of
between 22 and 25°C. On the morning of each study day, subjects were
asked to drink 450 ml of water at 7:00 AM (~3 hours before the first
baseline measurements). After arrival at the laboratory, subjects voided
urine and then drank 450 ml water at 8:00 AM. Subjects were then asked
to void at intervals of -30 min, with water intake adjusted before dosing
with TAK-044 or placebo to induce a diuresis of-10 ml.min"1. Except
when voiding, subjects rested in a recumbent position. A plastic cannula
was inserted under local anesthesia into a superficial antecubital vein of
the right arm for blood sampling. Two plastic cannulas were inserted into
superficial antecubital veins of the left arm for administration of
PAH/poyfructosan-S and TAK-044/placebo. Intravenous infusion of the
priming doses of PAH and poyfructosan-S started at -8:30 AM. During the
90-minute equilibration period, the subject was acclimatised to the
haemodynamic assessments by measuring blood pressure and cardiac
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function every 15 minutes. Baseline assessments started at ~10:00 AM,
when blood samples were obtained before and after two accurately timed
30-minute urine collections. At -11:00 AM, TAK-044 100 or 750 mg, or
placebo in 50 ml 0.9% saline was infused intravenously over 15 minutes.
An additional accurately timed 30-minute urine collection was made. After
dosing, to maintain strict fluid balance, water intake was varied only to
match fluid losses (urine and blood), taking into account intravenous
infusion volumes. Blood pressure and cardiac function were measured at
15-minute intervals before and after dosing with TAK-044. Blood samples
were obtained at 30-minute intervals throughout, except for estimation of
plasma renin, ANG II, aldosterone, ANP and catecholamines which were
taken at hourly intervals. Blood samples for estimation of plasma
immunoreactive endothelin peptides were taken at just before and 15, 60
and 120-minutes after TAK-044.
8.2.6 Data presentation and Statistical Analysis
Mean arterial pressure was calculated as diastolic blood pressure plus one-
third pulse pressure. Data for stroke volume and cardiac output were
corrected for body surface area, calculated according to a standard
normogram, to provide measures of stroke and cardiac index. Total
peripheral resistance was calculated as (MAP x 72.269)/cardiac index, and
expressed in dyn.sec.cm"5. Renal clearance was calculated using the
formula UV/P, where U is the urinary concentration, V is the urinary flow
rate, and P is the mean of the plasma concentrations at the beginning and
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end of a clearance period. Effective renal vascular resistance (ERVR) was
calculated using a formula that assumed a constant renal venous pressure
of 10 mm Hg:
ERVR = 72,269 x (MAP - 10) x(1"Hct) dvn.sec.cm'5
ERPF
Filtration fraction was calculated as (GFR/ERPF) x 100%. Lithium ions
are reabsorbed almost exclusively in the proximal tubule and to the same
degree as sodium and water. Thus clearance of lithium (Cy) is thought to
be representative of proximal tubular sodium clearance. The fractional
(corrected for GFR) excretions of sodium (FEn3) and lithium (FEu) were
also calculated.
Data are presented as means ± SEM. Placebo-corrected changes from
baseline were arithmetically averaged over the relevant measurement
period (0 to 240 minutes for haemodynamic changes and 0 to 120 minutes
for renal function), with uniform weighting given to each timepoint. Data
were analysed statistically by repeated measures analysis of variance
(ANOVA). Factors included in the ANOVA were subject, dose of TAK-
044, timepoint, and dose-timepoint interaction. In none of the analyses
(except plasma endothelin concentrations which were analysed as absolute
values by the Kruskal-Wallis non-parametric test with Dunn's multiple
comparisons post-tests) was there any evidence of a statistically significant
dose-timepoint interaction. Therefore, the adjusted dose group means from
the ANOVA were compared with the null hypothesis by a two-sided /-test.
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Statistical analyses were performed by the use of the software package
SAS (version 6.07, SAS Institute Inc).
8.3 Results
Baseline data
There were no significant differences between basal values for any
parameter on any of the study days. There were no significant changes in
any parameter following administration of placebo.
Systemic haemodynamics
Compared with placebo, both doses of TAK-044 decreased MAP, with a
decrease of 5% after 100 mg and 6% after 750 mg (Table 8.1). Both
systolic and diastolic blood pressure decreased after TAK-044, although
this was only significant for diastolic blood pressure with a decrease of 6%
after 100 mg and 8% after 750 mg (Table 8.1). These decreases in blood
pressure occurred despite significant increases in heart rate and cardiac
index with both doses of TAK-044 (Table 8.1). There was, therefore, a
substantial decrease in total peripheral resistance index of 13% after 100
mg and 16% after 750 mg TAK-044 (Table 8.1).
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Renal function
There were significant reductions in ERVR with a reduction of 5% after
both 100 mg and 750 mg TAK-044 (Table 8.2). There was a trend for
TAK-044 to decrease GFR. However, the decrease was only significant
after 100 mg TAK-044 (Table 8.2). There was also a trend for TAK-044 to
increase ERPF although this did not achieve statistical significance (Table
8.2). However, relative trends in decrease in GFR and increase in ERPF
meant that the filtration fraction was significantly lowered by 14% after
100 mg and 13% after 750 mg TAK-044 (Table 8.2). Infusion of TAK-
044, at both doses, had no effect on sodium and lithium clearance or on
overall and fractional sodium and lithium excretions (Table 8.2).
Immunoreative endothelin, big ET-1 and C-terminal fragment
Infusion of 750 mg, but not 100 mg, TAK-044 rapidly increased plasma
immunoreactive endothelin concentrations but had no effect on plasma big
ET-1 or C-terminal fragment concentrations (Figure 8.1).
Vasoactive hormones
TAK-044, at both doses, tended to increase plasma active renin
concentrations although this effect was not significant (Table 8.3).
However, TAK-044 did increase plasma ANG II concentrations by 24%
after 100 mg and 42% after 750 mg (Table 8.3). Neither dose of TAK-044
had any effect on plama aldosterone concentrations (Table 8.3). There was
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a trend for TAK-044 to increase circulating plasma ANP concentrations,
although this effect was only significant after 100 mg TAK-044 (Table
8.3). TAK-044 had no effect on plasma adrenaline or noradrenaline
concentrations (Table 8.3).
8.4 Discussion
This present study confirms the previously presented findings that
combined ETa/b receptor antagonism with TAK-044 lowers blood pressure
and peripheral vascular resistance, as well as increasing heart rate and
cardiac index, in healthy subjects (see Studies 3, 4 and 5). This provides
further evidence supporting endogenously generated endothelin plays a
significant physiological role in the maintainance of blood pressure in man.
In healthy subjects, systemic infusions of ET-1 increased ERVR and
decreased both GFR and ERJPF.t442' 5241 The decrease in ERPF
proportionally exceeded the decrease in GFR, as reflected by an increase in
the filtration fraction. In this study, TAK-044 decreased ERVR suggesting
that endogenously generated endothelin also contributes to renal vascular
resistance. However, despite the substantial decrease in ERVR in this
study, TAK-044 did not increase ERPF, although there did appear to be a
trend. Interestingly, GFR tended to decrease after TAK-044 although this
was only significant after the 100 mg dose. As a consequence of these
opposing trends in ERPF and GFR there was a significant decrease in
filtratration fraction observed with both doses of TAK-044. This finding is
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in agreement with exogenous infusion of ET-1 filtration fraction in
man!442- 5241 and suggests that endothelin acts preferentially on the
efferent arteriole in healthy subjects. In laboratory animals, ET-1 contracts
both afferent and efferent arterioles and the relative responsiveness of
these vessels differs among species. !145> 269!
The increase in filtration fraction with endothelin agonism and increase
with endothelin antagonism are similar to the changes observed with
agonism and antagonism of renal ANG II receptors. !2501 It is possible that
the actions of endothelin on renal haemodynamics could be mediated by
ANG II. In rats and dogs the decrease in GFR and ERPF caused by ET-1
were abolished by ACE inhibition.!36- 75, 326] However, ANG II
anatgonists do not appear to prevent the decrease in ERPF and GFR caused
by ET-1182] suggesting that the actions of ACE inhibitors were being
mediated by decreasesd breakdown of bradykinin and stimulation of nitric
oxide production. In healthy human subjects, both ACE inhibition!252! and
infusion of L-arginine,!59! the substrate for nitric oxide synthesis,
prevented the hypertensive effects of ET-1 but neither blocked the increase
in renal vascular resistance. Furthermore, in this present study, plasma
concentrations of ANG II were significantly increased after administration
of TAK-044. These findings strongly suggest that ANG II is not a
significant mediator of the renal actions of endothelin in humans.
Endogenously generated renal endothelin is thought to promote sodium
.excretion and inhibit water resorption. !2771 However, systemic infusion of
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ET-1 in healthy subjects paradoxically reduces salt and water
excretion.!442- 524] Combined ETa/b receptor antagonism with TAK-044
had no clear action on the clearance or fractional excretion of sodium or
lithium although this study did not have the power to detect small changes.
Furthermore, any potential antinatriuretic effect of antagonism of tubular
endothelin receptors (mainly ETb) may have been counteracted by the
haemodynamic changes as a result of vascular endothelin receptor (mainly
ETa) antagonism. Thus, selective ETA receptor antagonists could
potentially have natriuretic actions and further studies with these agents are
needed.
TAK-044 tended to increase plasma active renin and ANG II
concentrations although the increase was only statistically significant for
ANG II. There are several potential mechanisms for this increase,
including decreased delivery of sodium to the macula densa, activation of
baroreceptor sensors in the afferent arterioles and a decrease in blood
pressure. The rise in ANG II observed may have, by negative feedback,
inhibited further release of renin. Despite the observed increase in ANG II,
there was no demonstrable increase in plasma aldosterone concentrations
as might have been expected. However, it is possible that any changes may
have been obscured by the normal diurnal variation in plasma aldosterone
concentrations, as well as by the effects of prolonged supine posture.
Furthermore, ET-1 is known to potentiate ANG Il-induced aldosterone
secretion!109] and, therefore, endothelin receptor antagonism with TAK-
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044 may have attenuated the expected increase in aldosterone
concentrations.
TAK-044 at both doses tended to increase plasma ANP concentrations,
although these increases were relatively small and only just achieved
statistical significance (p=0.05) after the 100 mg dose. The mechanism for
this increase is not clear especially given that TAK-044 has been shown to
be a potent vasodilator in humans (Studies 3 & 4) and this is likely to
result in reduced atrial stretch, a primary stimulus for ANP secretion. !5161
Furthermore, ET-1 is known to be a stimulator of ANP secretion by atrial
myocytes!488! and, therefore, TAK-044 would be expected to have an
inhibitory action on ANP release by these cells. Given that this study only
demonstrated a small increase in ANP, and that this increase only occurred
after the lower dose of TAK-044, it would appear that this unexpected
finding requires further confirmation in larger studies with endothelin
receptor antagonism.
Plasma concentrations of adrenaline and noradrenaline did not increase
after TAK-044. Thus combined ETa/b receptor antagonism does not appear
to activate the sympathetic nervous system. However, the limitations of
using a single method for evaluating sympathetic activity have been
previously highlighted!330] and these results should, therefore, be
interpreted cautiously.
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As previously reported,14351 in this study the higher dose of TAK-044, 750
mg, increased plasma immunoreactive endothelin concentrations but not
big ET-1 or the C-terminal fragment. This suggests that the observed
increase in plasma endothelin concentrations are a result of receptor
displacement and not de novo synthesis and is a consistent feature of drugs
with ETb receptor antagonist properties.
In conclusion, systemic combined ETa/b receptor blockade with TAK-044
caused peripheral and renal vasodilatation, and lowered blood pressure in
healthy subjects. In addition, TAK-044 produced a significant decrease in
filtration fraction with only minor changes in GFR and ERPF. These
findings suggest an important role for endogenously generated endothelin
in controlling systemic and renal haemodynamics in health.
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8.5 Table Legends
Table 8.1 Effects of TAK-044 (lOOmg or 750 mg) given
intravenously over 15 minutes on systemic haemodynamics.
Footer:
Mean changes (A) from basal over 4 hours are shown corrected for changes
with placebo. Values are mean ± SEM in 8 subjects. CI, confidence
intervals; SBP, systolic blood pressure; DBP, diastolic blood pressure;
MAP, mean arterial pressure; HR, heart rate; CI, cardiac index; SI, stroke
index; TPR, total peripheral resistance. P values are for changes vs.
baseline.
Table 8.2 Effects of TAK-044 (lOOmg or 750 mg) given
intravenously over 15 minutes on renal function.
Footer:
Mean changes (A) from basal over 4 hours are shown corrected for changes
with placebo. Values are mean ± SEM in 8 subjects. CI, confidence
intervals; ERPF, effective renal plasma flow; ERVR, effective renal
vascular resistance; GFR, glomerular filtration rate; Na, sodium; Li,
lithium; FEn3, fractional sodium excretion; FEy, fractional lithium
excretion. P values are for changes vs. baseline.
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Table 8.3 Effects of TAK-044 (lOOmg or 750 mg) given
intravenously over 15 minutes on plasma renin, angiotensin
II, aldosterone, atrial natriuretic peptide, adrenaline and
noradrenaline.
Footer:
Mean changes (A) from basal over 4 hours are shown corrected for changes
with placebo. Values are mean ± SEM in 8 subjects. CI, confidence
intervals. P values are for changes vs. baseline.
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8.6 Figure Legends
Figure 8.1 Effect of TAK-044 on plasma concentrations of endothelin,
big endothelin-1 and C-terminal fragment
Effect of intravenous infusion of placebo or TAK-044 (100 mg or 750 mg)
for 15 minutes on immunoreactive plasma endothelin (solid columns), big
endothelin-1 (hatched columns) and C-terminal fragment of big
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ET-1, is the principal isoform present in the human renal!257] and
cardiovascular system!259] where the peptide interacts with the two
receptor subtypes, ETa and ETb-!115> 257] In human kidney ETb receptors
predominate and are mainly localised to tubules and collecting ducts.!257]
In contrast, the ETA subtype is largely confined to the smooth muscle of
the renal vasculature!360] which is exquisitively sensitive to the
vasoconstrictor action of this peptide.!328] Intravenous infusion of ET-1 in
healthy humans increases blood pressure, systemic and renal vascular
resistance and lowers GFR, ERPF and sodium excretion.!442' 5241 Plasma
concentrations of endothelin are substantially raised in chronic renal
failure!289! and may have a role in the progression of this condition,
contributing to the increased vascular tone and high incidence of
cardiovascular mortality as well as playing a role in the progression of
renal failure.!277] In support of this hypothesis, endothelin receptor
antagonists have been shown to be particularly effective in animal models
of renal failure.!49' 3781
This study examines the acute actions of a combined ETa/b receptor
antagonist, TAK-044, on systemic and renal haemodynamics as well as
renal tubular function in patients with chronic renal failure. The effects of
acute endothelin receptor antagonism on the plasma concentrations of the
precursor big ET-1 and the two products of cleavage by the endothelin
248
converting enzyme, the mature peptide and the inactive C-terminal
fragment were also examined.
9.2 Methods
9.2.1 Patients
Seven male patients with chronic renal failure (age 45 ± 3 years)
participated in this study. Subjects had plasma creatinine concentrations
>150 mmol.r1 and no change in renal function in the 2 months preceding
the study; and had no other significant concurrent illness other than
hypertension. All medications (Table 9.1) were withheld on the morning of
the studies.
9.2.2 Measurements
Blood pressure was measured using a well validated semi-automated
technique (see Section 2.2.1) and cardiac function (stroke volume, cardiac
output and heart rate) was measured using a non-invasive bioimpedance
method (see Section 2.3). ERPF and GFR were estimated by measuring the
renal clearances of p-aminohippurate sodium (PAH) and polyfructosan-S
respectively (see Sections 2.4.1 & 2.4.2). Proximal tubular reabsorptive
capacity of sodium was assessed using a physiologically inert dose of oral
lithium carbonate (see Sections 2.4.3). Venous blood samples for separate
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assay of plasma endothelin, big ET-1 and C-terminal fragment
concentrations were collected, stored and analysed (see Section 2.5.7).
9.2.3 Study Design
Subjects participated in a three-phase, double-blind, randomised, placebo-
controlled crossover study, with at least 7 days between phases. The
detailed protocols for administration of the combined endothelin ETa/b
receptor antagonist, TAK-044 (see Section 5.2). and conducting clearance
studies have been previously described (see Sections 2.4 & 8.2). In brief,
subjects completed a 24-hour urine collection at 7:00 AM on the morning
of the study and received oral lithium carbonate (Camcolit, 250 mg
sustained release; Norgine, Elarefield, UK) 14 hours before baseline
measurements. On each study day, two intravenous cannulae were placed
in the antecubital fossa of the non-dominant arm for infusion of
PAH/polyfructosan-S, and TAK-044 (100 mg or 750 mg given over 15
minutes) or placebo (dextrose 50 mg). A third cannula was placed in the
antecubital fossa of the opposite arm for blood sampling. Priming doses of
PAH and polyfructosan-S were followed by maintenance infusions. After
an equilibration period, blood samples were drawn and urine collected at
the beginning and at the end of accurately timed 30 minute clearance
periods. A volume of water was drunk by the subjects after all urine
collections sufficient to maintain a urine output of 10 ml.min"1 throughout
the study. Two baseline collection periods preceded, and 4 followed,
infusion of TAK-044 or placebo.
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9.2.4 Data Presentation and Statistical Analysis
Mean arterial pressure, stroke index, cardiac index, systemic vascular
resistance index (SVRI), renal clearances, effective filtration fraction (EFF;
GFR/ERPF x 100%), effective renal vascular resistance (ERVR) and
fractional sodium (FEn3) and lithium excretion (FEy) were calculated
using standard formulae.!212' 442]
Data are presented as mean ± SEM. Baseline values were calculated as the
mean of all three phases for each individual subject. Placebo-corrected
changes from baseline were arithmetically averaged over the relevant
measurement period (0 to 240 minutes for haemodynamic changes and 0 to
120 minutes for renal function), with uniform weighting given to each
timepoint. Data were analysed statistically by repeated measures analysis
of variance (ANOVA). Factors included in the ANOVA were subject, dose
of TAK-044, timepoint, and dose-timepoint interaction. In none of the
analyses (except plasma endothelin concentrations which were analysed as
absolute values by the Kruskal-Wallis non-parametric test with Dunn's
multiple comparisons post-tests) was there any evidence of a statistically
significant dose-timepoint interaction. Therefore, the adjusted dose group
means from the ANOVA were compared with the null hypothesis by a
two-sided /-test. Statistical analyses were performed by the use of the
software package SAS (version 6.07, SAS Institute Inc).
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9.3 Results
The patients' diagnoses and medication are presented in Table 9.1. Five of
the 7 patients were hypertensive at screening, with MAP > 105 mmHg.
Patient 1 withdrew after completing the TAK-044 100 mg and placebo
phases and was, therefore, included in the analysis. All the other subjects
completed all 3 phases. TAK-044 was well tolerated at the doses used,
with no difference between placebo and TAK-044 phases in the prevalence
of minor symptoms. In particular, there was no evidence of the symptoms
being dose-related and there was no excess of symptoms associated with
hypotension (dizziness, headache, tachycardia) reported during the TAK-
044 phases compared with placebo.
TAK-044 significantly lowered MAP by 11 ± 4% and SVRI by 24 ± 6% at
the highest dose (Figure 9.1). TAK-044 750 mg increased cardiac index by
15 ± 2%, stroke index by 8 ± 3% and ejection fraction by 4 ± 1%. There
was a trend for TAK-044 to increase heart rate, but this was only
significant after 100 mg TAK-044 (9 ± 3%).
TAK-044, at both doses, had no significant effect on GFR (-4 ± 10% after
750 mg) or ERPF (22 ± 17%). However, relative trends in decrease in GFR
and increase in ERPF meant that EFF was significantly lowered after 100
mg (22 ± 5%) and 750 mg (26 ± 8%) TAK-044 (Figure 9.2). ERVR was
also lowered by 100 mg (11 ± 4%) and 750 mg (10 ± 6%) TAK-044
(Figure 9.2). Both doses of TAK-044 had no significant effects on sodium
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(-3 ± 5% after 750 mg) or lithium clearance (2 ± 9%) or on FEn3 (0.4 ±
5.1%) orFEu (0.1 ±8.4%).
Baseline plasma endothelin and C-terminal fragment, but not big ET-1,
concentrations were significantly raised in patients with chronic renal
failure when compared with sex and age matched controls (Table 9.2).
Infusion of 750 mg TAK-044 rapidly increased plasma endothelin but had
no effect on big ET-1 or C-terminal fragment concentrations (Figure 9.3).
9.4 Discussion
This study is the first report of the effects of systemic endothelin
antagonism on the systemic haemodynamics and renal function of renally
impaired subjects.
The finding that systemic administration of a combined ETa/b receptor
antagonist causes peripheral vasodilatation and lowers blood pressure in
patients with chronic renal failure strongly suggests that ET-1 is important
in the maintenance of basal vascular tone and blood pressure in this
condition. This is consistent with, and extends, the previous findings that
endogenous generation of ET-1 plays a fundamental physiological role in
the maintenance of basal vascular tone!218] and blood pressure (Study 3) in
healthy subjects. Endothelin receptor antagonists may have a potential
beneficial role as vasodilators and blood pressure lowering agents in the
treatment of patient with chronic renal failure. It should be noted that the
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vasodilator and blood pressure lowering actions of TAK-044 occurred
despite the patients antihypertensive medication having only been
discontinued on the morning of the study.
In healthy subjects, systemic infusion of ET-1 increases ERVR and
decreases both GFR and ERPF.i442- 5241 The decrease in ERPF
proportionally exceeds the decrease in GFR, as reflected by an increase in
EFF. In this present study, TAK-044 significantly decreased ERVR, and
tended to decrease GFR and increase ERPF. As a consequence of these
opposing trends, EFF decreased significantly with both doses of TAK-044.
The increase in EFF with ET-1 infusion and the currently reported
decrease with endothelin antagonism are similar to the changes observed
with agonists and antagonists of renal ANG II receptors.12501 Furthermore,
the reduction in EFF, and the consequent reduction of glomerular
hydrostatic pressure, may account for the success of ACE inhibitors in
slowing the progression of renal failure.t250- 3371 The reduction in EFF
seen with TAK-044 occurred despite 4 of the 7 patients studied were
already on treatment with an ACE inhibitor. This would tend to suggest
that endothelin antagonism could potentially be used in the treatment of
chronic renal failure in conjunction with ACE inhibitors.
Endogenously generated renal endothelin is thought to promote sodium
excretion and inhibit water resorption. f277l However, systemic infusion of
ET-1 paradoxically reduces salt and water excretioni442- 5241 TAK-044 had
no clear action on the clearance or fractional excretion of sodium or
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lithium although this study did not have the power to detect small changes.
Furthermore, any potential antinatriuretic effect of antagonism of tubular
endothelin receptors (mainly ETb) may have been counteracted by the
haemodynamic changes as a result of vascular endothelin receptor (mainly
ETa) antagonism. Thus, selective ETA receptor antagonists could
potentially have natriuretic actions and further studies with these agents are
needed. However, overall, the renal actions of TAK-044 do not discourage
the further development of endothelin antagonists for use in chronic renal
failure.
In this study, basal concentrations of immunoreactive endothelin where
raised more than five-fold in patients with chronic renal failure compared
with healthy controls, whereas C-terminal fragment was raised only two¬
fold and big ET-1 concentrations where not raised at all. These results
support the hypothesis that endothelin levels are raised in patients with
renal failure mainly because of decreased clearance (possibly degradation
by renal neutral endopeptidase)Pl rather than increased synthesis. This
contrasts with congestive heart failure, where big ET-1 is raised and
increased production appears to be the major source of ET-1.P71' 61E This
study has also shown that after infusion of 750 mg TAK-044,
concentrations of plasma immunoreactive endothelin were significantly
elevated but levels of big ET-1 and C-terminal fragment were unaltered.
This is a feature of drugs with ETb antagonist properties, probably
reflecting endothelin displacement from clearance receptors and is
consistent with previous studies in healthy humans.i435i
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In conclusion, systemic combined ETa/b receptor blockade with TAK-044
caused peripheral and renal vasodilatation, and lowered blood pressure in
renally impaired subjects. In addition, TAK-044 produced a significant
decrease in EFF with only minor changes in GFR and ERJPF. These
findings suggest an important role for endogenously generated endotheiin
in controlling systemic and renal haemodynamics in patients with chronic
renal failure. In particular, by lowering blood pressure and having
potentially antiatherogenic properties^197! endotheiin receptor antagonists
may also be useful in slowing the progression of renal insufficiency in
various kidney diseases. This study of the acute effects a single infusion of
TAK-044 are encouraging for the further development of endotheiin
receptor antagonists for the treatment of chronic renal failure and longer-
term studies are now warranted.
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9.4 Table Legends
Table 9.1 Chronic renal failure patient characteristics.
Footer:
Subject 1 completed placebo and 100 mg TAK-044 phases. Subjects 2-7
completed all three study phases. (IgA, Immunoglobin A).
Table 9.2 Mean baseline haemodynamic, renal function and
immunoreactive endothelin peptide values before administration of TAK-
044 or placebo in patients with chronic renal failure and in 8 sex and age
matched controls.
Footer:
*p<0.05, JpO.0005 and §p<0.0001.
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9.5 Figure Legends
Figure 9.1 Systemic Haemodynamics
Mean changes (A) over 4 hours after dosing with placebo (P), TAK-044
100 mg (100) and 750 mg (750) in mean arterial pressure (MAP; mm Hg);
systemic vascular resistance index (SVRJ; dyn.sec.cm~5m~2) and stroke
index (SI; ml.m"). For the placebo columns (open), mean change from
predose is shown. For the active treatment columns (stipled), placebo-
corrected changes from predose are shown (change from predose {active}
minus mean change from predose {placebo}). *P=0.001 and §p<0.01 for
comparison with predose.
Figure 9.2 Renal Haemodynamics
Mean changes (A) over 2 hours after dosing with placebo (P), TAK-044
100 mg (100) and 750 mg (750) in effective renal vascular resistance
(ERVR; dyn.sec.m~2) and effective filtration fraction (EFF; %). For the
active treatment columns (stipled), placebo-corrected changes from
predose are shown (change from predose {active} minus mean change
from predose {placebo}). *P=0.05, JpO.005 and §p<0.001 for
comparison with predose.
Figure 9.3 Plasma Endothelin Concentrations
Effect of intravenous infusion of placebo (□); 100 mg TAK-044 (■) and
750 mg TAK-044 (•) on plasma immunoreactive endothelin
concentrations. *P<0.05 for comparison from predose.
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Table 9.1
Patient Age Diagnosis Antihypertensive medication
1 40 Obstructive nephropathy
2 37 Polycystic kidneys enalapril/frusemide/metropolol
3 47 IgA nephropathy enalapril
4 48 IgA nephropathy doxasosin/enalapril/metropolol
5 44 Glomerulosclerosis doxasosin/amlodipine/bendrofluazide
6 65 Obstructive nephropathy doxasosin/nifedipine





Heart rate (beats/min) 57 ± 3 58 ± 3
Systolic blood pressure (mm Hg)* 137 ± 21 119 ± 5
Diastolic blood pressure (mm Hg)* 86 ±7 76 ± 5
MAP (mm Hg)* 103 ±4 90 ±2
SVRI (dyn.sec.cm"5.m"2)* 3649 ±425 2554± 178
Cardiac index (I.min.m"2)* 2.3 ± 0.2 2.8 ±0.2
Stroke index (ml.mf2) 41 ±2 48 ±3
Ejection fraction (%) 59.7 ± 1.9 59.1 ± 1.6
Renal Function
24 hour creatinine clearance (ml.min"')§ 36 ± 7 110 ± 7
Glomerular filtration rate (ml.min"')J 25 ±4 136 ± 8.8
Effective renal plasma flow (ml.min"')§ 110 ±25 598 ±33
Effective filtration fraction (%) 26 ±3 24 ±2
Effective renal vascular resistance (dyn.sec.cm~5)* 6660 ±302 5768±126
24 hour sodium excretion (mmol.day'1) 94 ±9 131 ±22
Sodium clearance (ml.min"1) 2.2 ±0.2 2.2 ± 0.2
Lithium clearance (ml.min_1)J 11.1 ± 1. 30.1 ±2.4
Fractional sodium excretion (%)% 2.0 ±0.2 7.1 ±0.6
Fractional lithium excretion (%) 26.7 ±2.7 31.6 ± 2.8
Endothelin Peptides
Endothelin (pM)J 34.5 ± 6.5 6.0 ±0.7
Big endothelin-1 (pM) 2.5 ±0.3 2.5 ±0.2



















































10. Forearm vasoconstriction to endothelin-1 is impaired in













Of the three endothelin isoforms, ET-1 is the predominant isoform
produced by vascular endothelial cells!60! and has been implicated in the
pathophysiology of several cardiovascular conditions including essential
hypertension. !1971 Circulating concentrations of ET-1 are low!439! and
approximately 80% of ET-1 synthesised by endothelial cells is secreted
abluminally,!593! suggesting that ET-1 has primarily paracrine and
autocrine actions.
On the basis of molecular studies, two endothelin receptors have so far
been characterized in mammalian species. !21> 48 E The ETA receptor is
relatively selective for ET-1,!21! whereas the ETb receptor has equal
affinity for all three endothelin isoforms.I48 E Results from early studies
suggested that the ETA receptor was restricted to the vascular smooth
muscle and mediates vasoconstriction, whereas the ETb receptor was
restricted to the endothelium where it mediates vasodilatation through the
production of endothelium-dependent vasodilators, such as nitric oxide and
prostacyclin.!220' 2421 However, it is now recognized that this concept is an
oversimplification because ETb receptors are also expressed on vascular
smooth muscle cells!1171 and contraction of human smooth muscle cells
can be generated through either ETA or ETB receptor stimulation.!217' 577]
However, in a wide range of human vessels in vitro, ET-1 mediated
vasoconstriction occurs predominantly via the ETA receptor!1161 and the
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importance of the smooth muscle ETB receptor in humans remains to be
clarified.
In addition to its vasoconstrictor and pressor effects, ET-1 has several
other actions which implicate it in the pathophysiology of essential
hypertension (see Section 1.3.1). It would, therefore, appear possible that
disturbances in the control of ET-1 production or sensitivity of tissues to
ET-1 could participate in the mechanisms of blood pressure elevation in
essential hypertension.
Studies measuring plasma concentrations of endothelin in patients with
essential hypertension have produced conflicting results, with several
studies reporting increased concentrations!283' 307' 476> 505! whilst others
have not.!114' 213, 357, 439, 492] Th]s apparent inconsistency has been
variously attributed to the presence of vascular injury and hypertensive
target organ damage.!446' 489] However, given that ET-1 appears to be
mainly a paracrine agent it is possible that increased endothelial synthesis
of ET-1 in essential hypertension is not necessarily reflected in raised
plasma concentrations. Indeed, enhanced expression of ET-1 gene has been
found in resistance arteries of rat models of hypertension!174' 3551 as well
as in humans with severe essential hypertension.!4911
In vitro vasoconstrictor responses to ET-1 are blunted in resistance arteries
taken from patients with essential hypertension. !49°! However, in vivo
responses to ET-1 by capacitance vessels is markedly enhanced in
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hypertensive patients and sympathetically mediated venoconstriction was
also substantially potentiated in these patients but not in normotensive
subjects.Studies with endothelin receptor antagonists have been
shown to lower blood pressure in both normotensive (Studies 3-6) and
hypertensive subjects.P90] However, the direct contribution of the
endothelin system to the raised blood pressure in essential hypertension
has not yet been examined.
This study investigates whether the endothelin system contributes to the
raised vascular tone associated with essential hypertension by infusing
locally active doses of the selective ETA receptor antagonist, BQ-123, into
the brachial artery of patients with essential hypertension and
normotensive subjects and measuring forearm blood flow (FBF) by venous
occlusion plethysmography. l604i This study also examines the in vivo
arterial responsiveness to the non-selective ETA and ETb agonist ET-1 and
the selective ETb agonist, sarafotoxin S6c in these subjects. In view of the
potential interaction between endothelin and activity of the sympathetic
nervous system, and the known increase in sympathetic nervous activity in
hypertension, ['4] lower body negative pressure (LBNPjt604! was used to
assess the effect of ET-1 and sarafotoxin S6c on sympathetically mediated




Consecutive patients with hypertension (BP > 160/100 mmHg) attending
the Cardiovascular Risk Clinic at the Western General Hospital were
considered for the study. Patients were only eligible for recruitment if there
was no evidence of a secondary cause for hypertension; if mean daytime
awake blood pressure was more than 140/90 mmHg on ambulatory
monitoring (measurements every 30 minutes using Spacelabs 90207l395i;
if there were no significant concurrent illnesses; and if they had never
received antihypertensive therapy. Normotensive (BP < 140/90 mmHg)
were recruited by advertisement. Control subjects were matched for age,
sex, weight and height. A total of 27 hypertensive patients and 30
normotensive subjects participated in these studies (some subjects
participated in more than one study). No subject received vasoactive or
nonsteroidal anti-inflammatory drugs in the week before each phase of the
study, and all abstained from alcohol for 24 hours, and from food, caffeine
containing drinks, and cigarettes for at least 3 hours before any
measurements were made.
10.2.2 Drug Infusion and Forearm Blood Flow Measurement
Studies were performed with subjects resting supine in a quiet clinical
laboratory maintained at a constant temperature 25°C.
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The brachial artery of the non-dominant arm was cannulated as described
in Section 2.1.1. Physiological saline (0.9% NaCl; Baxter Healthcare Ltd,
Thetford, UK) was infused at 1 ml.min"1 for an equilibration period of at
least 30 minutes prior to infusion of study agents. Locally active doses of
drugs were dissolved in physiological saline and administered at 1 ml.min"
1. Infusions of different study agents were separated by at least 20 minutes
of infusion of physiological saline or longer if FBF had not returned to
baseline values.
Blood flow was measured in both forearms by venous occlusion
plethysmography, using indium/gallium-in-Silastic (see Section 2.1.1).
LBNP was applied using the method described by Brown and colleagues
(see Section 2.1.1). A well-validated semiautomated noninvasive
oscillometric sphygmomanometer (see Section 2.2.1) was used to make
duplicate measurements of blood pressure in the noninfused arm, which
were then averaged.
10.2.3 Data Presentation and Statistical Analysis
Data are shown as mean ± SEM in the figures and with confidence
intervals (CI) in the text and tables where appropriate. Results were
examined by repeated measures analysis of variance (ANOVA) and paired
t-tests where appropriate using Statview 512+ software (Brainpower Inc,
Calabasas, Ca, USA) for the Apple Macintosh personal computer.
Differences were considered statistically significant at a value of P<0.05.
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10.2.4 Detailed Protocols
Study A: Selective ETa receptor antagonism in healthy
subjects
Six healthy male volunteers participated in a single-blind, randomised, 4-
way crossover placebo-controlled study. In 3 of the 4 phases of the study,
the selective ETA receptor antagonist, BQ-123 (American Peptide
Company, Sunnyvale, CA), was infused at 10, 30 and 100 nmol.min"1 for
120 minutes. The highest dose of BQ-123 (100 nmol.min"1) used in this
study has been shown to produce a slowly progressive increase in FBF of
-40% when infused via the brachial artery for 60 minutes.!218' 318] jn the
fourth phase, physiological saline was infused for 120 minutes instead of
BQ-123.
Study B: Selective ETB receptor agonism in healthy subjects
Six healthy male volunteers participated in a single-blind, randomised, 2-
way crossover placebo-controlled study. Subjects received a brachial artery
infusion of sarafotoxin S6c (Clinalfa AG, Novabiochem, Laurelfingen,
Switzerland) at a dose of 5 pmol.min"1 and 10 pmol.min"1. Intra-arterial
sarafotoxin S6c at 5 pmol.min"1 is known to produce -20%
vasoconstriction after 60 minutes of infusion.!2171 The 10 pmol.min"1 dose
was chosen in an attempt to produce a similar vasoconstriction to ET-1 of
-40% after 60-120 minutes. [217,218,318]
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Study C: Selective ETA receptor antagonism in essential
hypertension
Ten patients with essential hypertension and 10 matched controls
participated in this study (Table 10.1). After the initial 30 minute saline
infusion, sodium nitroprusside (Roche, Basel, Switzerland) was infused at
incremental doses of 1, 3 and 10 pg.min"1, each for 5 minutes. FBF was
measured for the last 3 minutes of each 5 minute infusion. After a minimal
20 minute "washout" infusion with saline, a 90 minute infusion of BQ-
123, at a dose of 100 nmol.min"1 was started. The choice of this dose was
based on the results of Study A.
Study D: Non-selective ETA and ETB receptor agonism in
essential hypertension
Ten patients with essential hypertension and 10 matched controls
participated in this study (Table 10.1). After the initial 30 minute saline
infusion, noradrenaline (Sterling-Winthrop, Guildford, UK) with ascorbic
acid as antioxidant (Evans Medical, Horsham, UK) was infused at
incremental doses of 10, 20, 40 and 80 ng.min"1, each for 5 minutes. FBF
was measured for the last 3 minutes of each 5 minute infusion. After a
minimal 20 minute "washout" infusion with saline, a 90 minute infusion of
ET-1 (Clinalfa AG), at a dose of 5 pmol.min"1 was started. This dose is
known to produce -40% vasoconstriction after 60-120 minutes.i217> 318J
LBNP was applied at the end of both saline infusions, at the end of the
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highest dose of noradrenaline and after 15 and 90 minutes of ET-1
infusion.
Study E: Selective ETB receptor agonism in essential
hypertension
Ten patients with essential hypertension and 10 matched controls
participated in this study (Table 10.1). After the initial 30 minute saline
infusion, noradrenaline was infused at incremental doses of 10, 20, 40 and
80 ng.min"1, each for 5 minutes. FBF was measured for the last 3 minutes
of each 5 minute infusion. After a minimal 20 minute "washout" infusion
with saline, a 90 minute infusion of sarafotoxin S6c, at a dose of 10
pmol.min"1 was started. This dose was chosen based on the results of Study
B. LBNP was applied at the end of both saline infusions, at the end of the
highest dose of noradrenaline and after 15 and 90 minutes of sarafotoxin
S6c infusion.
10.3 Results
Heart rate, blood pressure and FBF in the infused arm did not change
significantly in any study protocol, confirming that drugs had only local
actions on the forearm vasculature of the infused arm and had no systemic
haemodynamic effects.
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Study A: Selective ETA receptor antagonism in healthy
subjects
BQ-123 caused slow-onset vasodilatation at all three doses (Table 10.2).
Vasodilatation was maximum by 60 minutes and was not significantly
increased by a further 60 minutes of infusion (Table 10.2). Infusion of
saline for 120 minutes had no effect on FBF.
Study B: Selective ETB receptor agonism in healthy subjects
Both doses of sarafotoxin S6c, 5 and 10 pmol.min"1, caused a slowly
progressive vasoconstriction (Table 10.2). The vasoconstriction to 10
pmol.min"1 was significantly greater than that caused by 5 pmol.min"1
(P=0.02).
Study C: Selective ETA receptor antagonism in essential
hypertension
Sodium nitroprusside caused a dose-dependent vasodilatation in both
hypertensive patients and control subjects (Figure 10.1) which was not
significantly different between groups (P=0.48). BQ-123 caused a slowly-
progressive vasodilatation in control subjects, with an increase in FBF of
40 ± 8% at 60 minutes (CI, 22% to 59%; P=0.0001; Figure 10.1). BQ-123
also caused a slowly progressive vasodilatation in hypertensive patients,
with an increase in FBF of 35 ± 5% at 60 minutes (CI, 23% to 46%;
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P=0.0001). The vasodilatation to BQ-123 was not significantly different
between hypertensive patients and controls (P=0.49).
Study D: Non-selective ETA and ETB receptor agonism in
essential hypertension
Noradrenaline caused a dose-dependent vasoconstriction in both
hypertensive patients and control subjects (Figure 10.2) which was not
significantly different between groups (P=0.93). ET-1 caused a slowly-
progressive vasoconstriction in control subjects, with a decrease in FBF of
37 ± 3% at 90 minutes (CI, -45% to -29%; P=0.0001; Figure 10.2). ET-1
also caused a slowly progressive vasoconstriction in hypertensive patients,
with a decrease in FBF of 21 ± 4% at 90 minutes (CI, -30% to -12%;
P=0.001; Figure 10.2). The vasoconstriction to ET-1 was significantly
blunted in hypertensive patients compared with controls (P=0.001; Figure
10.2). Application of LBNP produced a vasoconstriction of -20% in both
the infused and control arms (Table 10.3). This vasoconstriction in the
infused arm was not affected by infusion of either noradrenaline or ET-1 in
hypertensive patients or control subjects (Table 10.3). There were no
significant differences in the vasoconstriction caused by LBNP in
hypertensive patients or control subjects (Table 10.3).
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Study E: Selective ETb receptor agonism in essential
hypertension
Noradrenaline caused a dose-dependent vasoconstriciton in both
hypertensive patients and control subjects (Figure 10.3) which was not
significantly different between groups (P=0.89). Sarafotoxin S6c caused a
slowly-progressive vasoconstriction in control subjects, with a decrease in
FBF of 44 ± 5% at 90 minutes (CI, -55% to -33%; P=0.0001; Figure 10.3).
Sarafotoxin S6c also caused a slowly progressive vasoconstriction in
hypertensive patients, with a decrease in FBF of 48 ± 4% at 90 minutes
(CI, -57% to -39%; P=0.0001; Figure 10.3). The vasoconstriction to
sarafotoxin S6c was not significantly different between hypertensive
patients and controls (P=0.95; Figure 10.3). Application of LBNP
produced a vasoconstriction of -20% in both the infused and control arms
(Table 10.3). This vasoconstriction in the infused arm was not affected by
infusion of either noradrenaline or sarafotoxin S6c in hypertensive patients
or control subjects (Table 10.3). There were no significant differences in
the vasoconstriction caused by LBNP in hypertensive patients or control
subjects (Table 10.3).
10.4 Discussion
These studies demonstrate that endothelin contributes significantly to
peripheral vascular resistance in patients with essential hypertension and
suggest that ETA receptor antagonists may be useful as vasodilator agents
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in the treatment of this condition. They also show that both ETA and ETb
receptors can mediate vasoconstriction in the peripheral vasculature of
healthy subjects and patients with essential hypertension, a finding that
may have important implications for the potential therapeutic use of
endothelin receptor antagonists.
Evidence that endothelin contributes to peripheral vascular resistance in
essential hypertension is provided by these studies with the selective ETA
receptor antagonist BQ-123. Brachial artery infusion of a locally active
dose of BQ-123 for 60 minutes increased FBF by -40% in patients with
essential hypertension in study C (Figure 10.1). This response was
probably maximal by 60 minutes, given that in study A (Table 10.1)
infusion of BQ-123 for 120 minutes in healthy volunteers did not produce
a greater vasodilatation. Although bigger doses of BQ-123 may have
produced greater vasodilatation, this appears unlikely given that in study A
doses of BQ-123 10-fold different produced similar increases in FBF
(Table 10.2).
Though these studies only investigated the short-term effects of ETA
receptor blockade in a single vascular bed, responses in human forearm
resistance vessels are thought to be broadly representative of responses in
other vascular beds.t604! Indeed, these observations support the recent
findings by Krum et al,[290i who reported that sustained oral
administration of a combined ETA and ETb receptor antagonist, bosentan,
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significantly reduced blood pressure in patients with essential
hypertension.
These studies have shown that the forearm vasodilator effects of the
selective ETA receptor antagonist BQ-123, and the control vasodilator
sodium nitroprusside, and were not different in patients with essential
hypertension compared with normotensive controls (Figure 10.1). These
findings suggest that endothelin does not contribute to the raised vascular
tone associated with essential hypertension, at least not by ETA receptor
mediated actions. However, any comparison of the effects of BQ-123
between patients with essential hypertension and normotensive controls
must be made with some caution. The time course of the effect of BQ-123
and the need for brachial artery cannulation do not lend themselves to
repeated dose-response studies. Consequently these studies may not have
not demonstrated the maximal effect of BQ-123 in the forearm
vasculature, although the results of study A would suggest they have, at
least in healthy subjects.
These studies with BQ-123 support an important role for ETA receptors in
mediating the constrictor effects of endogenous endothelin in patients with
essential hypertension, but the role of ETb receptors in this regard needs
further clarification. A recent study with BQ-788, a selective ETB receptor
antagonist, caused vasoconstriction in the forearm vasculature of healthy
subjects.t592l This study suggests that endogenous activation of ETB
receptors causes vasodilatation. The result of ETB receptor antagonism in
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patients with essential hypertension is not currently known and cannot be
determined from this study. Further studies with selective ETA and ETB
antagonists in hypertensive patients are necessary to further clarify this
issue.
Collectively, these agonist and antagonist studies suggest that both ETA
and ETb receptors can mediate vasoconstriction in forearm resistance
vessels of healthy subjects and patients with essential hypertension. These
agonist studies in healthy volunteers are consistent with similar recently
reported studies (Table 10.2, Figures 10.2 & 10.3).t217i Double the dose of
sarafotoxin S6c was required to produce a similar vasoconstriction to ET-1
in control subjects, implying that both ETA and ETB receptors mediate
vasoconstriction, but it is difficult to extrapolate these results to quantify
the relative contribution of each receptor subtype in mediating the effects
of endogenous endothelin.
The finding that the vasoconstrictor effects of ET-1 was blunted in the
forearm vasculature of patients with essential hypertension (Figure 10.3)
are very similar to those observed in vitro by Schiffrin et ah490! in
resistance vessels taken from buttock biopsies. These findings may be
related to several events. First, there could be diminished responsiveness of
signal transduction mechanisms coupled to endothelin receptors. This
mechanism appears unlikely given that responses to sarafotoxin S6c in
hypertensive patients were not affected in study E. Second, there could be
a generalised decrease in response involving either intracellular excitation-
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contraction coupling or the contractile mechanism of vascular smooth
muscle cells. This latter explanation may be excluded by the finding that
responses to noradrenaline were not diminished in these patients (Figures
10.2 & 10.3). Similarly, vasoconstrictor responses to noradrenaline, ANG
II and arginine vasopressin in vitro are not diminished in arteries taken
from hypertensive patients.t1. 490] Third, there could be decreased
availability of endothelin receptors due to either down-regulation or prior
receptor occupation. Endothelin receptor number at the smooth muscle cell
surface is reduced by prolonged exposure to ET-1 itself227- 468] and there
is recent evidence suggesting that ET-1 mRNA expression is increased in
resistance vessels taken from patients with severe essential
hypertension. [491] In DOCA-salt hypertensivet126] anc] spontaneously
hypertensive ratsf91! decreased density of endothelin binding sites have
been demonstrated. Therefore, the finding of diminished responsiveness to
ET-1 appears to provide indirect evidence of excess production of
endothelin in human hypertensive blood vessels or of excess exposure of
these vessels to endothelin in mild to moderate essential hypertension.
In contrast to the effects of ET-1, forearm vasculature responsiveness to
sarafotoxin S6c was not diminished in patients with essential hypertension
(Figure 10.3). Endothelin receptor expression and distribution may be
altered in essential hypertension. As previously discussed, endothelin
receptor number at the smooth muscle cell surface is reduced by prolonged
exposure to ET-1 itself227' 468] jn endothelial cells, ETb receptor
expression is also decreased by exposure to high local concentrations of
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ET-1 .[480] However, ETb receptor expression by smooth muscle cells is
increased in hypertension,P47l and under the influence of ANG Il.i256! The
preserved vasoconstriction to sarafotoxin S6c may partly be related to
endothelial dysfunction in essential hypertension resulting in diminished
endothelial ETb receptor-mediated release of dilator substances, but
whether this is indicative of a shift in the relative functional importance of
endothelial and vascular smooth muscle ETb receptors in essential
hypertension requires further investigation. It is, however, important to
acknowledge that these studies cannot definitively exclude the possible
existence of a dilator subtype of ETA receptor sensitive to ET-1 or another
species of constrictor receptor sensitive to sarafotoxin S6c in patients with
essential hypertension.
It has been suggested from in vitro studies that endothelin may increase
peripheral sympathetic activity through postsynaptic potentiation of the
effects of noradrenaline.[6371 However, these findings have not been
confirmed in vivo in resistance vessels of normotensive subjetcs in this
study (Table 10.3) or in a previous report, t97] Further this study did not
show a potentiation of sympathetically mediated vasoconstriction by ET-1
or sarafotoxin S6c in hypertensive subjects (Table 10.3). These findings
appear to be at variance with previously reported work where
sympathetically mediated dorsal hand vein constriction was potentiated by
ET-1 in patients with essential hypertension but not in normotensive
controls.Furthermore, venoconstriction to ET-1 was also enhanced in
hypertensive patients in this study. P13! However, dorsal hand veins have
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no underlying tone!604! and are probably not exposed to high
concentrations of locally produced endothelin, as has been suggested are
resistance vessels in essential hypertension,!491J given the normal
concentrations of plasma endothelin found in patients with essential
hypertension in several studies.!114> 213> 357> 439> 4921 Therefore, hand veins
may not be affected by down-regulatory factors as forearm resistance
vessels appear to be and this could explain the apparent contradictory
findings in veins and arteries. Nevertheless, the exaggerated
responsiveness to ET-1 may contribute to reduced venous compliance in
hypertension. This may, in turn, contribute to the raised cardiac preload
and cardiac output observed in the early stages of essential
hypertension.!149' 4731 Thus, it is possible that the reduced reactivity of
forearm resistance vessels to ET-1 is an epiphenomenon and that the
enhanced venoconstriction to ET-1 in hypertensive subjects may be a
causative factor in the pathophysiology of essential hypertension. This
possibility would require further investigation perhaps by examining
responses to ET-1 in the capacitance and resistance vessels of
normotensive patients with several 'risk' factors for developing
hypertension in later life.
Hypertension is associated with the development of several cardiovascular
diseases, including angina pectoris, myocardial infarction, peripheral
vascular disease and cerebrovascular disease. It is possible that the
vasoconstrictive properties of endothelin could contribute to myocardial
ischemia and that the proliferative effects of endothelin could contribute to
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vascular and cardiac hypertrophy and the atherosclerotic process. Indeed,
plasma endothelin concetrations are increased in atherosclerosis,f308! and
expression of ET-1 mRNA is increased in the vascular smooth muscle of
atherosclerotic human arteries.t625! Furthermore, increased tissue
endothelin activity has been reported in the active atherosclerotic lesions
associated with unstable angina. I649! With the multitude of drugs already
available to treat hypertension, a new class of antihypertensive agents may
seem unnecessary. However, endothelin receptor antagonists may prove
more effective than current therapies in preventing or reversing some of
the important complications that are little affected by current therapy, such
as myocardial infarction. I106!
In summary, these findings have potentially important therapeutic
implications in essential hypertension. Selective ETA receptor blockade
produced a significant reduction in forearm vascular resistance in patients
with essential hypertension. These studies have also shown that
vasoconstriction to endothelin is mediated by both ETA and ETB receptors
in these patients and that vasoconstricor ETB receptors may be functionally
more important in hypertensive patients than in normotensive controls.
This suggests that a non-selective ETA and ETB receptor antagonist would
be necessary to achieve optimal inhibition of the constrictor effects of
endogenous endothelin. The ideal receptor antagonist would probably be
one that blocked constrictor ETA and ETB receptors but preserved
endothelial ETB-receptor mediated vasodilatation. An orally active non¬
selective ETa and ETB receptor antagonist has very recently been shown to
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lower blood pressure in hypertensive patients during sustained
administration. !2901 Given that endothelin may mediate some of the
consequences of hypertension such as myocardial infarction!197] which
appear to be little affected by current treatments, the results of long term








fExpressed as mean of infused and noninfused arms.
Table 10.2 Baseline forearm blood flow and percentage changes from
baseline in Studies A and B.
Footer:
There were no significant differences between baseline values on the
different study days. N/A, data not available because infusion continued
for only 90 minutes; FBF indicates forearm blood flow.
*P<0.01 vs baseline, tPOTOOOl vs baseline.
^Expressed as mean of infused and noninfused arms.
Table 10.3 Percentage vasoconstriction to lower body negative
pressure in the infused and noninfused arms of patients and
controls.
Footer:
There were no significant differences in the vasoconstriction caused by
lower body negative pressure in the infused and noninfused arms or




Figure 10.1 Intra-arterial sodium nitroprusside and BQ-123
Effect of brachial artery infusion of sodium nitroprusside (1, 3 and 10
pg.min"1 each for 5 minutes) and BQ-123 (10 nmol.min"1 for 60 minutes)
in 10 patients with essential hypertension (•) and 10 age-matched healthy
control subjects (o). There were no significant differences in the
vasodilatation caused by both agents in the two groups studied.
Figure 10.2 Intra-arterial noradrenaline and endothelin-1
Effect of brachial artery infusion of noradrenaline (10, 20, 40 and 80
ng.min"1 each for 5 minutes) and endothelin-1 (5 pmol.min"1 for 90
minutes) in 10 patients with essential hypertension (•) and 10 age-matched
healthy control subjects (o). There was no difference in the
vasoconstriction caused by noradrenaline in the two groups studied. The
vasoconstriction to endothelin-1 in patients with essential hypertension
was significantly blunted compared to healthy control subjects (P=0.001).
Figure 10.3 Intra-arterial noradrenaline and sarafotoxin S6c
Effect of brachial artery infusion of noradrenaline (10, 20, 40 and 80
ng.min"1 each for 5 minutes) and sarafotoxin S6c (10 pmol.min"1 for 90
minutes) in 10 patients with essential hypertension (•) and 10 age-matched
healthy control subjects (O). There were no significant differences in the
































































Hypertensives51±47/3127 ±3119 ±387±45.5 ±0.24.02 ±0.27
Normotensives50±37/390±4NA92±45.4±0.33.56 ±0.32


























































































































































































Infusion Arm Normotensives Hypertensives
Saline (30 min) Control -21 ±2 -18 ± 4
Infused -21 ±3 -20 ±3
NA (80 ng.min"1) Control -20 ±2 -25 ±2
Infused -15 ± 1 -18 ± 3
Saline (90 min) Control -26 ±2 -21 ±5
Infused -30 ±2 -20 ±4
Endothelin-1 (15 min) Control -30 ±4 -28 ±7
Infused -25 ±3 -19 ± 3
Endothelin-1 (90 minutes) Control -18 ± 2 -27 ±4




Infusion Arm Normotensives Hypertensives
Saline (30 minutes) Control -21 ±2 -21 ±4
Infused -20 ±2 -14 ± 7
NA (80 ng.min"1) Control -21 ±3 -21 ±2
Infused -15 ± 3 -16 ± 2
Saline (20 min) Control -29 ±3 -21 ±3
Infused -28 ±3 -17 ± 8
Sarafotoxin S6c (15 minutes) Control -22 ±3 -17 ± 3
Infused -23 ±4 -17 ± 3
Sarafotoxin S6c (90 min) Control -23 ±3 -24 ±3
















































The publication of the discovery of endothelin by Yanagisawa and
colleagues in 1988 in that celebrated article in Nature was received with
considerable acclaim by the scientific community. The description of this
molecule's structure, actions in vitro and in vivo, DNA sequence and
synthesis pathway in a single article was incredible. In fact Sir John Vane,
organiser of the 4th International Congress on Endothelin, thought it was an
April's Fool Joke! It was no joke. The discovery of such an agent was
thought by many to have heralded a new era of discovery for the
pathophysiology of several diseases and of drug development. Indeed there
has been a phenomenal amount of interest and research activity into the
endothelin system of peptides resulting in several thousand publications
every year. By necessity, most of the initial research activity was in the
preclinical sciences. However, there have now been several studies in
humans examining the effects of intervention in the endothelin system in
both health and disease. Some of these studies are presented in this thesis. I
firmly believe we are now entering the most exciting stage in endothelin
research. Drugs which block endothelin receptors are being rapidly
developed and large trials are already under way. In particular, a
multicentre international trial in essential hypertension was only recently
published in the New England Journal ofMedicine. I am sure this will not
be the last and much more exciting developments are still to come in the
not to distant future.
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